{
    "studies": [
        {
            "protocolSection": {
                "identificationModule": {
                    "nctId": "NCT05388760",
                    "orgStudyIdInfo": {
                        "id": "LP0162-1335"
                    },
                    "secondaryIdInfos": [
                        {
                            "id": "2021-005573-12",
                            "type": "EUDRACT_NUMBER"
                        },
                        {
                            "id": "U1111-1282-4394",
                            "type": "OTHER",
                            "domain": "World Health Organization (WHO)"
                        }
                    ],
                    "organization": {
                        "fullName": "LEO Pharma",
                        "class": "INDUSTRY"
                    },
                    "briefTitle": "Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)",
                    "officialTitle": "A Single (Assessor) Blinded, Randomized, Parallel-group, Monotherapy Trial to Evaluate the Pharmacokinetics and Safety of Tralokinumab in Children (Age 6 to <12 Years) With Moderate-to-severe Atopic Dermatitis"
                },
                "statusModule": {
                    "statusVerifiedDate": "2024-10",
                    "overallStatus": "ACTIVE_NOT_RECRUITING",
                    "expandedAccessInfo": {
                        "hasExpandedAccess": false
                    },
                    "startDateStruct": {
                        "date": "2022-09-07",
                        "type": "ACTUAL"
                    },
                    "primaryCompletionDateStruct": {
                        "date": "2023-10-20",
                        "type": "ACTUAL"
                    },
                    "completionDateStruct": {
                        "date": "2026-04-23",
                        "type": "ESTIMATED"
                    },
                    "studyFirstSubmitDate": "2022-05-19",
                    "studyFirstSubmitQcDate": "2022-05-19",
                    "studyFirstPostDateStruct": {
                        "date": "2022-05-24",
                        "type": "ACTUAL"
                    },
                    "dispFirstSubmitDate": "2024-10-18",
                    "dispFirstPostDateStruct": {
                        "date": "2024-10-21",
                        "type": "ACTUAL"
                    },
                    "lastUpdateSubmitDate": "2024-10-18",
                    "lastUpdatePostDateStruct": {
                        "date": "2024-10-21",
                        "type": "ACTUAL"
                    }
                },
                "sponsorCollaboratorsModule": {
                    "responsibleParty": {
                        "type": "SPONSOR"
                    },
                    "leadSponsor": {
                        "name": "LEO Pharma",
                        "class": "INDUSTRY"
                    }
                },
                "oversightModule": {
                    "oversightHasDmc": true,
                    "isFdaRegulatedDrug": true,
                    "isFdaRegulatedDevice": false
                },
                "descriptionModule": {
                    "briefSummary": "The main purpose of this trial is to investigate what happens to the trial drug in the body and to confirm that it is safe to use and effective for treating atopic dermatitis (AD) in children.\n\nThe trial will last up to maximum of approximately 194 weeks, and there will be up to 59 visits. The visits will be held approximately every second week for the first 68 weeks, then the visits will be held every six weeks for the rest of the treatment period. From week 26, every second visit will be held by phone and every second visit will be held on site.\n\nThe first part of the trial is called a screening period and will last between 2 and 6 weeks. After the screening period, the trial drug will be administered to the child by subcutaneous (SC) injection. The treatment period with tralokinumab is divided in 3 parts: 1.) initial treatment period for 16 weeks, 2.) open-label treatment period for 52 weeks and 3.) long-term extension treatment period for up to 106 weeks followed by a 14-week safety follow-up period.\n\nAll children will use an emollient twice daily (or more) for at least 14 days prior to start of treatment and will continue this treatment throughout the trial. If medically necessary, rescue treatment for AD is allowed at the discretion of the trial doctor."
                },
                "conditionsModule": {
                    "conditions": [
                        "Atopic Dermatitis"
                    ]
                },
                "designModule": {
                    "studyType": "INTERVENTIONAL",
                    "phases": [
                        "PHASE2"
                    ],
                    "designInfo": {
                        "allocation": "RANDOMIZED",
                        "interventionModel": "PARALLEL",
                        "primaryPurpose": "TREATMENT",
                        "maskingInfo": {
                            "masking": "SINGLE",
                            "maskingDescription": "This trial will be assessor blinded (efficacy and safety assessments) to ensure an objective evaluation of efficacy and safety of the Investigational Medicinal Product (IMP). Due to differences in number of injections of IMP, blinding will only be maintained for the assessor. For the initial treatment period (Week 0-Week 16), the assessor will be a different person than the person administering the IMP. Subjects and the caregivers will be instructed that it is important for the trial results that they refrain from revealing their treatment allocation to the assessor.",
                            "whoMasked": [
                                "OUTCOMES_ASSESSOR"
                            ]
                        }
                    },
                    "enrollmentInfo": {
                        "count": 24,
                        "type": "ESTIMATED"
                    }
                },
                "armsInterventionsModule": {
                    "armGroups": [
                        {
                            "label": "Cohort 1 (6 to <12 years) - tralokinumab dose regimen A",
                            "type": "EXPERIMENTAL",
                            "interventionNames": [
                                "Drug: Tralokinumab"
                            ]
                        },
                        {
                            "label": "Cohort 1 (6 to <12 years) - tralokinumab dose regimen B",
                            "type": "EXPERIMENTAL",
                            "interventionNames": [
                                "Drug: Tralokinumab"
                            ]
                        }
                    ],
                    "interventions": [
                        {
                            "type": "DRUG",
                            "name": "Tralokinumab",
                            "description": "A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment) and a long-term extension treatment period for up to 106 weeks.",
                            "armGroupLabels": [
                                "Cohort 1 (6 to <12 years) - tralokinumab dose regimen A",
                                "Cohort 1 (6 to <12 years) - tralokinumab dose regimen B"
                            ]
                        }
                    ]
                },
                "outcomesModule": {
                    "primaryOutcomes": [
                        {
                            "measure": "Ctrough (trough concentration)",
                            "timeFrame": "at Week 16"
                        },
                        {
                            "measure": "Cmax (maximum serum concentration)",
                            "timeFrame": "between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W)"
                        },
                        {
                            "measure": "AUC (area under the curve)",
                            "timeFrame": "between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W)"
                        },
                        {
                            "measure": "Tmax (time to maximum serum concentration)",
                            "timeFrame": "between Week 12-Week 14 for Q2W (Week 12-Week 16 for Q4W)"
                        }
                    ],
                    "secondaryOutcomes": [
                        {
                            "measure": "Number of treatment-emergent adverse events in the initial treatment period",
                            "description": "An Adverse Event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An event will be considered treatment-emergent if started after the first use of IMP or if started before the first use of IMP and worsened in severity after first dose of IMP.",
                            "timeFrame": "Week 0-Week 16"
                        },
                        {
                            "measure": "Anti-drug antibodies (status) in the initial treatment period",
                            "timeFrame": "Week 0-Week 16"
                        },
                        {
                            "measure": "Number of treatment-emergent adverse events in the open-label treatment period",
                            "description": "An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An event will be considered treatment-emergent if started after the first use of IMP or if started before the first use of IMP and worsened in severity after first dose of IMP.",
                            "timeFrame": "Week 16-Week 68"
                        },
                        {
                            "measure": "Anti-drug antibodies (status) in the open-label treatment period",
                            "timeFrame": "Week 16-Week 68"
                        },
                        {
                            "measure": "Change in Scoring Atopic Dermatitis (SCORAD)",
                            "description": "The SCORAD is a validated tool to evaluate the extent and severity of atopic dermatitis (AD) lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.",
                            "timeFrame": "from Week 0-Week 68"
                        },
                        {
                            "measure": "Change in Patient-Oriented Eczema Measure (POEM)",
                            "description": "The POEM is a validated questionnaire used to assess disease symptoms in atopic eczema patients in both clinical practice and clinical trials (30, 31). The tool consists of 7 items each addressing a specific symptom (itching, sleep, bleeding, weeping, cracking, flaking, and dryness). POEM for proxy completion is used, where the caregiver will report their perception of how often the subject has experienced each symptom over the previous week on a 5-point categorical response scale (0 = 'no days'; 1 = '1 to 2 days'; 2 = '3 to 4 days'; 3 = '5 to 6 days'; 4 = 'every day'). The total score is the sum of the 7 items (range 0 to 28) and reflects disease-related morbidity; a high score is indicative of a worse disease severity.",
                            "timeFrame": "from Week 0-Week 68"
                        },
                        {
                            "measure": "Change in Eczema Area and Severity Index (EASI)",
                            "description": "The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe or more extensive condition.",
                            "timeFrame": "from Week 0-Week 68"
                        }
                    ]
                },
                "eligibilityModule": {
                    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of AD (as defined by Hanifin and Rajka criteria for AD).\n* Age 6 to \\<12 years at time of the baseline visit.\n* Body weight at baseline of \u226517 kg.\n* History of AD for \u2265 12 months at screening.\n* History of TCS and/or TCI treatment failure (due to inadequate response or intolerance) or subjects for whom these topical AD treatments are medically inadvisable.\n* AD involvement of \u226510% body surface area at screening and baseline.\n* An EASI score of \u226516 at screening and at baseline.\n* An Investigator's Global Assessment (IGA) score of \u22653 at screening and at baseline.\n* Emollient twice daily (or more) for at least 14 days prior to baseline.\n\nExclusion Criteria:\n\n* Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment.\n* Treatment with topical PDE-4 inhibitor within 2 weeks prior to randomization.\n* Treatment with the following immunomodulatory medications or bleach baths within 4 weeks prior to baseline:\n\n  * Systemic immunosuppressive/immunomodulating drugs (e.g. methotrexate, cyclosporine, azathioprine, mycophenolate mofetil, JAK inhibitors).\n  * Systemic corticosteroid use (excludes topical, inhaled, ophthalmic, or intranasal delivery).\n  * 3 or more bleach baths during any week within the 4 weeks.\n* Receipt of any marketed biological therapy or investigational biologic agents (including immunoglobulin, anti-IgE, or dupilumab):\n\n  * Any cell-depleting agents, including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.\n  * Other biologics (including dupilumab): within 3 months or 5 halflives, whichever is longer, prior to baseline.\n* Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antifungals, or antiprotozoals within 2 weeks before the baseline visit.\n* History of malignancy at any time before the baseline visit.\n* History of anaphylaxis following any biological therapy.\n* History of immune complex disease.\n* Active or suspected endoparasitic infections.\n* History of past or current tuberculosis or other mycobacterial infection.\n* Established diagnosis of a primary immunodeficiency disorder.",
                    "healthyVolunteers": false,
                    "sex": "ALL",
                    "minimumAge": "6 Years",
                    "maximumAge": "11 Years",
                    "stdAges": [
                        "CHILD"
                    ]
                },
                "contactsLocationsModule": {
                    "overallOfficials": [
                        {
                            "name": "Medical Expert",
                            "affiliation": "LEO Pharma",
                            "role": "STUDY_DIRECTOR"
                        }
                    ],
                    "locations": [
                        {
                            "facility": "LEO Pharma Investigational Site",
                            "city": "Brno",
                            "zip": "625 00",
                            "country": "Czechia",
                            "geoPoint": {
                                "lat": 49.19522,
                                "lon": 16.60796
                            }
                        },
                        {
                            "facility": "LEO Pharma Investigational Site",
                            "city": "Praha",
                            "zip": "150 06",
                            "country": "Czechia",
                            "geoPoint": {
                                "lat": 50.08804,
                                "lon": 14.42076
                            }
                        },
                        {
                            "facility": "LEO Pharma Investigational Site",
                            "city": "Reims",
                            "state": "Ardennes",
                            "zip": "51100",
                            "country": "France",
                            "geoPoint": {
                                "lat": 49.25,
                                "lon": 4.03333
                            }
                        },
                        {
                            "facility": "LEO Pharma Investigational Site",
                            "city": "Rotterdam",
                            "zip": "3011 TG",
                            "country": "Netherlands",
                            "geoPoint": {
                                "lat": 51.9225,
                                "lon": 4.47917
                            }
                        },
                        {
                            "facility": "LEO Pharma Investigational Site",
                            "city": "Utrecht",
                            "zip": "3584 CX",
                            "country": "Netherlands",
                            "geoPoint": {
                                "lat": 52.09083,
                                "lon": 5.12222
                            }
                        },
                        {
                            "facility": "LEO Pharma Investigational Site",
                            "city": "C\u00e1diz",
                            "state": "Andaluc\u00eda",
                            "zip": "11009",
                            "country": "Spain",
                            "geoPoint": {
                                "lat": 36.52672,
                                "lon": -6.2891
                            }
                        },
                        {
                            "facility": "LEO Pharma Investigational Site",
                            "city": "Esplugues de Llobregat",
                            "state": "Barcelona",
                            "zip": "08950",
                            "country": "Spain",
                            "geoPoint": {
                                "lat": 41.37732,
                                "lon": 2.08809
                            }
                        },
                        {
                            "facility": "LEO Pharma Investigational Site",
                            "city": "Alicante",
                            "zip": "03010",
                            "country": "Spain",
                            "geoPoint": {
                                "lat": 38.34517,
                                "lon": -0.48149
                            }
                        },
                        {
                            "facility": "LEO Pharma Investigational Site",
                            "city": "Manchester",
                            "state": "Greater Manchester",
                            "zip": "M13 9WL",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 53.48095,
                                "lon": -2.23743
                            }
                        },
                        {
                            "facility": "LEO Pharma Investigational Site",
                            "city": "London",
                            "zip": "SE1 9RT",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 51.50853,
                                "lon": -0.12574
                            }
                        },
                        {
                            "facility": "LEO Pharma Investigational Site",
                            "city": "Sheffield",
                            "zip": "S10 2TH",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 53.38297,
                                "lon": -1.4659
                            }
                        }
                    ]
                },
                "ipdSharingStatementModule": {
                    "ipdSharing": "YES",
                    "infoTypes": [
                        "STUDY_PROTOCOL",
                        "SAP"
                    ],
                    "accessCriteria": "De-identified Individual Participant Data can be made available to researchers and is subject to approved scientifically sound research proposal and signed data-sharing agreement.",
                    "url": "http://leopharmatrials.com/for-researchers"
                }
            },
            "derivedSection": {
                "miscInfoModule": {
                    "versionHolder": "2024-11-18"
                },
                "conditionBrowseModule": {
                    "meshes": [
                        {
                            "id": "D003876",
                            "term": "Dermatitis, Atopic"
                        },
                        {
                            "id": "D003872",
                            "term": "Dermatitis"
                        },
                        {
                            "id": "D004485",
                            "term": "Eczema"
                        }
                    ],
                    "ancestors": [
                        {
                            "id": "D012871",
                            "term": "Skin Diseases"
                        },
                        {
                            "id": "D012873",
                            "term": "Skin Diseases, Genetic"
                        },
                        {
                            "id": "D030342",
                            "term": "Genetic Diseases, Inborn"
                        },
                        {
                            "id": "D017443",
                            "term": "Skin Diseases, Eczematous"
                        },
                        {
                            "id": "D006969",
                            "term": "Hypersensitivity, Immediate"
                        },
                        {
                            "id": "D006967",
                            "term": "Hypersensitivity"
                        },
                        {
                            "id": "D007154",
                            "term": "Immune System Diseases"
                        }
                    ],
                    "browseLeaves": [
                        {
                            "id": "M7071",
                            "name": "Dermatitis, Atopic",
                            "asFound": "Atopic Dermatitis",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M7067",
                            "name": "Dermatitis",
                            "asFound": "Dermatitis",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M7655",
                            "name": "Eczema",
                            "asFound": "Atopic Dermatitis",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M15674",
                            "name": "Skin Diseases",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M15676",
                            "name": "Skin Diseases, Genetic",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M23686",
                            "name": "Genetic Diseases, Inborn",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M19712",
                            "name": "Skin Diseases, Eczematous",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M10018",
                            "name": "Hypersensitivity",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M10020",
                            "name": "Hypersensitivity, Immediate",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M10200",
                            "name": "Immune System Diseases",
                            "relevance": "LOW"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "BC16",
                            "name": "Diseases and Abnormalities at or Before Birth"
                        },
                        {
                            "abbrev": "BC17",
                            "name": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "abbrev": "BC20",
                            "name": "Immune System Diseases"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Conditions"
                        }
                    ]
                }
            },
            "hasResults": false
        },
        {
            "protocolSection": {
                "identificationModule": {
                    "nctId": "NCT06067191",
                    "orgStudyIdInfo": {
                        "id": "REVD002"
                    },
                    "secondaryIdInfos": [
                        {
                            "id": "C5251002",
                            "type": "OTHER",
                            "domain": "Alias Study Number"
                        }
                    ],
                    "organization": {
                        "fullName": "Pfizer",
                        "class": "INDUSTRY"
                    },
                    "briefTitle": "Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)",
                    "officialTitle": "A RANDOMISED, PHASE 1B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF RV299 AGAINST RESPIRATORY SYNCYTIAL VIRUS IN THE VIRAL CHALLENGE MODEL"
                },
                "statusModule": {
                    "statusVerifiedDate": "2024-07",
                    "overallStatus": "COMPLETED",
                    "expandedAccessInfo": {
                        "hasExpandedAccess": false
                    },
                    "startDateStruct": {
                        "date": "2022-08-08",
                        "type": "ACTUAL"
                    },
                    "primaryCompletionDateStruct": {
                        "date": "2022-12-02",
                        "type": "ACTUAL"
                    },
                    "completionDateStruct": {
                        "date": "2022-12-02",
                        "type": "ACTUAL"
                    },
                    "studyFirstSubmitDate": "2023-09-27",
                    "studyFirstSubmitQcDate": "2023-09-27",
                    "studyFirstPostDateStruct": {
                        "date": "2023-10-04",
                        "type": "ACTUAL"
                    },
                    "resultsFirstSubmitDate": "2023-11-30",
                    "resultsFirstSubmitQcDate": "2024-07-25",
                    "resultsFirstPostDateStruct": {
                        "date": "2024-10-21",
                        "type": "ACTUAL"
                    },
                    "lastUpdateSubmitDate": "2024-07-25",
                    "lastUpdatePostDateStruct": {
                        "date": "2024-10-21",
                        "type": "ACTUAL"
                    }
                },
                "sponsorCollaboratorsModule": {
                    "responsibleParty": {
                        "type": "SPONSOR"
                    },
                    "leadSponsor": {
                        "name": "Pfizer",
                        "class": "INDUSTRY"
                    }
                },
                "oversightModule": {
                    "oversightHasDmc": true,
                    "isFdaRegulatedDrug": false,
                    "isFdaRegulatedDevice": false
                },
                "descriptionModule": {
                    "briefSummary": "The purpose of the study is to learn about the safety, pharmacokinetics and antiviral activity of the study medicine (RV299) for the potential treatment of respiratory syncytial virus (RSV). RSV is a highly contagious virus that can lead to serious lung infections in patients with reduced ability to fight infection. Most vulnerable populations include babies, the elderly and patients that have received a bone marrow transplant.",
                    "detailedDescription": "This study is seeking healthy participants who are:\n\nHealthy adult male and female participants aged between 18 to 55 years, with a total body weight \u226550 kg and body mass index (BMI) \u226518 kg/m2 and \u226435kg/m2 and who have been screened to be sero-suitable for infection with the RSV-A Memphis 37b virus challenge virus.\n\nA total of 80 participants is planned: 40 participants on RV299 and 40 participants on placebo.\n\nThe study is divided into 3 phases:\n\n* Screening phase: from Day -90 to Day-3 pre-human viral challenge (HVC).\n* Inpatient phase: Participants will be resident in the quarantine unit for approximately 15 days (from Day -2 to Day 12).\n\n  * Post RSV-A Memphis 37b virus inoculation on Day 0, participants will be randomized to receive RV299 or matched placebo.\n  * Administration of RV299 or placebo will be twice daily (\\~12 hours interval) for 5 consecutive days and will start on confirmation of RSV infection.\n* Outpatient phase: Day 28 (\u00b13 days)"
                },
                "conditionsModule": {
                    "conditions": [
                        "Respiratory Syncytial Virus (RSV)"
                    ],
                    "keywords": [
                        "Anti-viral",
                        "Challenge"
                    ]
                },
                "designModule": {
                    "studyType": "INTERVENTIONAL",
                    "phases": [
                        "PHASE1"
                    ],
                    "designInfo": {
                        "allocation": "RANDOMIZED",
                        "interventionModel": "PARALLEL",
                        "primaryPurpose": "BASIC_SCIENCE",
                        "maskingInfo": {
                            "masking": "TRIPLE",
                            "whoMasked": [
                                "PARTICIPANT",
                                "INVESTIGATOR",
                                "OUTCOMES_ASSESSOR"
                            ]
                        }
                    },
                    "enrollmentInfo": {
                        "count": 82,
                        "type": "ACTUAL"
                    }
                },
                "armsInterventionsModule": {
                    "armGroups": [
                        {
                            "label": "Active",
                            "type": "EXPERIMENTAL",
                            "description": "spray-dried dispersion (SDD) for Oral Suspension",
                            "interventionNames": [
                                "Drug: RV299"
                            ]
                        },
                        {
                            "label": "Placebo",
                            "type": "PLACEBO_COMPARATOR",
                            "description": "spray-dried dispersion (SDD) for Oral Suspension",
                            "interventionNames": [
                                "Drug: Placebo"
                            ]
                        }
                    ],
                    "interventions": [
                        {
                            "type": "DRUG",
                            "name": "RV299",
                            "description": "Oral Suspension",
                            "armGroupLabels": [
                                "Active"
                            ]
                        },
                        {
                            "type": "DRUG",
                            "name": "Placebo",
                            "description": "matching placebo",
                            "armGroupLabels": [
                                "Placebo"
                            ]
                        }
                    ]
                },
                "outcomesModule": {
                    "primaryOutcomes": [
                        {
                            "measure": "Area Under the Curve (AUC) for RSV-A Memphis 37b Viral Load Determined by Quantitative Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR)",
                            "description": "Area under the curve (AUC) for RSV viral load measured in nasal washes by qRT-PCR in participants inoculated with RSV-A Memphis 37b, from initial administration of IMP up to the morning of Day 12 (Quarantine discharge) was presented in this outcome measure.",
                            "timeFrame": "From initial administration of IMP up to the morning of quarantine discharge (up to Day 12)"
                        }
                    ],
                    "secondaryOutcomes": [
                        {
                            "measure": "Peak Viral Load of RSV Determined by qRT-PCR",
                            "description": "Peak viral load of RSV as defined by the maximum viral load determined by qRT-PCR measurements in nasal samples starting from initial administration of IMP up to planned discharge from quarantine was reported in this outcome measure.",
                            "timeFrame": "From initial administration of IMP up to planned discharge from quarantine (Up to Day 12)"
                        },
                        {
                            "measure": "Time to Confirmed Negative Test by qRT-PCR Measurement Starting From Initial Administration of Investigational Medicinal Product (IMP) to First Confirmed Undetectable Assessment After Peak Measure",
                            "description": "The time from the first administration of IMP to the first confirmed negative qRT-PCR test after the peak qRT-PCR measurement was calculated as: Date and time of first confirmed negative test after peak qRT-PCR measurement minus Date and time of first IMP administration. A negative test was defined as two consecutive 'Not Detected' results in the qRT-PCR test. The peak qRT-PCR was defined as the highest viral load value obtained by a participant after their first administration of IMP. Participants without a confirmed undetectable assessment after their peak, were censored at their last detected qRT-PCR assessment.",
                            "timeFrame": "From first administration of IMP to the first confirmed negative qRT-PCR test or censoring date (up to Day 12)"
                        },
                        {
                            "measure": "Time to Confirmed Negative Test by qRT-PCR Measurement Starting From Peak qRT-PCR After Initial Administration of IMP to First Confirmed Undetectable Assessment After Peak Measure",
                            "description": "The time from the peak qRT-PCR measurement after administration of IMP to the first confirmed negative qRT-PCR test was calculated as (Date and time of first confirmed negative test after peak qRT-PCR measurement minus Date and time of peak qRT-PCR measurement). A negative test was defined as two consecutive 'Not Detected' results in the qRT-PCR test. The peak qRT-PCR was defined as the highest viral load value obtained by a participant after their first administration of IMP. Participants without a confirmed undetectable assessment after their peak, were censored at their last detected qRT-PCR assessment.",
                            "timeFrame": "From peak qRT-PCR measurement to the first confirmed negative qRT-PCR test or censoring date (up to Day 12)"
                        },
                        {
                            "measure": "Time to Peak qRT-PCR Starting From Initial Administration of IMP",
                            "description": "The time to the peak qRT-PCR measurement starting from the initial administration of IMP was calculated as: Date and time of peak qRT-PCR measurement minus Date and time of first IMP administration. The peak qRT-PCR was defined as the highest viral load value obtained by a participant after their first administration of IMP.",
                            "timeFrame": "From first administration of IMP to peak qRT-PCR measurement (up to Day 12)"
                        },
                        {
                            "measure": "Area Under the Viral Load-Time Curve (VL-AUC) for RSV-A Memphis 37b Determined by Viral Culture",
                            "description": "Area under the viral load-time curve (VL-AUC) of RSV challenge virus as determined by viral culture on nasal samples, starting at initial administration of IMP up to planned discharge from quarantine was reported in this outcome measure.",
                            "timeFrame": "From initial administration of IMP up to planned discharge from quarantine (up to Day 12)"
                        },
                        {
                            "measure": "Peak Viral Load of RSV Determined by Viral Culture",
                            "description": "Peak viral load of RSV as defined by the maximum viral load determined by viral culture measurements in nasal samples starting from initial administration of IMP up to planned discharge from quarantine was reported in this outcome measure.",
                            "timeFrame": "From initial administration of IMP up to planned discharge from quarantine (up to Day 12)"
                        },
                        {
                            "measure": "Time to Confirmed Negative Test by Viral Culture Measurement Starting From at Initial Administration of IMP to First Confirmed Undetectable Assessment After Peak Measure",
                            "description": "Time to confirmed negative test by viral culture measurements in nasal samples from initial administration of IMP up to first confirmed negative viral culture measurement after the peak viral culture measurement was calculated as: Date and time of first confirmed negative test after peak viral culture measurement minus Date and time of first IMP administration. A negative test was defined as two consecutive 'Not Detected' results in the viral culture test. The peak viral culture measurement was defined as the highest viral load value obtained by a participant after their first administration of IMP. Participants who did not have a confirmed undetectable assessment after their peak viral culture measurement after first administration of IMP were censored at their last detectable assessment.",
                            "timeFrame": "From initial administration of IMP up to first confirmed undetectable assessment or censoring date (up to Day 12)"
                        },
                        {
                            "measure": "Time to Confirmed Negative Test by Viral Culture Measurement Starting From Peak Viral Culture After Initial Administration of IMP to First Confirmed Undetectable Assessment After Peak Measure",
                            "description": "The time from the peak viral culture measurement after administration of IMP to the first confirmed negative viral culture measurement was calculated in days as: Date of and time first confirmed negative test minus Date and time of peak qRT-PCR measurement. A negative test was defined as two consecutive 'Not Detected' results in the viral culture test. The peak viral culture measurement was defined as the highest viral load value obtained by a participant after their first administration of IMP. Participants who did not have a confirmed undetectable assessment after their peak viral culture measurement after first administration of IMP were censored at their last detectable assessment.",
                            "timeFrame": "From peak qRT-PCR measurement to first confirmed undetectable assessment or censoring date (up to Day 12)"
                        },
                        {
                            "measure": "Area Under the Curve Over Time of Total Clinical Symptoms as Measured From 10 Symptoms Within the Graded Symptom Scoring System",
                            "description": "Area under the Curve over Time of Total Clinical Symptoms (TSS-AUC) as measured from 10 symptoms within Graded Symptom Scoring System Collected 3 Times Daily Starting at Initial Administration up to Planned Discharge from Quarantine. TSS (from 10 items of the 13-item symptom diary card) was used to calculate the AUC, from the assessment nearest to the time of the first administration of IMP until Day 12. Following types of symptoms were recorded on symptom diary cards: Upper Respiratory Tract (URT): runny nose, stuffy nose, sore throat, sneezing, earache; Lower Respiratory Tract (LRT): cough, shortness of breath; Systemic: headache, malaise, muscle/joint ache/stiffness. Each symptom was recorded on a grading scale of 0 to 3 (or 0 to 4 for the Shortness of Breath symptom), higher scores = greater severity of symptoms. Total symptom score was calculated as sum of the 10 observed symptom grade values and ranged from 0 to 31, where higher scores indicated more severe symptoms.",
                            "timeFrame": "From initial administration of IMP (before or after administration) up to planned discharge from quarantine (up to Day 12)"
                        },
                        {
                            "measure": "Area Under the Curve Over Time of Total Clinical Symptoms Change From Baseline (TSS-AUC-CFB) as Measured From 10 Symptoms Within the Graded Symptom Scoring System",
                            "description": "Area under the curve over time of total clinical symptoms change from baseline (TSS-AUC-CFB) as measured from 10 symptoms within the graded symptom scoring system collected 3 times daily starting at initial administration of IMP up to planned discharge from quarantine (Day 12, am). The following types of symptoms were recorded: Upper Respiratory Tract (URT): runny nose, stuffy nose, sore throat, sneezing, earache; Lower Respiratory Tract (LRT): cough, shortness of breath; Systemic: headache, malaise, muscle/joint ache/stiffness. Each symptom was recorded on a grading scale of 0 to 3 (or 0 to 4 for the Shortness of Breath symptom), where higher scores indicated greater severity of symptoms. TSS was calculated as sum of the 10 observed symptom grade values and ranged from 0 to 31, where higher scores indicated more severe symptoms. The AUC calculation was based on the available non-missing calculated total symptom scores between the start and end of the defined AUC time.",
                            "timeFrame": "Baseline (assessment nearest to the time of the first administration of IMP) up to Day 12"
                        },
                        {
                            "measure": "Overall Peak Total Clinical Symptoms (TSS) Score",
                            "description": "Peak total clinical symptoms (TSS) as measured from 10 symptoms within the graded symptom scoring system collected 3 times daily starting from initial administration of IMP up to planned discharge from quarantine. The following types of symptoms were recorded: Upper Respiratory Tract (URT): runny nose, stuffy nose, sore throat, sneezing, earache; Lower Respiratory Tract (LRT): cough, shortness of breath; Systemic: headache, malaise, muscle/joint ache/stiffness. Each symptom was recorded on a grading scale of 0 to 3 (or 0 to 4 for the Shortness of Breath symptom), where higher scores indicated greater severity of symptoms. The total symptom score was calculated as sum of the 10 observed symptom grade values and ranged from 0 to 31, where higher scores indicated more severe symptoms. The overall peak score was defined as the highest scoring symptom diary card observed from the first administration of IMP until quarantine discharge.",
                            "timeFrame": "From initial administration of IMP (before or after administration) up to planned discharge from quarantine (up to Day 12)"
                        },
                        {
                            "measure": "Individual Maximum Daily Peak Symptom Score",
                            "description": "Individual maximum daily sum of symptom score from initial administration of IMP up to planned discharge from quarantine. The following types of symptoms were recorded: Upper Respiratory Tract (URT): runny nose, stuffy nose, sore throat, sneezing, earache; Lower Respiratory Tract (LRT): cough, shortness of breath; Systemic: headache, malaise, muscle/joint ache/stiffness. Each symptom was recorded on a grading scale of 0 to 3 (or 0 to 4 for the Shortness of Breath symptom), where higher scores indicated greater severity of symptoms. The total symptom score was calculated as sum of the 10 observed symptom grade values and ranged from 0 to 31, where higher scores indicated more severe symptoms. The highest total symptom score recorded on each day, across the three assessments was reported in this outcome measure. The peak daily score was defined as the highest scoring symptom diary card observed on each day from the first administration of IMP until quarantine discharge.",
                            "timeFrame": "Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8 and Day 9 (days relative to first administration of IMP)"
                        },
                        {
                            "measure": "Time to Symptom Resolution Starting at Initial Administration of IMP to 24 Hours Symptom Free",
                            "description": "Symptom resolution was defined as a participant scoring 0 for the total symptom score for a 24-hour period (e.g., a minimum of three consecutive symptom diary cards, each with a score of 0) after their peak symptom score. The time from the assessment at the time of the first administration of IMP until symptom resolution was calculated as: Date and time of symptom resolution minus Date and time of assessment at IMP administration. If the peak symptom score occurred on more than one day then the first occurrence was selected. Participants who did not record 24 hours symptom free after their highest total symptom score during the quarantine period were censored at their last assessment.",
                            "timeFrame": "From first administration of IMP until time of symptom resolution or censoring date (up to Day 12)"
                        },
                        {
                            "measure": "Time to Symptom Resolution Starting at Peak Symptoms After Initial Administration to 24 Hours Symptom Free",
                            "description": "Symptom resolution was defined as a participant scoring 0 for the total symptom score for a 24-hour period (e.g., a minimum of three consecutive symptom diary cards, each with a score of 0) after their peak symptom score. The time from the highest total symptom score following administration of IMP until symptom resolution was calculated as: Date and time of symptom resolution minus Date and time of highest total symptom score. If the peak symptom score occurred on more than one day then the first occurrence was selected. Participants who did not record 24 hours symptom free after their highest total symptom score during the quarantine period were censored at their last assessment.",
                            "timeFrame": "From time of highest total symptom score until time of symptom resolution or censoring date (up to Day 12)"
                        },
                        {
                            "measure": "Time to Peak Symptom Score From Initial Administration of IMP",
                            "description": "Time to peak as measured from 10 symptoms within the graded daily symptom scoring system starting from initial administration of IMP to the time of peak daily symptom score. If the peak symptom score occurred on more than one day then the first occurrence was selected. Participants were censored at their last assessment if they did not record any symptoms during the quarantine period.",
                            "timeFrame": "From first dose of IMP until time of highest total symptom score or censoring date (Up to Day 12)"
                        },
                        {
                            "measure": "Total Weight of Mucus Produced Starting at Initial Administration of IMP up to Planned Discharge From Quarantine",
                            "description": "Total weight of nasal mucus was calculated as the sum of mucus weights taken from the assessment at the time of the first administration of IMP (prior to or after dosing, depending on whether dosed in the morning or evening) to morning of Day 12 (Quarantine discharge).",
                            "timeFrame": "From first administration of IMP up to planned discharge from quarantine (up to Day 12)"
                        },
                        {
                            "measure": "Total Number of Tissues Used by Participants Starting At Initial Administration of IMP up to Planned Discharge From Quarantine",
                            "description": "Total number of tissues was counted from the assessment at the time of the first dose of IMP (prior to or after dosing, depending on whether dosed in the morning or evening) to morning of Day 12 (Quarantine discharge).",
                            "timeFrame": "From first administration of IMP up to planned discharge from quarantine (up to Day 12)"
                        },
                        {
                            "measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                            "description": "An adverse event was defined as any untoward medical occurrence in clinical study participants administered a pharmaceutical product. An AE did not necessarily have a causal relationship with the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect or important medical event.",
                            "timeFrame": "From first dose of IMP until end of follow-up visit (up to Day 28)"
                        },
                        {
                            "measure": "Number of Participants With AEs Related to Viral Challenge",
                            "description": "An Adverse Event was defined as any untoward medical occurrence in clinical study participants administered a pharmaceutical product. An AE did not necessarily have a causal relationship with the study intervention. Number of participants with AEs possibly, probably or definitely related to viral challenge agents were reported by preferred terms in this outcome measure.",
                            "timeFrame": "From viral challenge on Day 0 up to end of follow-up (Day 28)"
                        },
                        {
                            "measure": "Number of Participants With Concomitant Medications",
                            "description": "Number of participants with concomitant medications were reported in this outcome measure.",
                            "timeFrame": "From viral challenge on Day 0 up to end of follow-up (Day 28)"
                        },
                        {
                            "measure": "Time to Maximum Plasma Concentration (Tmax) for RV299",
                            "timeFrame": "Pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8,10, 12, 24, 36, 48, 60, 72, 84 and 96-hours post-dose 1 and dose 10"
                        },
                        {
                            "measure": "Terminal Half-Life (t1/2) for RV299",
                            "timeFrame": "Pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8,10, 12, 24, 36, 48, 60, 72, 84 and 96 hours post-dose 1 and dose 10"
                        },
                        {
                            "measure": "Maximum Observed Plasma Concentration for RV299",
                            "timeFrame": "Pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8,10, 12, 24, 36, 48, 60, 72, 84 and 96 hours post-dose 1 and dose 10"
                        },
                        {
                            "measure": "Area Under the Plasma Concentration-Time Curve From Time Zero to the End of the Dosing Interval for RV299",
                            "description": "Area under the plasma concentration-time curve from time zero to the end of the dosing interval for RV299 where dosing interval=12 hours.",
                            "timeFrame": "Pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8,10, 12 hours post-dose 1 and dose 10"
                        },
                        {
                            "measure": "Area Under the Plasma Concentration-Time Curve Over the Last 24 Hours Dosing Interval for RV299",
                            "timeFrame": "Pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8,10, 12, 24 hours post-dose 1 and dose 10"
                        },
                        {
                            "measure": "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity for RV299 on Day 1",
                            "timeFrame": "Pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8,10, 12, 24, 36, 48, 60, 72, 84 and 96 hours post-dose 1"
                        }
                    ]
                },
                "eligibilityModule": {
                    "eligibilityCriteria": "Inclusion Criteria:\n\n* Total body weight \\>= 50 kg and body mass index (BMI) \\>=18 kg/m2 and \\<=35 kg/m2\n* in good health with no history, or current evidence of clinically significant medical condition of laboratory, ECG or vital sign abnormality\n* Sero suitable for challenge virus\n\nExclusion Criteria:\n\n* History of or currently active symptoms or signs suggestive of upper or lower respiratory tract infection within 4 weeks prior to first study visit\n* Any history or evidence of any clinically significant or currently active cardiovascular, respiratory, dermatological, gastrointestinal, endocrinological, haematological, hepatic, immunological (including immunosuppression),metabolic, urological, renal, neurological, or psychiatric disease and/or other major disease\n* females who are breastfeeding or have been pregnant within 6 months prior to the study or have a positive pregnancy test\n* Lifetime history of anaphylaxis and/or a lifetime history of severe allergic reaction\n* Any significant abnormality altering the anatomy of the nose in a substantial way\n* Any clinically significant history of epistaxis (large nosebleeds)\n* Any nasal or sinus surgery within 3 months of first study visit\n* Evidence of vaccinations within 4 weeks of Day 0\n* Receipt of blood or blood products, or loss of 550 mL or more blood within last 3 months\n* Receipt of 3 or more investigational drug within last 12 months\n* Prior inoculation with a virus from the same virus-family as the challenge\n* Prior participation in another HVC study with a respiratory virus in last 3 months\n* Use or anticipated use during the conduct of the study of protocol specified concomitant medications\n* Systemic antiviral administration within 4 weeks of viral challenge\n* Confirmed positive test for drugs of abuse\n* History or presence of alcohol addiction, or excessive use of alcohol\n* A forced expiratory volume in 1 second (FEV1) \\<80%\n* Positive HIV, hepatitis B virus, or hepatitis C virus test\n* Presence of fever upto 2 days prior to Day 0.",
                    "healthyVolunteers": true,
                    "sex": "ALL",
                    "minimumAge": "18 Years",
                    "maximumAge": "55 Years",
                    "stdAges": [
                        "ADULT"
                    ]
                },
                "contactsLocationsModule": {
                    "overallOfficials": [
                        {
                            "name": "Pfizer CT.gov Call Center",
                            "affiliation": "Pfizer",
                            "role": "STUDY_DIRECTOR"
                        }
                    ],
                    "locations": [
                        {
                            "facility": "Pfizer",
                            "city": "London",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 51.50853,
                                "lon": -0.12574
                            }
                        }
                    ]
                },
                "referencesModule": {
                    "seeAlsoLinks": [
                        {
                            "label": "To obtain contact information for a study center near you, click here.",
                            "url": "https://pmiform.com/clinical-trial-info-request?StudyID=REVD002"
                        }
                    ]
                },
                "ipdSharingStatementModule": {
                    "ipdSharing": "NO",
                    "description": "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."
                }
            },
            "resultsSection": {
                "participantFlowModule": {
                    "preAssignmentDetails": "A total of 82 healthy participants were enrolled in the study and received Respiratory Syncytial Virus (RSV) - A Memphis 37b virus inoculation (challenge agent) intranasally on Day 0. Three participants withdrew from study (2 withdrew consent and 1 not randomized because of influenza infection) before randomization and a total of 79 participants were randomized in the study.",
                    "groups": [
                        {
                            "id": "FG000",
                            "title": "RV299",
                            "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                        },
                        {
                            "id": "FG001",
                            "title": "Placebo",
                            "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                        }
                    ],
                    "periods": [
                        {
                            "title": "Overall Study",
                            "milestones": [
                                {
                                    "type": "STARTED",
                                    "achievements": [
                                        {
                                            "groupId": "FG000",
                                            "numSubjects": "39"
                                        },
                                        {
                                            "groupId": "FG001",
                                            "numSubjects": "40"
                                        }
                                    ]
                                },
                                {
                                    "type": "COMPLETED",
                                    "achievements": [
                                        {
                                            "groupId": "FG000",
                                            "numSubjects": "39"
                                        },
                                        {
                                            "groupId": "FG001",
                                            "numSubjects": "39"
                                        }
                                    ]
                                },
                                {
                                    "type": "NOT COMPLETED",
                                    "achievements": [
                                        {
                                            "groupId": "FG000",
                                            "numSubjects": "0"
                                        },
                                        {
                                            "groupId": "FG001",
                                            "numSubjects": "1"
                                        }
                                    ]
                                }
                            ],
                            "dropWithdraws": [
                                {
                                    "type": "Withdrawal by Subject",
                                    "reasons": [
                                        {
                                            "groupId": "FG000",
                                            "numSubjects": "0"
                                        },
                                        {
                                            "groupId": "FG001",
                                            "numSubjects": "1"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                "baselineCharacteristicsModule": {
                    "populationDescription": "Safety population consisted of all randomized participants who received challenge virus and at least one dose of investigational medicinal product (IMP).",
                    "groups": [
                        {
                            "id": "BG000",
                            "title": "RV299",
                            "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                        },
                        {
                            "id": "BG001",
                            "title": "Placebo",
                            "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                        },
                        {
                            "id": "BG002",
                            "title": "Total",
                            "description": "Total of all reporting groups"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "BG000",
                                    "value": "39"
                                },
                                {
                                    "groupId": "BG001",
                                    "value": "40"
                                },
                                {
                                    "groupId": "BG002",
                                    "value": "79"
                                }
                            ]
                        }
                    ],
                    "measures": [
                        {
                            "title": "Age, Continuous",
                            "paramType": "MEAN",
                            "dispersionType": "STANDARD_DEVIATION",
                            "unitOfMeasure": "Years",
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "25.7",
                                                    "spread": "6.21"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "26.2",
                                                    "spread": "7.29"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "25.9",
                                                    "spread": "6.74"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Sex: Female, Male",
                            "paramType": "COUNT_OF_PARTICIPANTS",
                            "unitOfMeasure": "Participants",
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "title": "Female",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "17"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "17"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "34"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "Male",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "22"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "23"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "45"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Race (NIH/OMB)",
                            "paramType": "COUNT_OF_PARTICIPANTS",
                            "unitOfMeasure": "Participants",
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "title": "American Indian or Alaska Native",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "0"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "Asian",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "2"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "2"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "4"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "Native Hawaiian or Other Pacific Islander",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "0"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "Black or African American",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "3"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "4"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "7"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "White",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "30"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "30"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "60"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "More than one race",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "0"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "Unknown or Not Reported",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "4"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "4"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "8"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                "outcomeMeasuresModule": {
                    "outcomeMeasures": [
                        {
                            "type": "PRIMARY",
                            "title": "Area Under the Curve (AUC) for RSV-A Memphis 37b Viral Load Determined by Quantitative Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR)",
                            "description": "Area under the curve (AUC) for RSV viral load measured in nasal washes by qRT-PCR in participants inoculated with RSV-A Memphis 37b, from initial administration of IMP up to the morning of Day 12 (Quarantine discharge) was presented in this outcome measure.",
                            "populationDescription": "Intent-to-Treat Infected (ITT-I) Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEAN",
                            "dispersionType": "Standard Deviation",
                            "unitOfMeasure": "Hours*log10 copies per milliliter",
                            "timeFrame": "From initial administration of IMP up to the morning of quarantine discharge (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "350.99",
                                                    "spread": "289.79"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "616.97",
                                                    "spread": "374.143"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ],
                            "analyses": [
                                {
                                    "groupIds": [
                                        "OG000",
                                        "OG001"
                                    ],
                                    "nonInferiorityType": "OTHER",
                                    "pValue": "0.0009",
                                    "statisticalMethod": "ANCOVA",
                                    "paramType": "Difference in Least Square Mean",
                                    "paramValue": "-312.28",
                                    "ciPctValue": "95",
                                    "ciNumSides": "TWO_SIDED",
                                    "ciLowerLimit": "-489.17",
                                    "ciUpperLimit": "-135.38",
                                    "estimateComment": "Analysis was performed using ANCOVA with treatment group as a fixed effect and baseline viral load as the covariate."
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Peak Viral Load of RSV Determined by qRT-PCR",
                            "description": "Peak viral load of RSV as defined by the maximum viral load determined by qRT-PCR measurements in nasal samples starting from initial administration of IMP up to planned discharge from quarantine was reported in this outcome measure.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEAN",
                            "dispersionType": "Standard Deviation",
                            "unitOfMeasure": "Log10 copies per milliliter",
                            "timeFrame": "From initial administration of IMP up to planned discharge from quarantine (Up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "5.01",
                                                    "spread": "1.968"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "6.23",
                                                    "spread": "1.735"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ],
                            "analyses": [
                                {
                                    "groupIds": [
                                        "OG000",
                                        "OG001"
                                    ],
                                    "nonInferiorityType": "OTHER",
                                    "pValue": "0.0047",
                                    "statisticalMethod": "ANCOVA",
                                    "paramType": "Difference in Least Square Mean",
                                    "paramValue": "-1.45",
                                    "ciPctValue": "95",
                                    "ciNumSides": "TWO_SIDED",
                                    "ciLowerLimit": "-2.43",
                                    "ciUpperLimit": "-0.47",
                                    "estimateComment": "Analysis was performed using ANCOVA with treatment group as a fixed effect and baseline viral load as the covariate."
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Time to Confirmed Negative Test by qRT-PCR Measurement Starting From Initial Administration of Investigational Medicinal Product (IMP) to First Confirmed Undetectable Assessment After Peak Measure",
                            "description": "The time from the first administration of IMP to the first confirmed negative qRT-PCR test after the peak qRT-PCR measurement was calculated as: Date and time of first confirmed negative test after peak qRT-PCR measurement minus Date and time of first IMP administration. A negative test was defined as two consecutive 'Not Detected' results in the qRT-PCR test. The peak qRT-PCR was defined as the highest viral load value obtained by a participant after their first administration of IMP. Participants without a confirmed undetectable assessment after their peak, were censored at their last detected qRT-PCR assessment.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEDIAN",
                            "dispersionType": "Inter-Quartile Range",
                            "unitOfMeasure": "Days",
                            "timeFrame": "From first administration of IMP to the first confirmed negative qRT-PCR test or censoring date (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "4.2",
                                                    "lowerLimit": "2.0",
                                                    "upperLimit": "6.5"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "8.5",
                                                    "lowerLimit": "6.0",
                                                    "upperLimit": "9.0"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ],
                            "analyses": [
                                {
                                    "groupIds": [
                                        "OG000",
                                        "OG001"
                                    ],
                                    "nonInferiorityType": "OTHER",
                                    "pValue": "<0.0001",
                                    "statisticalMethod": "Log Rank"
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Time to Confirmed Negative Test by qRT-PCR Measurement Starting From Peak qRT-PCR After Initial Administration of IMP to First Confirmed Undetectable Assessment After Peak Measure",
                            "description": "The time from the peak qRT-PCR measurement after administration of IMP to the first confirmed negative qRT-PCR test was calculated as (Date and time of first confirmed negative test after peak qRT-PCR measurement minus Date and time of peak qRT-PCR measurement). A negative test was defined as two consecutive 'Not Detected' results in the qRT-PCR test. The peak qRT-PCR was defined as the highest viral load value obtained by a participant after their first administration of IMP. Participants without a confirmed undetectable assessment after their peak, were censored at their last detected qRT-PCR assessment.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEDIAN",
                            "dispersionType": "Inter-Quartile Range",
                            "unitOfMeasure": "Days",
                            "timeFrame": "From peak qRT-PCR measurement to the first confirmed negative qRT-PCR test or censoring date (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "2.5",
                                                    "lowerLimit": "1.5",
                                                    "upperLimit": "4.5"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "5.0",
                                                    "lowerLimit": "2.5",
                                                    "upperLimit": "NA",
                                                    "comment": "Upper limit of interquartile range could not be calculated due to insufficient number of participants with events."
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ],
                            "analyses": [
                                {
                                    "groupIds": [
                                        "OG000",
                                        "OG001"
                                    ],
                                    "nonInferiorityType": "OTHER",
                                    "pValue": "0.0051",
                                    "statisticalMethod": "Log Rank"
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Time to Peak qRT-PCR Starting From Initial Administration of IMP",
                            "description": "The time to the peak qRT-PCR measurement starting from the initial administration of IMP was calculated as: Date and time of peak qRT-PCR measurement minus Date and time of first IMP administration. The peak qRT-PCR was defined as the highest viral load value obtained by a participant after their first administration of IMP.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEDIAN",
                            "dispersionType": "Inter-Quartile Range",
                            "unitOfMeasure": "Days",
                            "timeFrame": "From first administration of IMP to peak qRT-PCR measurement (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "1.5",
                                                    "lowerLimit": "0.5",
                                                    "upperLimit": "2.0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "1.5",
                                                    "lowerLimit": "1.5",
                                                    "upperLimit": "4.0"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ],
                            "analyses": [
                                {
                                    "groupIds": [
                                        "OG000",
                                        "OG001"
                                    ],
                                    "nonInferiorityType": "OTHER",
                                    "pValue": "0.0077",
                                    "statisticalMethod": "Log Rank"
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Area Under the Viral Load-Time Curve (VL-AUC) for RSV-A Memphis 37b Determined by Viral Culture",
                            "description": "Area under the viral load-time curve (VL-AUC) of RSV challenge virus as determined by viral culture on nasal samples, starting at initial administration of IMP up to planned discharge from quarantine was reported in this outcome measure.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEAN",
                            "dispersionType": "Standard Deviation",
                            "unitOfMeasure": "Hours*log10 plaque forming units/mL",
                            "timeFrame": "From initial administration of IMP up to planned discharge from quarantine (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "106.48",
                                                    "spread": "133.187"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "212.51",
                                                    "spread": "170.700"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ],
                            "analyses": [
                                {
                                    "groupIds": [
                                        "OG000",
                                        "OG001"
                                    ],
                                    "nonInferiorityType": "OTHER",
                                    "pValue": "0.0268",
                                    "statisticalMethod": "ANCOVA",
                                    "paramType": "Difference in Least Square Mean",
                                    "paramValue": "-87.40",
                                    "ciPctValue": "95",
                                    "ciNumSides": "TWO_SIDED",
                                    "ciLowerLimit": "-164.30",
                                    "ciUpperLimit": "-10.49",
                                    "estimateComment": "Analysis was performed using ANCOVA with treatment group as a fixed effect and baseline viral load as the covariate."
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Peak Viral Load of RSV Determined by Viral Culture",
                            "description": "Peak viral load of RSV as defined by the maximum viral load determined by viral culture measurements in nasal samples starting from initial administration of IMP up to planned discharge from quarantine was reported in this outcome measure.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEAN",
                            "dispersionType": "Standard Deviation",
                            "unitOfMeasure": "Log10 plaque forming units/mL",
                            "timeFrame": "From initial administration of IMP up to planned discharge from quarantine (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "2.43",
                                                    "spread": "2.030"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "3.63",
                                                    "spread": "2.285"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ],
                            "analyses": [
                                {
                                    "groupIds": [
                                        "OG000",
                                        "OG001"
                                    ],
                                    "nonInferiorityType": "OTHER",
                                    "pValue": "0.0865",
                                    "statisticalMethod": "ANCOVA",
                                    "paramType": "Difference in Least Square Mean",
                                    "paramValue": "-0.99",
                                    "ciPctValue": "95",
                                    "ciNumSides": "TWO_SIDED",
                                    "ciLowerLimit": "-2.13",
                                    "ciUpperLimit": "0.15",
                                    "estimateComment": "Analysis was performed using ANCOVA with treatment group as a fixed effect and baseline viral load as the covariate."
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Time to Confirmed Negative Test by Viral Culture Measurement Starting From at Initial Administration of IMP to First Confirmed Undetectable Assessment After Peak Measure",
                            "description": "Time to confirmed negative test by viral culture measurements in nasal samples from initial administration of IMP up to first confirmed negative viral culture measurement after the peak viral culture measurement was calculated as: Date and time of first confirmed negative test after peak viral culture measurement minus Date and time of first IMP administration. A negative test was defined as two consecutive 'Not Detected' results in the viral culture test. The peak viral culture measurement was defined as the highest viral load value obtained by a participant after their first administration of IMP. Participants who did not have a confirmed undetectable assessment after their peak viral culture measurement after first administration of IMP were censored at their last detectable assessment.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEDIAN",
                            "dispersionType": "Inter-Quartile Range",
                            "unitOfMeasure": "Days",
                            "timeFrame": "From initial administration of IMP up to first confirmed undetectable assessment or censoring date (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "3.2",
                                                    "lowerLimit": "2.5",
                                                    "upperLimit": "3.8"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "5.0",
                                                    "lowerLimit": "3.6",
                                                    "upperLimit": "6.0"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ],
                            "analyses": [
                                {
                                    "groupIds": [
                                        "OG000",
                                        "OG001"
                                    ],
                                    "nonInferiorityType": "OTHER",
                                    "pValue": "0.0008",
                                    "statisticalMethod": "Log Rank"
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Time to Confirmed Negative Test by Viral Culture Measurement Starting From Peak Viral Culture After Initial Administration of IMP to First Confirmed Undetectable Assessment After Peak Measure",
                            "description": "The time from the peak viral culture measurement after administration of IMP to the first confirmed negative viral culture measurement was calculated in days as: Date of and time first confirmed negative test minus Date and time of peak qRT-PCR measurement. A negative test was defined as two consecutive 'Not Detected' results in the viral culture test. The peak viral culture measurement was defined as the highest viral load value obtained by a participant after their first administration of IMP. Participants who did not have a confirmed undetectable assessment after their peak viral culture measurement after first administration of IMP were censored at their last detectable assessment.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEDIAN",
                            "dispersionType": "Inter-Quartile Range",
                            "unitOfMeasure": "Days",
                            "timeFrame": "From peak qRT-PCR measurement to first confirmed undetectable assessment or censoring date (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "1.3",
                                                    "lowerLimit": "0.7",
                                                    "upperLimit": "2.5"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "1.6",
                                                    "lowerLimit": "1.0",
                                                    "upperLimit": "2.0"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ],
                            "analyses": [
                                {
                                    "groupIds": [
                                        "OG000",
                                        "OG001"
                                    ],
                                    "nonInferiorityType": "OTHER",
                                    "pValue": "0.8579",
                                    "statisticalMethod": "Log Rank"
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Area Under the Curve Over Time of Total Clinical Symptoms as Measured From 10 Symptoms Within the Graded Symptom Scoring System",
                            "description": "Area under the Curve over Time of Total Clinical Symptoms (TSS-AUC) as measured from 10 symptoms within Graded Symptom Scoring System Collected 3 Times Daily Starting at Initial Administration up to Planned Discharge from Quarantine. TSS (from 10 items of the 13-item symptom diary card) was used to calculate the AUC, from the assessment nearest to the time of the first administration of IMP until Day 12. Following types of symptoms were recorded on symptom diary cards: Upper Respiratory Tract (URT): runny nose, stuffy nose, sore throat, sneezing, earache; Lower Respiratory Tract (LRT): cough, shortness of breath; Systemic: headache, malaise, muscle/joint ache/stiffness. Each symptom was recorded on a grading scale of 0 to 3 (or 0 to 4 for the Shortness of Breath symptom), higher scores = greater severity of symptoms. Total symptom score was calculated as sum of the 10 observed symptom grade values and ranged from 0 to 31, where higher scores indicated more severe symptoms.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEAN",
                            "dispersionType": "Standard Deviation",
                            "unitOfMeasure": "Hours*score",
                            "timeFrame": "From initial administration of IMP (before or after administration) up to planned discharge from quarantine (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "180.77",
                                                    "spread": "242.274"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "240.94",
                                                    "spread": "224.439"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ],
                            "analyses": [
                                {
                                    "groupIds": [
                                        "OG000",
                                        "OG001"
                                    ],
                                    "nonInferiorityType": "OTHER",
                                    "pValue": "0.0658",
                                    "statisticalMethod": "ANCOVA",
                                    "paramType": "Difference in Least Square Mean",
                                    "paramValue": "-93.95",
                                    "ciPctValue": "95",
                                    "ciNumSides": "TWO_SIDED",
                                    "ciLowerLimit": "-194.26",
                                    "ciUpperLimit": "6.36",
                                    "estimateComment": "Analysis was performed using ANCOVA with treatment group as a fixed effect and baseline viral load as the covariate."
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Area Under the Curve Over Time of Total Clinical Symptoms Change From Baseline (TSS-AUC-CFB) as Measured From 10 Symptoms Within the Graded Symptom Scoring System",
                            "description": "Area under the curve over time of total clinical symptoms change from baseline (TSS-AUC-CFB) as measured from 10 symptoms within the graded symptom scoring system collected 3 times daily starting at initial administration of IMP up to planned discharge from quarantine (Day 12, am). The following types of symptoms were recorded: Upper Respiratory Tract (URT): runny nose, stuffy nose, sore throat, sneezing, earache; Lower Respiratory Tract (LRT): cough, shortness of breath; Systemic: headache, malaise, muscle/joint ache/stiffness. Each symptom was recorded on a grading scale of 0 to 3 (or 0 to 4 for the Shortness of Breath symptom), where higher scores indicated greater severity of symptoms. TSS was calculated as sum of the 10 observed symptom grade values and ranged from 0 to 31, where higher scores indicated more severe symptoms. The AUC calculation was based on the available non-missing calculated total symptom scores between the start and end of the defined AUC time.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEAN",
                            "dispersionType": "Standard Deviation",
                            "unitOfMeasure": "Hours*score",
                            "timeFrame": "Baseline (assessment nearest to the time of the first administration of IMP) up to Day 12",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "-17.23",
                                                    "spread": "202.602"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "103.75",
                                                    "spread": "212.465"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ],
                            "analyses": [
                                {
                                    "groupIds": [
                                        "OG000",
                                        "OG001"
                                    ],
                                    "nonInferiorityType": "OTHER",
                                    "pValue": "0.0658",
                                    "statisticalMethod": "ANCOVA",
                                    "paramType": "Difference in Least Square Mean",
                                    "paramValue": "-93.95",
                                    "ciPctValue": "95",
                                    "ciNumSides": "TWO_SIDED",
                                    "ciLowerLimit": "-194.26",
                                    "ciUpperLimit": "6.36",
                                    "estimateComment": "Analysis was performed using ANCOVA with treatment group as a fixed effect and baseline viral load as the covariate."
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Overall Peak Total Clinical Symptoms (TSS) Score",
                            "description": "Peak total clinical symptoms (TSS) as measured from 10 symptoms within the graded symptom scoring system collected 3 times daily starting from initial administration of IMP up to planned discharge from quarantine. The following types of symptoms were recorded: Upper Respiratory Tract (URT): runny nose, stuffy nose, sore throat, sneezing, earache; Lower Respiratory Tract (LRT): cough, shortness of breath; Systemic: headache, malaise, muscle/joint ache/stiffness. Each symptom was recorded on a grading scale of 0 to 3 (or 0 to 4 for the Shortness of Breath symptom), where higher scores indicated greater severity of symptoms. The total symptom score was calculated as sum of the 10 observed symptom grade values and ranged from 0 to 31, where higher scores indicated more severe symptoms. The overall peak score was defined as the highest scoring symptom diary card observed from the first administration of IMP until quarantine discharge.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEAN",
                            "dispersionType": "Standard Deviation",
                            "unitOfMeasure": "Units on a scale",
                            "timeFrame": "From initial administration of IMP (before or after administration) up to planned discharge from quarantine (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "3.30",
                                                    "spread": "2.835"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "3.90",
                                                    "spread": "3.063"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ],
                            "analyses": [
                                {
                                    "groupIds": [
                                        "OG000",
                                        "OG001"
                                    ],
                                    "nonInferiorityType": "OTHER",
                                    "pValue": "0.2030",
                                    "statisticalMethod": "ANCOVA",
                                    "paramType": "Difference in Least Square Mean",
                                    "paramValue": "-0.93",
                                    "ciPctValue": "95",
                                    "ciNumSides": "TWO_SIDED",
                                    "ciLowerLimit": "-2.38",
                                    "ciUpperLimit": "0.52",
                                    "estimateComment": "Analysis was performed using ANCOVA with treatment group as a fixed effect and baseline viral load as the covariate."
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Individual Maximum Daily Peak Symptom Score",
                            "description": "Individual maximum daily sum of symptom score from initial administration of IMP up to planned discharge from quarantine. The following types of symptoms were recorded: Upper Respiratory Tract (URT): runny nose, stuffy nose, sore throat, sneezing, earache; Lower Respiratory Tract (LRT): cough, shortness of breath; Systemic: headache, malaise, muscle/joint ache/stiffness. Each symptom was recorded on a grading scale of 0 to 3 (or 0 to 4 for the Shortness of Breath symptom), where higher scores indicated greater severity of symptoms. The total symptom score was calculated as sum of the 10 observed symptom grade values and ranged from 0 to 31, where higher scores indicated more severe symptoms. The highest total symptom score recorded on each day, across the three assessments was reported in this outcome measure. The peak daily score was defined as the highest scoring symptom diary card observed on each day from the first administration of IMP until quarantine discharge.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection. Here, 'Number Analyzed' signifies participants evaluable for the specified timepoints.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEAN",
                            "dispersionType": "Standard Deviation",
                            "unitOfMeasure": "Units on a scale",
                            "timeFrame": "Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8 and Day 9 (days relative to first administration of IMP)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "title": "Day 0",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "23"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "29"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "2.1",
                                                    "spread": "2.32"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "1.2",
                                                    "spread": "1.70"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Day 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "23"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "29"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "2.0",
                                                    "spread": "2.70"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "1.8",
                                                    "spread": "2.12"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Day 2",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "23"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "29"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "1.9",
                                                    "spread": "2.73"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "3.0",
                                                    "spread": "3.01"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Day 3",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "23"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "29"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "1.9",
                                                    "spread": "2.83"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "2.6",
                                                    "spread": "2.54"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Day 4",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "23"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "29"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "1.1",
                                                    "spread": "1.71"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "2.1",
                                                    "spread": "2.17"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Day 5",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "23"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "29"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0.7",
                                                    "spread": "1.27"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "1.6",
                                                    "spread": "2.11"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Day 6",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "23"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "29"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0.6",
                                                    "spread": "1.12"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "1.0",
                                                    "spread": "1.86"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Day 7",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "14"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "16"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0.6",
                                                    "spread": "1.16"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "1.1",
                                                    "spread": "1.53"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Day 8",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "5"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "13"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "1.0",
                                                    "spread": "1.22"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0.4",
                                                    "spread": "0.51"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Day 9",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "2"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "2"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0.0",
                                                    "spread": "0.0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0.0",
                                                    "spread": "0.0"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Time to Symptom Resolution Starting at Initial Administration of IMP to 24 Hours Symptom Free",
                            "description": "Symptom resolution was defined as a participant scoring 0 for the total symptom score for a 24-hour period (e.g., a minimum of three consecutive symptom diary cards, each with a score of 0) after their peak symptom score. The time from the assessment at the time of the first administration of IMP until symptom resolution was calculated as: Date and time of symptom resolution minus Date and time of assessment at IMP administration. If the peak symptom score occurred on more than one day then the first occurrence was selected. Participants who did not record 24 hours symptom free after their highest total symptom score during the quarantine period were censored at their last assessment.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection. Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEDIAN",
                            "dispersionType": "Inter-Quartile Range",
                            "unitOfMeasure": "Days",
                            "timeFrame": "From first administration of IMP until time of symptom resolution or censoring date (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "19"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "25"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "3.99",
                                                    "lowerLimit": "1.45",
                                                    "upperLimit": "6.65"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "6.40",
                                                    "lowerLimit": "4.48",
                                                    "upperLimit": "7.99"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Time to Symptom Resolution Starting at Peak Symptoms After Initial Administration to 24 Hours Symptom Free",
                            "description": "Symptom resolution was defined as a participant scoring 0 for the total symptom score for a 24-hour period (e.g., a minimum of three consecutive symptom diary cards, each with a score of 0) after their peak symptom score. The time from the highest total symptom score following administration of IMP until symptom resolution was calculated as: Date and time of symptom resolution minus Date and time of highest total symptom score. If the peak symptom score occurred on more than one day then the first occurrence was selected. Participants who did not record 24 hours symptom free after their highest total symptom score during the quarantine period were censored at their last assessment.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection. Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEDIAN",
                            "dispersionType": "Inter-Quartile Range",
                            "unitOfMeasure": "Days",
                            "timeFrame": "From time of highest total symptom score until time of symptom resolution or censoring date (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "19"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "25"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "1.44",
                                                    "lowerLimit": "0.67",
                                                    "upperLimit": "3.66"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "3.67",
                                                    "lowerLimit": "2.37",
                                                    "upperLimit": "4.64"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Time to Peak Symptom Score From Initial Administration of IMP",
                            "description": "Time to peak as measured from 10 symptoms within the graded daily symptom scoring system starting from initial administration of IMP to the time of peak daily symptom score. If the peak symptom score occurred on more than one day then the first occurrence was selected. Participants were censored at their last assessment if they did not record any symptoms during the quarantine period.",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEDIAN",
                            "dispersionType": "Inter-Quartile Range",
                            "unitOfMeasure": "Days",
                            "timeFrame": "From first dose of IMP until time of highest total symptom score or censoring date (Up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "1.61",
                                                    "lowerLimit": "0.42",
                                                    "upperLimit": "4.63"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "2.74",
                                                    "lowerLimit": "1.99",
                                                    "upperLimit": "3.97"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Total Weight of Mucus Produced Starting at Initial Administration of IMP up to Planned Discharge From Quarantine",
                            "description": "Total weight of nasal mucus was calculated as the sum of mucus weights taken from the assessment at the time of the first administration of IMP (prior to or after dosing, depending on whether dosed in the morning or evening) to morning of Day 12 (Quarantine discharge).",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEAN",
                            "dispersionType": "Standard Deviation",
                            "unitOfMeasure": "Grams",
                            "timeFrame": "From first administration of IMP up to planned discharge from quarantine (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "7.49",
                                                    "spread": "14.516"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "16.23",
                                                    "spread": "21.850"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Total Number of Tissues Used by Participants Starting At Initial Administration of IMP up to Planned Discharge From Quarantine",
                            "description": "Total number of tissues was counted from the assessment at the time of the first dose of IMP (prior to or after dosing, depending on whether dosed in the morning or evening) to morning of Day 12 (Quarantine discharge).",
                            "populationDescription": "ITT-I Population consisted of all randomized participants who received challenge virus and at least 1 dose of IMP and met the criterion for RSV infection.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEAN",
                            "dispersionType": "Standard Deviation",
                            "unitOfMeasure": "Tissues",
                            "timeFrame": "From first administration of IMP up to planned discharge from quarantine (up to Day 12)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "29"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "14.09",
                                                    "spread": "21.067"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "28.17",
                                                    "spread": "33.078"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                            "description": "An adverse event was defined as any untoward medical occurrence in clinical study participants administered a pharmaceutical product. An AE did not necessarily have a causal relationship with the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect or important medical event.",
                            "populationDescription": "Safety analysis population was defined as all randomized participants who received challenge virus and at least 1 dose of IMP.",
                            "reportingStatus": "POSTED",
                            "paramType": "COUNT_OF_PARTICIPANTS",
                            "unitOfMeasure": "Participants",
                            "timeFrame": "From first dose of IMP until end of follow-up visit (up to Day 28)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "39"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "40"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "title": "Adverse Event",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "12"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "12"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Serious Adverse Event",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Number of Participants With AEs Related to Viral Challenge",
                            "description": "An Adverse Event was defined as any untoward medical occurrence in clinical study participants administered a pharmaceutical product. An AE did not necessarily have a causal relationship with the study intervention. Number of participants with AEs possibly, probably or definitely related to viral challenge agents were reported by preferred terms in this outcome measure.",
                            "populationDescription": "Safety analysis population was defined as all randomised participants who received challenge virus and at least 1 dose of IMP.",
                            "reportingStatus": "POSTED",
                            "paramType": "COUNT_OF_PARTICIPANTS",
                            "unitOfMeasure": "Participants",
                            "timeFrame": "From viral challenge on Day 0 up to end of follow-up (Day 28)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "39"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "40"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "title": "Headache (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "2"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Headache (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "1"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Headache (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Ageusia (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "1"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Ageusia (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Ageusia (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Anosmia (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "1"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Anosmia (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Anosmia (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Syncope (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Syncope (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Syncope (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Nausea (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Nausea (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Nausea (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Abdominal distension (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Abdominal distension (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Abdominal distension (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Diarrhoea (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Diarrhoea (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Diarrhoea (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Mouth ulceration (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "1"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Mouth ulceration (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Mouth ulceration (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Malaise (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "2"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Malaise (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Malaise (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Chest discomfort (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Chest discomfort (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Chest discomfort (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Chills (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "1"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Chills (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Chills (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Dyspnoea (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Dyspnoea (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Dyspnoea (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Cough (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "1"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Cough (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Cough (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Electrocardiogram T wave abnormal (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "1"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Electrocardiogram T wave abnormal (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Electrocardiogram T wave abnormal (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Platelet count decreased (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Platelet count decreased (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Platelet count decreased (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Tachycardia (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Tachycardia (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Tachycardia (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Upper respiratory tract infection (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Upper respiratory tract infection (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Upper respiratory tract infection (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Musculoskeletal pain (Possibly Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "1"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Musculoskeletal pain (Probably Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Musculoskeletal pain (Definitely Related)",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Number of Participants With Concomitant Medications",
                            "description": "Number of participants with concomitant medications were reported in this outcome measure.",
                            "populationDescription": "Safety analysis population was defined as all randomized participants who received challenge virus and at least 1 dose of IMP.",
                            "reportingStatus": "POSTED",
                            "paramType": "COUNT_OF_PARTICIPANTS",
                            "unitOfMeasure": "Participants",
                            "timeFrame": "From viral challenge on Day 0 up to end of follow-up (Day 28)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Placebo",
                                    "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "39"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "40"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "17"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "16"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Time to Maximum Plasma Concentration (Tmax) for RV299",
                            "populationDescription": "Pharmacokinetic (PK) population consisted of all participants from ITT population (all randomized participants who received challenge virus and at least 1 dose of IMP) with at least one post-dose PK result.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEDIAN",
                            "dispersionType": "Full Range",
                            "unitOfMeasure": "Hours",
                            "timeFrame": "Pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8,10, 12, 24, 36, 48, 60, 72, 84 and 96-hours post-dose 1 and dose 10",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "39"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "title": "Dose 1",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "2.85",
                                                    "lowerLimit": "0.93",
                                                    "upperLimit": "10.00"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Dose 10",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "2.45",
                                                    "lowerLimit": "0.92",
                                                    "upperLimit": "12.13"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Terminal Half-Life (t1/2) for RV299",
                            "populationDescription": "PK population consisted of all participants from ITT population (all randomized participants who received challenge virus and at least 1 dose of IMP) with at least one post-dose PK result. Here, 'Number Analyzed' signifies participants evaluable for specified timepoints. t1/2 for dose 1 could not be calculated as at least 3 data points were required in terminal elimination phase within same participant; this criteria could not be fulfilled due to insufficient data above limit of quantification.",
                            "reportingStatus": "POSTED",
                            "paramType": "GEOMETRIC_MEAN",
                            "dispersionType": "Geometric Coefficient of Variation",
                            "unitOfMeasure": "Hours",
                            "timeFrame": "Pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8,10, 12, 24, 36, 48, 60, 72, 84 and 96 hours post-dose 1 and dose 10",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "39"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "title": "Dose 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "39"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "NA",
                                                    "spread": "NA",
                                                    "comment": "t1/2 for dose 1 data could not be calculated as the percentage AUC extrapolated was greater than 20% and also due to inadequate characterization of the terminal elimination phase."
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Dose 10",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "37"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "12.1",
                                                    "spread": "6.0"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Maximum Observed Plasma Concentration for RV299",
                            "populationDescription": "PK population consisted of all participants from ITT population (all randomized participants who received challenge virus and at least 1 dose of IMP) with at least one post-dose PK result.",
                            "reportingStatus": "POSTED",
                            "paramType": "GEOMETRIC_MEAN",
                            "dispersionType": "Geometric Coefficient of Variation",
                            "unitOfMeasure": "Nanograms per milliliter",
                            "timeFrame": "Pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8,10, 12, 24, 36, 48, 60, 72, 84 and 96 hours post-dose 1 and dose 10",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "39"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "title": "Dose 1",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "448",
                                                    "spread": "155"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Dose 10",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "1144",
                                                    "spread": "647"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Area Under the Plasma Concentration-Time Curve From Time Zero to the End of the Dosing Interval for RV299",
                            "description": "Area under the plasma concentration-time curve from time zero to the end of the dosing interval for RV299 where dosing interval=12 hours.",
                            "populationDescription": "PK population consisted of all participants from ITT population (all randomized participants who received challenge virus and at least 1 dose of IMP) with at least one post-dose PK result Here, 'Number Analyzed' signifies participants evaluable for the specified timepoints.",
                            "reportingStatus": "POSTED",
                            "paramType": "GEOMETRIC_MEAN",
                            "dispersionType": "Geometric Coefficient of Variation",
                            "unitOfMeasure": "Hours*nanograms per milliliter",
                            "timeFrame": "Pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8,10, 12 hours post-dose 1 and dose 10",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "39"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "title": "Dose 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "38"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "3500",
                                                    "spread": "825"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Dose 10",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "39"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "7845",
                                                    "spread": "3004"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Area Under the Plasma Concentration-Time Curve Over the Last 24 Hours Dosing Interval for RV299",
                            "populationDescription": "PK population consisted of all participants from ITT population (all randomized participants who received challenge virus and at least 1 dose of IMP) with at least one post-dose PK result. Only participants with evaluable results for this PK parameter were reported.",
                            "reportingStatus": "POSTED",
                            "paramType": "GEOMETRIC_MEAN",
                            "dispersionType": "Geometric Coefficient of Variation",
                            "unitOfMeasure": "Hours*nanograms per milliliter",
                            "timeFrame": "Pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8,10, 12, 24 hours post-dose 1 and dose 10",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "39"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "NA",
                                                    "spread": "NA",
                                                    "comment": "AUC24 over the dosing interval could not be computed as the dosing interval was not 24 hours."
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity for RV299 on Day 1",
                            "populationDescription": "PK population consisted of all participants from ITT population (all randomized participants who received challenge virus and at least 1 dose of IMP) with at least one post-dose PK result. AUC(0-infinity) could not be calculated as atleast 3 data points are required in terminal elimination phase within same participant; this criteria could not be fulfilled due to insufficient data above limit of quantification and did not include a characterization of the terminal elimination.",
                            "reportingStatus": "POSTED",
                            "paramType": "GEOMETRIC_MEAN",
                            "dispersionType": "Geometric Coefficient of Variation",
                            "unitOfMeasure": "Hours*nanograms per milliliter",
                            "timeFrame": "Pre-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8,10, 12, 24, 36, 48, 60, 72, 84 and 96 hours post-dose 1",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "RV299",
                                    "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "39"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "NA",
                                                    "spread": "NA",
                                                    "comment": "Data could not be calculated as the percentage AUC extrapolated was greater than 20% and also due to inadequate characterization of the terminal elimination phase."
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                "adverseEventsModule": {
                    "frequencyThreshold": "0",
                    "timeFrame": "From first dose of IMP until end of follow-up visit (up to Day 28) and from viral challenge on Day 0 up to end of follow-up (Day 28)",
                    "eventGroups": [
                        {
                            "id": "EG000",
                            "title": "RV299",
                            "description": "Participants were administered an oral suspension of 65 milligrams (mg) RV299 twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered RV299 from Day 5.",
                            "deathsNumAffected": 0,
                            "deathsNumAtRisk": 39,
                            "seriousNumAffected": 0,
                            "seriousNumAtRisk": 39,
                            "otherNumAffected": 12,
                            "otherNumAtRisk": 39
                        },
                        {
                            "id": "EG001",
                            "title": "Placebo",
                            "description": "Participants were administered an oral suspension of placebo twice daily at an interval of approximately 12 hours for 5 consecutive days from Day 2 following confirmation of RSV infection. Participants without a positive result for RSV infection were administered placebo from Day 5.",
                            "deathsNumAffected": 0,
                            "deathsNumAtRisk": 40,
                            "seriousNumAffected": 0,
                            "seriousNumAtRisk": 40,
                            "otherNumAffected": 12,
                            "otherNumAtRisk": 40
                        }
                    ],
                    "otherEvents": [
                        {
                            "term": "Headache",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Dizziness",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Ageusia",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Anosmia",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Syncope",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Vessel puncture site bruise",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Chills",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Malaise",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Vessel puncture site haematoma",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Upper respiratory tract infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Urinary tract infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Nausea",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Diarrhoea",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Mouth ulceration",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Blood potassium increased",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Electrocardiogram T wave abnormal",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Platelet count decreased",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Back pain",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Musculoskeletal pain",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Cough",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Dyspnoea",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Eczema",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Rash",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Bundle branch block",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 40
                                }
                            ]
                        },
                        {
                            "term": "Dysmenorrhoea",
                            "organSystem": "Reproductive system and breast disorders",
                            "sourceVocabulary": "MedDRA version 25.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 39
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 40
                                }
                            ]
                        }
                    ]
                },
                "moreInfoModule": {
                    "certainAgreement": {
                        "piSponsorEmployee": false,
                        "restrictionType": "OTHER",
                        "restrictiveAgreement": true,
                        "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."
                    },
                    "pointOfContact": {
                        "title": "Pfizer ClinicalTrials.gov Call Center",
                        "organization": "Pfizer Inc.",
                        "email": "ClinicalTrials.gov_Inquiries@pfizer.com",
                        "phone": "1-800-718-1021"
                    }
                }
            },
            "documentSection": {
                "largeDocumentModule": {
                    "largeDocs": [
                        {
                            "typeAbbrev": "Prot",
                            "hasProtocol": true,
                            "hasSap": false,
                            "hasIcf": false,
                            "label": "Study Protocol",
                            "date": "2022-10-31",
                            "uploadDate": "2023-11-30T08:08",
                            "filename": "Prot_000.pdf",
                            "size": 1346327
                        },
                        {
                            "typeAbbrev": "SAP",
                            "hasProtocol": false,
                            "hasSap": true,
                            "hasIcf": false,
                            "label": "Statistical Analysis Plan",
                            "date": "2022-12-20",
                            "uploadDate": "2023-11-30T08:08",
                            "filename": "SAP_001.pdf",
                            "size": 1230169
                        }
                    ]
                }
            },
            "derivedSection": {
                "miscInfoModule": {
                    "versionHolder": "2024-11-18"
                },
                "conditionBrowseModule": {
                    "meshes": [
                        {
                            "id": "D014777",
                            "term": "Virus Diseases"
                        }
                    ],
                    "ancestors": [
                        {
                            "id": "D007239",
                            "term": "Infections"
                        }
                    ],
                    "browseLeaves": [
                        {
                            "id": "M17522",
                            "name": "Virus Diseases",
                            "asFound": "Virus",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M10283",
                            "name": "Infections",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M6368",
                            "name": "Communicable Diseases",
                            "relevance": "LOW"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "BC01",
                            "name": "Infections"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Conditions"
                        },
                        {
                            "abbrev": "BC23",
                            "name": "Symptoms and General Pathology"
                        }
                    ]
                },
                "interventionBrowseModule": {
                    "browseLeaves": [
                        {
                            "id": "M4314",
                            "name": "Antiviral Agents",
                            "relevance": "LOW"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "Infe",
                            "name": "Anti-Infective Agents"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Drugs and Chemicals"
                        }
                    ]
                }
            },
            "hasResults": true
        },
        {
            "protocolSection": {
                "identificationModule": {
                    "nctId": "NCT02252172",
                    "orgStudyIdInfo": {
                        "id": "CR104762"
                    },
                    "secondaryIdInfos": [
                        {
                            "id": "54767414MMY3008",
                            "type": "OTHER",
                            "domain": "Janssen Research & Development, LLC"
                        },
                        {
                            "id": "2014-002273-11",
                            "type": "EUDRACT_NUMBER"
                        }
                    ],
                    "organization": {
                        "fullName": "Janssen Research & Development, LLC",
                        "class": "INDUSTRY"
                    },
                    "briefTitle": "Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",
                    "officialTitle": "A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy"
                },
                "statusModule": {
                    "statusVerifiedDate": "2024-10",
                    "overallStatus": "ACTIVE_NOT_RECRUITING",
                    "expandedAccessInfo": {
                        "hasExpandedAccess": false
                    },
                    "startDateStruct": {
                        "date": "2015-02",
                        "type": "ACTUAL"
                    },
                    "primaryCompletionDateStruct": {
                        "date": "2018-09",
                        "type": "ACTUAL"
                    },
                    "completionDateStruct": {
                        "date": "2024-10",
                        "type": "ESTIMATED"
                    },
                    "studyFirstSubmitDate": "2014-08-11",
                    "studyFirstSubmitQcDate": "2014-09-25",
                    "studyFirstPostDateStruct": {
                        "date": "2014-09-30",
                        "type": "ESTIMATED"
                    },
                    "resultsFirstSubmitDate": "2019-09-24",
                    "resultsFirstSubmitQcDate": "2019-12-20",
                    "resultsFirstPostDateStruct": {
                        "date": "2020-01-09",
                        "type": "ACTUAL"
                    },
                    "lastUpdateSubmitDate": "2024-10-08",
                    "lastUpdatePostDateStruct": {
                        "date": "2024-10-21",
                        "type": "ACTUAL"
                    }
                },
                "sponsorCollaboratorsModule": {
                    "responsibleParty": {
                        "type": "SPONSOR"
                    },
                    "leadSponsor": {
                        "name": "Janssen Research & Development, LLC",
                        "class": "INDUSTRY"
                    }
                },
                "oversightModule": {
                    "oversightHasDmc": true,
                    "isFdaRegulatedDrug": true,
                    "isFdaRegulatedDevice": false
                },
                "descriptionModule": {
                    "briefSummary": "The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not candidates for high dose chemotherapy (treatment of disease, usually cancer, by chemical agents) and autologous stem cell transplant (ASCT).",
                    "detailedDescription": "This is a Phase 3, randomized (study drug assigned by chance), open-label (participants and researchers are aware about the treatment, participants are receiving), active-controlled (study in which the experimental treatment or procedure is compared to a standard treatment or procedure), parallel-group (each group of participants will be treated at the same time), and multicenter (when more than one hospital or medical school team work on a medical research study) study in participants with newly diagnosed multiple myeloma and who are not candidates for high dose chemotherapy and ASCT. All the eligible participants will be randomly assigned to receive either lenalidomide and dexamethasone (Rd) (Arm A) or daratumumab in combination with lenalidomide and dexamethasone (DRd) (Arm B). Daratumumab (16 milligram per kilogram \\[mg/kg\\]) will be administered weekly for first 8 weeks (Cycles 1 to 2) of treatment and then every other week for 16 weeks (Cycles 3 to 6), then every 4 weeks (from Cycle 7 and beyond) until progression of disease or unacceptable toxicity. Lenalidomide will be administered at a dose of 25 mg orally on Days 1 through 21 of each 28-day cycle, and dexamethasone will be administered at a dose of 40 mg once a week for both treatment arms. Participants in both treatment arms will continue lenalidomide and dexamethasone until disease progression or unacceptable toxicity. All participants randomized to Treatment Arm B (DRd) in this study initially received daratumumab IV formulation; however, following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Participants in Arm A who have sponsor-confirmed disease progression may have the option to receive daratumumab provided by the sponsor (in any subsequent line of therapy) in the Follow-up phase. The study consists of 3 phases: Screening Phase (within 21 days prior to the first dose administration on Day 1), Treatment Phase (Day 1 up to discontinuation of all study treatment), and Follow-up Phase (from discontinuation of all study treatment up to death, lost to follow up, consent withdrawal, or study end, whichever occurs first). The maximum duration of study will be 7 years after last participant is randomized. Efficacy will primarily be evaluated by PFS. Participants' safety will be monitored throughout the study."
                },
                "conditionsModule": {
                    "conditions": [
                        "Multiple Myeloma"
                    ],
                    "keywords": [
                        "Multiple Myeloma",
                        "Daratumumab",
                        "JNJ-54767414",
                        "Lenalidomide",
                        "Dexamethasone"
                    ]
                },
                "designModule": {
                    "studyType": "INTERVENTIONAL",
                    "phases": [
                        "PHASE3"
                    ],
                    "designInfo": {
                        "allocation": "RANDOMIZED",
                        "interventionModel": "PARALLEL",
                        "primaryPurpose": "TREATMENT",
                        "maskingInfo": {
                            "masking": "NONE"
                        }
                    },
                    "enrollmentInfo": {
                        "count": 737,
                        "type": "ACTUAL"
                    }
                },
                "armsInterventionsModule": {
                    "armGroups": [
                        {
                            "label": "Lenalidomide and Dexamethasone (Rd)",
                            "type": "ACTIVE_COMPARATOR",
                            "description": "Participants will receive Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.",
                            "interventionNames": [
                                "Drug: Daratumumab IV",
                                "Drug: Lenalidomide",
                                "Drug: Dexamethasone"
                            ]
                        },
                        {
                            "label": "Daratumumab + Lenalidomide + Dexamethasone (DRd)",
                            "type": "ACTIVE_COMPARATOR",
                            "description": "Participants will receive Daratumumab 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks, Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.",
                            "interventionNames": [
                                "Drug: Lenalidomide",
                                "Drug: Dexamethasone",
                                "Drug: Daratumumab SC"
                            ]
                        }
                    ],
                    "interventions": [
                        {
                            "type": "DRUG",
                            "name": "Daratumumab IV",
                            "description": "Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).",
                            "armGroupLabels": [
                                "Lenalidomide and Dexamethasone (Rd)"
                            ],
                            "otherNames": [
                                "JNJ-54767414"
                            ]
                        },
                        {
                            "type": "DRUG",
                            "name": "Lenalidomide",
                            "description": "Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.",
                            "armGroupLabels": [
                                "Daratumumab + Lenalidomide + Dexamethasone (DRd)",
                                "Lenalidomide and Dexamethasone (Rd)"
                            ]
                        },
                        {
                            "type": "DRUG",
                            "name": "Dexamethasone",
                            "description": "Dexamethasone 40 mg orally or intravenously once in a week.",
                            "armGroupLabels": [
                                "Daratumumab + Lenalidomide + Dexamethasone (DRd)",
                                "Lenalidomide and Dexamethasone (Rd)"
                            ]
                        },
                        {
                            "type": "DRUG",
                            "name": "Daratumumab SC",
                            "description": "Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study end. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator.",
                            "armGroupLabels": [
                                "Daratumumab + Lenalidomide + Dexamethasone (DRd)"
                            ],
                            "otherNames": [
                                "JNJ-54767414"
                            ]
                        }
                    ]
                },
                "outcomesModule": {
                    "primaryOutcomes": [
                        {
                            "measure": "Primary: Progression-free Survival (PFS)",
                            "description": "PFS is defined as time from date of randomization to either progressive disease (PD) or death, whichever occurs first based on computerized algorithm as per International Myeloma Working Group (IMWG) criteria. PD is defined as an increase of 25 percent (%) from the lowest response value in one of the following: serum and urine M-component (absolute increase must be greater than or equal to \\[\\>=\\] 0.5 gram per deciliter \\[g/dL\\] and \\>=200 milligram \\[mg\\]/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \\[\\>\\]10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \\>11.5 mg/dL) that can be attributed solely to Plasma cell (PC) proliferative disorder.",
                            "timeFrame": "From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years)"
                        }
                    ],
                    "secondaryOutcomes": [
                        {
                            "measure": "Percentage of Participants With Complete Response (CR) or Better",
                            "description": "CR or better is defined as percentage of participants with a CR or better (CR or stringent complete response \\[sCR\\]) based on computerized algorithm as per IMWG criteria. CR is defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and less than (\\<) 5 percent (%) PCs in bone marrow. In participants with only measurable disease by serum FLC levels a normal serum FLC ratio is required. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.",
                            "timeFrame": "From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)"
                        },
                        {
                            "measure": "Percentage of Participants With Very Good Partial Response (VGPR) or Better",
                            "description": "VGPR or better is defined as the percentage of participants with a response of VGPR or better (VGPR, CR or sCR) based on computerized algorithm as per IMWG criteria. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis or \\>=90% reduction in serum M-protein plus urine M-protein \\<100 mg/24 hours. In participants with only measurable disease by serum FLC levels a \\>90% decrease in the difference between involved and uninvolved FLC levels is required.",
                            "timeFrame": "From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)"
                        },
                        {
                            "measure": "Percentage of Participants With Negative Minimal Residual Disease (MRD)",
                            "description": "MRD negativity rate is defined as the percentage of participants who had negative MRD (detection of less than 1 malignant cell among 100,000 normal cells) assessment at any timepoint after the date of randomization by evaluation of bone marrow aspirates. MRD was assessed in participants who achieved CR or better.",
                            "timeFrame": "From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)"
                        },
                        {
                            "measure": "Overall Response Rate (ORR)",
                            "description": "ORR is defined as the percentage of participants who achieved partial response (PR) or better (PR, VGPR, CR or sCR) based on computerized algorithm as per IMWG criteria. PR is defined as \\>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to \\<200 mg/24 hours. If the serum and urine M-protein are not measurable, a decrease of \\>=50% in the difference between involved and uninvolved FLC levels is required. A \\>=50% reduction in the size of soft tissue plasmacytomas is also required.",
                            "timeFrame": "From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)"
                        },
                        {
                            "measure": "Overall Survival (OS)",
                            "description": "OS was measured from the date of randomization to the date of the death.",
                            "timeFrame": "From randomization to death, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)"
                        },
                        {
                            "measure": "Time to Disease Progression (TTP)",
                            "description": "TTP is defined as the time from the date of randomization to the date of PD based on computerized algorithm as per IMWG criteria, or death due to PD.",
                            "timeFrame": "From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)"
                        },
                        {
                            "measure": "Time to Response",
                            "description": "Time to response is defined as the time from the date of randomization to the first efficacy evaluation that met criteria for PR or better based on computerized algorithm as per IMWG criteria. PR: \\>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to \\<200 mg/24 hours. If the serum and urine M-protein are not measurable, a decrease of \\>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria; If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \\>=50% reduction in bone marrow PCs is required. A \\>=50% reduction in the size of soft tissue plasmacytomas is also required.",
                            "timeFrame": "From randomization to first response (PR or better) (up to 7.8 years)"
                        },
                        {
                            "measure": "Duration of Response (DoR)",
                            "description": "DoR is defined as the time from the date of initial response (PR or better) to the date of PD, based on computerized algorithm as per IMWG criteria.",
                            "timeFrame": "From first response (PR of better) to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)"
                        },
                        {
                            "measure": "Time to Subsequent Anti-myeloma Treatment",
                            "description": "Time to subsequent anti-myeloma treatment is defined as the time from randomization to the start of first line of subsequent anti-myeloma treatment or death, whichever occurs first.",
                            "timeFrame": "From randomization to start of first subsequent anti-myeloma treatment, death, withdrawal of consent to study participation or CCO whichever is first (up to 7.8 years)"
                        },
                        {
                            "measure": "Progression-free Survival on Next Line of Therapy (PFS2)",
                            "description": "PFS2 is defined as the time from randomization to progression on the first line of subsequent anti-myeloma therapy or death, whichever occurs first. Disease progression on first line of subsequent anti-myeloma treatment was based on investigator judgment. Participants that were censored for PFS1 were also censored for PFS2.",
                            "timeFrame": "From randomization to disease progression on first line of subsequent anti-myeloma therapy, death, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)"
                        },
                        {
                            "measure": "Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 Global Health Status Score to Day 1 of Cycle 3, 6, 9 and 12",
                            "description": "EORTC QLQ-C30 is 30 items self-reporting questionnaire, with 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Questionnaire includes 28 items with 4-point Likert type responses from \"1-not at all\" to \"4-very much\" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall health related QoL. Scores are transformed to 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms. Negative change from baseline values shows deterioration in quality of life or functioning and reduction in symptom and positive values indicate improvement and worsening of symptoms.",
                            "timeFrame": "Baseline and Day 1 of Cycle 3, 6, 9 and 12 (each Cycle of 28 days)"
                        },
                        {
                            "measure": "Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) to Day 1 of Cycle 3, 6, 9 and 12",
                            "description": "EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.",
                            "timeFrame": "Baseline and Day 1 of Cycle 3, 6, 9 and 12 (each Cycle of 28 days)"
                        },
                        {
                            "measure": "Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Utility Score to Day 1 of Cycle 3, 6, 9 and 12",
                            "description": "EQ-5D-5L is standardized, participant-reported questionnaire to assess health-related quality of life. EQ-5D-5L includes 2 components: EQ-5D-5L health state profile (descriptive system) and EQ-5D-5L VAS. EQ-5D-5L descriptive system provides a profile of participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. Responses to the 5-dimension scores were combined and converted into single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of individual (but allows for values less than 0 by United kingdom \\[UK\\] scoring algorithm).",
                            "timeFrame": "Baseline and Day 1 of Cycle 3, 6, 9 and 12 (each Cycle of 28 days)"
                        }
                    ]
                },
                "eligibilityModule": {
                    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must have documented multiple myeloma satisfying the CRAB (calcium elevation, renal insufficiency, anemia and bone abnormalities) criteria, monoclonal plasma cells in the bone marrow greater than or equal to (\\>=) 10 percent (%) or presence of a biopsy proven plasmacytoma and measurable disease as defined by any of the following: (a) immunoglobulin (Ig) G myeloma (serum monoclonal paraprotein \\[M-protein\\] level \\>=1.0 gram/deciliter \\[g/dL\\] or urine M-protein level \\>=200 milligram\\[mg\\]/24 hours\\[hrs\\]; or (b) IgA, IgM, IgD, or IgE multiple myeloma (serum M-protein level \\>=0.5 g/dL or urine M-protein level \\>=200 mg/24 hrs); or (c) light chain multiple myeloma without measurable disease in serum or urine (serum immunoglobulin free light chain \\>=10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio)\n* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2\n* Participants who are newly diagnosed and not considered for high-dose chemotherapy due to: being age \\>=65 years; or participants less than (\\<) 65 years with presence of important comorbid condition(s) likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation. Sponsor review and approval of participants below 65 years of age is required before randomization\n* Women of childbearing potential must commit to either abstain continuously from sexual intercourse or to use 2 methods of reliable birth control simultaneously as deemed appropriate by the Investigator. Contraception must begin 4 weeks prior to dosing and must continue for 3 months after the last dose of daratumumab\n* Man, who is sexually active with a woman of child-bearing potential must agree to use a latex or synthetic condom, even if he had a successful vasectomy, must agree to use an adequate contraception method as deemed appropriate by the Investigator, and must also agree to not donate sperm during the study and for 4 weeks after last dose of lenalidomide and 4 months after last dose of daratumumab\n\nExclusion Criteria:\n\n* Participant has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance (presence of serum M-protein \\<3 g/dL; absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the M-protein), or smoldering multiple myeloma (asymptomatic multiple myeloma with absence of related organ or tissue impairment end organ damage)\n* Participant has a diagnosis of Waldenstr\u00f6m's disease, or other conditions in which IgM M protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions\n* Participant has a history of malignancy (other than multiple myeloma) within 5 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence with the Sponsor's medical monitor, is considered cured with minimal risk of recurrence within 5 years)\n* Participant has prior or current systemic therapy or SCT for multiple myeloma, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for 4 days) of corticosteroids before treatment\n* Participant has had radiation therapy within 14 days of randomization\n* Participant has known chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume in 1 second \\[FEV1\\] \\<50% of predicted normal), persistent asthma, or a history of asthma within the last 2 years (controlled intermittent asthma or controlled mild persistent asthma is allowed)\n* Participants with known or suspected COPD must have a FEV1 test during Screening\n* Participant is known to be seropositive for human immunodeficiency virus (HIV) or hepatitis B (defined by a positive test for hepatitis B surface antigen \\[HBsAg\\] or antibodies to hepatitis B surface and core antigens \\[anti-HBs and anti-HBc, respectively\\]) or hepatitis C (anti-HCV antibody positive or HCV-ribonucleic acid \\[RNA\\] quantitation positive)",
                    "healthyVolunteers": false,
                    "sex": "ALL",
                    "minimumAge": "18 Years",
                    "stdAges": [
                        "ADULT",
                        "OLDER_ADULT"
                    ]
                },
                "contactsLocationsModule": {
                    "overallOfficials": [
                        {
                            "name": "Janssen Research & Development, LLC Clinical Trial",
                            "affiliation": "Janssen Research & Development, LLC",
                            "role": "STUDY_DIRECTOR"
                        }
                    ],
                    "locations": [
                        {
                            "city": "Birmingham",
                            "state": "Alabama",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 33.52066,
                                "lon": -86.80249
                            }
                        },
                        {
                            "city": "Mobile",
                            "state": "Alabama",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 30.69436,
                                "lon": -88.04305
                            }
                        },
                        {
                            "city": "Glendale",
                            "state": "Arizona",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 33.53865,
                                "lon": -112.18599
                            }
                        },
                        {
                            "city": "Berkeley",
                            "state": "California",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 37.87159,
                                "lon": -122.27275
                            }
                        },
                        {
                            "city": "Beverly Hills",
                            "state": "California",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 34.07362,
                                "lon": -118.40036
                            }
                        },
                        {
                            "city": "El Cajon",
                            "state": "California",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 32.79477,
                                "lon": -116.96253
                            }
                        },
                        {
                            "city": "Greenbrae",
                            "state": "California",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 37.94854,
                                "lon": -122.5247
                            }
                        },
                        {
                            "city": "Los Angeles",
                            "state": "California",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 34.05223,
                                "lon": -118.24368
                            }
                        },
                        {
                            "city": "Oceanside",
                            "state": "California",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 33.19587,
                                "lon": -117.37948
                            }
                        },
                        {
                            "city": "San Diego",
                            "state": "California",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 32.71533,
                                "lon": -117.15726
                            }
                        },
                        {
                            "city": "West Hills",
                            "state": "California",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 34.19731,
                                "lon": -118.64398
                            }
                        },
                        {
                            "city": "Whittier",
                            "state": "California",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 33.97918,
                                "lon": -118.03284
                            }
                        },
                        {
                            "city": "Denver",
                            "state": "Colorado",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 39.73915,
                                "lon": -104.9847
                            }
                        },
                        {
                            "city": "Fort Collins",
                            "state": "Colorado",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 40.58526,
                                "lon": -105.08442
                            }
                        },
                        {
                            "city": "Glenwood Springs",
                            "state": "Colorado",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 39.55054,
                                "lon": -107.32478
                            }
                        },
                        {
                            "city": "New Haven",
                            "state": "Connecticut",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 41.30815,
                                "lon": -72.92816
                            }
                        },
                        {
                            "city": "Norwalk",
                            "state": "Connecticut",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 41.1176,
                                "lon": -73.4079
                            }
                        },
                        {
                            "city": "Washington",
                            "state": "District of Columbia",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 38.89511,
                                "lon": -77.03637
                            }
                        },
                        {
                            "city": "Boca Raton",
                            "state": "Florida",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 26.3669,
                                "lon": -80.13033
                            }
                        },
                        {
                            "city": "Boynton Beach",
                            "state": "Florida",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 26.52535,
                                "lon": -80.06643
                            }
                        },
                        {
                            "city": "Fort Lauderdale",
                            "state": "Florida",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 26.12231,
                                "lon": -80.14338
                            }
                        },
                        {
                            "city": "Fort Myers",
                            "state": "Florida",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 26.62168,
                                "lon": -81.84059
                            }
                        },
                        {
                            "city": "Hollywood",
                            "state": "Florida",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 26.0112,
                                "lon": -80.14949
                            }
                        },
                        {
                            "city": "Jacksonville",
                            "state": "Florida",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 30.33218,
                                "lon": -81.65565
                            }
                        },
                        {
                            "city": "Lake City",
                            "state": "Florida",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 30.18968,
                                "lon": -82.63929
                            }
                        },
                        {
                            "city": "Saint Petersburg",
                            "state": "Florida",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 27.77086,
                                "lon": -82.67927
                            }
                        },
                        {
                            "city": "Weston",
                            "state": "Florida",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 26.10037,
                                "lon": -80.39977
                            }
                        },
                        {
                            "city": "Atlanta",
                            "state": "Georgia",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 33.749,
                                "lon": -84.38798
                            }
                        },
                        {
                            "city": "Augusta",
                            "state": "Georgia",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 33.47097,
                                "lon": -81.97484
                            }
                        },
                        {
                            "city": "Macon",
                            "state": "Georgia",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 32.84069,
                                "lon": -83.6324
                            }
                        },
                        {
                            "city": "Marietta",
                            "state": "Georgia",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 33.9526,
                                "lon": -84.54993
                            }
                        },
                        {
                            "city": "Chicago",
                            "state": "Illinois",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 41.85003,
                                "lon": -87.65005
                            }
                        },
                        {
                            "city": "Niles",
                            "state": "Illinois",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 42.01892,
                                "lon": -87.80284
                            }
                        },
                        {
                            "city": "Fort Wayne",
                            "state": "Indiana",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 41.1306,
                                "lon": -85.12886
                            }
                        },
                        {
                            "city": "Iowa City",
                            "state": "Iowa",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 41.66113,
                                "lon": -91.53017
                            }
                        },
                        {
                            "city": "Louisville",
                            "state": "Kentucky",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 38.25424,
                                "lon": -85.75941
                            }
                        },
                        {
                            "city": "Lafayette",
                            "state": "Louisiana",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 30.22409,
                                "lon": -92.01984
                            }
                        },
                        {
                            "city": "Marrero",
                            "state": "Louisiana",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 29.89937,
                                "lon": -90.10035
                            }
                        },
                        {
                            "city": "Shreveport",
                            "state": "Louisiana",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 32.52515,
                                "lon": -93.75018
                            }
                        },
                        {
                            "city": "Annapolis",
                            "state": "Maryland",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 38.97845,
                                "lon": -76.49218
                            }
                        },
                        {
                            "city": "Baltimore",
                            "state": "Maryland",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 39.29038,
                                "lon": -76.61219
                            }
                        },
                        {
                            "city": "Frederick",
                            "state": "Maryland",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 39.41427,
                                "lon": -77.41054
                            }
                        },
                        {
                            "city": "Boston",
                            "state": "Massachusetts",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 42.35843,
                                "lon": -71.05977
                            }
                        },
                        {
                            "city": "Detroit",
                            "state": "Michigan",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 42.33143,
                                "lon": -83.04575
                            }
                        },
                        {
                            "city": "Duluth",
                            "state": "Minnesota",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 46.78327,
                                "lon": -92.10658
                            }
                        },
                        {
                            "city": "Rochester",
                            "state": "Minnesota",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 44.02163,
                                "lon": -92.4699
                            }
                        },
                        {
                            "city": "Kansas City",
                            "state": "Missouri",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 39.09973,
                                "lon": -94.57857
                            }
                        },
                        {
                            "city": "Saint Louis",
                            "state": "Missouri",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 38.62727,
                                "lon": -90.19789
                            }
                        },
                        {
                            "city": "Omaha",
                            "state": "Nebraska",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 41.25626,
                                "lon": -95.94043
                            }
                        },
                        {
                            "city": "Hooksett",
                            "state": "New Hampshire",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 43.09675,
                                "lon": -71.46507
                            }
                        },
                        {
                            "city": "Brick",
                            "state": "New Jersey",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 40.05928,
                                "lon": -74.13708
                            }
                        },
                        {
                            "city": "Hackensack",
                            "state": "New Jersey",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 40.88593,
                                "lon": -74.04347
                            }
                        },
                        {
                            "city": "Livingston",
                            "state": "New Jersey",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 40.79593,
                                "lon": -74.31487
                            }
                        },
                        {
                            "city": "Plainfield",
                            "state": "New Jersey",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 40.63371,
                                "lon": -74.40737
                            }
                        },
                        {
                            "city": "Somerville",
                            "state": "New Jersey",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 40.57427,
                                "lon": -74.60988
                            }
                        },
                        {
                            "city": "Summit",
                            "state": "New Jersey",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 40.71562,
                                "lon": -74.36468
                            }
                        },
                        {
                            "city": "Mineola",
                            "state": "New York",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 40.74927,
                                "lon": -73.64068
                            }
                        },
                        {
                            "city": "New York",
                            "state": "New York",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 40.71427,
                                "lon": -74.00597
                            }
                        },
                        {
                            "city": "Rochester",
                            "state": "New York",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 43.15478,
                                "lon": -77.61556
                            }
                        },
                        {
                            "city": "Asheboro",
                            "state": "North Carolina",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 35.70791,
                                "lon": -79.81364
                            }
                        },
                        {
                            "city": "Charlotte",
                            "state": "North Carolina",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 35.22709,
                                "lon": -80.84313
                            }
                        },
                        {
                            "city": "Pinehurst",
                            "state": "North Carolina",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 35.19543,
                                "lon": -79.46948
                            }
                        },
                        {
                            "city": "Winston-Salem",
                            "state": "North Carolina",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 36.09986,
                                "lon": -80.24422
                            }
                        },
                        {
                            "city": "Canton",
                            "state": "Ohio",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 40.79895,
                                "lon": -81.37845
                            }
                        },
                        {
                            "city": "Cleveland",
                            "state": "Ohio",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 41.4995,
                                "lon": -81.69541
                            }
                        },
                        {
                            "city": "Columbus",
                            "state": "Ohio",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 39.96118,
                                "lon": -82.99879
                            }
                        },
                        {
                            "city": "Bend",
                            "state": "Oregon",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 44.05817,
                                "lon": -121.31531
                            }
                        },
                        {
                            "city": "Bethlehem",
                            "state": "Pennsylvania",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 40.62593,
                                "lon": -75.37046
                            }
                        },
                        {
                            "city": "Pittsburgh",
                            "state": "Pennsylvania",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 40.44062,
                                "lon": -79.99589
                            }
                        },
                        {
                            "city": "Spartanburg",
                            "state": "South Carolina",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 34.94957,
                                "lon": -81.93205
                            }
                        },
                        {
                            "city": "Sioux Falls",
                            "state": "South Dakota",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 43.54997,
                                "lon": -96.70033
                            }
                        },
                        {
                            "city": "Chattanooga",
                            "state": "Tennessee",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 35.04563,
                                "lon": -85.30968
                            }
                        },
                        {
                            "city": "Nashville",
                            "state": "Tennessee",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 36.16589,
                                "lon": -86.78444
                            }
                        },
                        {
                            "city": "Arlington",
                            "state": "Texas",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 32.73569,
                                "lon": -97.10807
                            }
                        },
                        {
                            "city": "Edinburg",
                            "state": "Texas",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 26.30174,
                                "lon": -98.16334
                            }
                        },
                        {
                            "city": "Fort Sam Houston",
                            "state": "Texas",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 29.45746,
                                "lon": -98.4472
                            }
                        },
                        {
                            "city": "Fort Worth",
                            "state": "Texas",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 32.72541,
                                "lon": -97.32085
                            }
                        },
                        {
                            "city": "Houston",
                            "state": "Texas",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 29.76328,
                                "lon": -95.36327
                            }
                        },
                        {
                            "city": "Plano",
                            "state": "Texas",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 33.01984,
                                "lon": -96.69889
                            }
                        },
                        {
                            "city": "San Antonio",
                            "state": "Texas",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 29.42412,
                                "lon": -98.49363
                            }
                        },
                        {
                            "city": "Ogden",
                            "state": "Utah",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 41.223,
                                "lon": -111.97383
                            }
                        },
                        {
                            "city": "Seattle",
                            "state": "Washington",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 47.60621,
                                "lon": -122.33207
                            }
                        },
                        {
                            "city": "Spokane",
                            "state": "Washington",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 47.65966,
                                "lon": -117.42908
                            }
                        },
                        {
                            "city": "Tacoma",
                            "state": "Washington",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 47.25288,
                                "lon": -122.44429
                            }
                        },
                        {
                            "city": "Box Hill",
                            "country": "Australia",
                            "geoPoint": {
                                "lat": -37.81887,
                                "lon": 145.12545
                            }
                        },
                        {
                            "city": "Fitzroy",
                            "country": "Australia",
                            "geoPoint": {
                                "lat": -37.79839,
                                "lon": 144.97833
                            }
                        },
                        {
                            "city": "Footscray",
                            "country": "Australia",
                            "geoPoint": {
                                "lat": -37.8,
                                "lon": 144.9
                            }
                        },
                        {
                            "city": "Kogarah",
                            "country": "Australia",
                            "geoPoint": {
                                "lat": -33.98333,
                                "lon": 151.11667
                            }
                        },
                        {
                            "city": "Kurralta Park",
                            "country": "Australia",
                            "geoPoint": {
                                "lat": -34.95142,
                                "lon": 138.56702
                            }
                        },
                        {
                            "city": "Nedlands",
                            "country": "Australia",
                            "geoPoint": {
                                "lat": -31.98184,
                                "lon": 115.8073
                            }
                        },
                        {
                            "city": "New South Wales",
                            "country": "Australia"
                        },
                        {
                            "city": "Woodville",
                            "country": "Australia",
                            "geoPoint": {
                                "lat": -34.88333,
                                "lon": 138.55
                            }
                        },
                        {
                            "city": "Woolloongabba N/a",
                            "country": "Australia"
                        },
                        {
                            "city": "Innsbruck",
                            "country": "Austria",
                            "geoPoint": {
                                "lat": 47.26266,
                                "lon": 11.39454
                            }
                        },
                        {
                            "city": "Linz",
                            "country": "Austria",
                            "geoPoint": {
                                "lat": 48.30639,
                                "lon": 14.28611
                            }
                        },
                        {
                            "city": "Salzburg",
                            "country": "Austria",
                            "geoPoint": {
                                "lat": 47.79941,
                                "lon": 13.04399
                            }
                        },
                        {
                            "city": "Wien N/a",
                            "country": "Austria",
                            "geoPoint": {
                                "lat": 48.20849,
                                "lon": 16.37208
                            }
                        },
                        {
                            "city": "Wien Wien",
                            "country": "Austria",
                            "geoPoint": {
                                "lat": 48.20849,
                                "lon": 16.37208
                            }
                        },
                        {
                            "city": "Brugge",
                            "country": "Belgium",
                            "geoPoint": {
                                "lat": 51.20892,
                                "lon": 3.22424
                            }
                        },
                        {
                            "city": "Brussels",
                            "country": "Belgium",
                            "geoPoint": {
                                "lat": 50.85045,
                                "lon": 4.34878
                            }
                        },
                        {
                            "city": "Brussel",
                            "country": "Belgium",
                            "geoPoint": {
                                "lat": 50.85045,
                                "lon": 4.34878
                            }
                        },
                        {
                            "city": "Haine Saint Paul La Louviere",
                            "country": "Belgium"
                        },
                        {
                            "city": "Leuven",
                            "country": "Belgium",
                            "geoPoint": {
                                "lat": 50.87959,
                                "lon": 4.70093
                            }
                        },
                        {
                            "city": "Liege",
                            "country": "Belgium",
                            "geoPoint": {
                                "lat": 50.63373,
                                "lon": 5.56749
                            }
                        },
                        {
                            "city": "Calgary",
                            "state": "Alberta",
                            "country": "Canada",
                            "geoPoint": {
                                "lat": 51.05011,
                                "lon": -114.08529
                            }
                        },
                        {
                            "city": "Toronto",
                            "state": "Ontario",
                            "country": "Canada",
                            "geoPoint": {
                                "lat": 43.70011,
                                "lon": -79.4163
                            }
                        },
                        {
                            "city": "Greenfield Park",
                            "state": "Quebec",
                            "country": "Canada",
                            "geoPoint": {
                                "lat": 45.48649,
                                "lon": -73.46223
                            }
                        },
                        {
                            "city": "Montreal",
                            "state": "Quebec",
                            "country": "Canada",
                            "geoPoint": {
                                "lat": 45.50884,
                                "lon": -73.58781
                            }
                        },
                        {
                            "city": "Montr\u00e9al",
                            "state": "Quebec",
                            "country": "Canada",
                            "geoPoint": {
                                "lat": 45.50884,
                                "lon": -73.58781
                            }
                        },
                        {
                            "city": "N/a N/a",
                            "country": "Canada"
                        },
                        {
                            "city": "Nova Scotia",
                            "country": "Canada",
                            "geoPoint": {
                                "lat": 44.99223,
                                "lon": -62.97803
                            }
                        },
                        {
                            "city": "Quebec",
                            "country": "Canada",
                            "geoPoint": {
                                "lat": 46.81228,
                                "lon": -71.21454
                            }
                        },
                        {
                            "city": "Aarhus C",
                            "country": "Denmark",
                            "geoPoint": {
                                "lat": 56.15674,
                                "lon": 10.21076
                            }
                        },
                        {
                            "city": "Odense",
                            "country": "Denmark",
                            "geoPoint": {
                                "lat": 55.39594,
                                "lon": 10.38831
                            }
                        },
                        {
                            "city": "Vejle",
                            "country": "Denmark",
                            "geoPoint": {
                                "lat": 55.70927,
                                "lon": 9.5357
                            }
                        },
                        {
                            "city": "Amiens N/a Picardie",
                            "country": "France"
                        },
                        {
                            "city": "Angers",
                            "country": "France",
                            "geoPoint": {
                                "lat": 47.46667,
                                "lon": -0.55
                            }
                        },
                        {
                            "city": "Bayonne Cedex",
                            "country": "France",
                            "geoPoint": {
                                "lat": 43.48333,
                                "lon": -1.48333
                            }
                        },
                        {
                            "city": "Bretagne",
                            "country": "France"
                        },
                        {
                            "city": "Caen",
                            "country": "France",
                            "geoPoint": {
                                "lat": 49.18585,
                                "lon": -0.35912
                            }
                        },
                        {
                            "city": "Cergy Pontoise",
                            "country": "France",
                            "geoPoint": {
                                "lat": 49.03894,
                                "lon": 2.07805
                            }
                        },
                        {
                            "city": "Chalons Sur Saone",
                            "country": "France"
                        },
                        {
                            "city": "Clermont-Ferrand",
                            "country": "France",
                            "geoPoint": {
                                "lat": 45.77966,
                                "lon": 3.08628
                            }
                        },
                        {
                            "city": "Creteil",
                            "country": "France",
                            "geoPoint": {
                                "lat": 48.78333,
                                "lon": 2.46667
                            }
                        },
                        {
                            "city": "Dijon",
                            "country": "France",
                            "geoPoint": {
                                "lat": 47.31667,
                                "lon": 5.01667
                            }
                        },
                        {
                            "city": "Dunkerque Cedex 1",
                            "country": "France",
                            "geoPoint": {
                                "lat": 51.03297,
                                "lon": 2.377
                            }
                        },
                        {
                            "city": "Grenoble Cedex 9",
                            "country": "France",
                            "geoPoint": {
                                "lat": 45.16667,
                                "lon": 5.71667
                            }
                        },
                        {
                            "city": "La Roche sur Yon Cedex 9",
                            "country": "France",
                            "geoPoint": {
                                "lat": 46.66667,
                                "lon": -1.43333
                            }
                        },
                        {
                            "city": "Le Chesnay Cedex",
                            "country": "France",
                            "geoPoint": {
                                "lat": 48.8222,
                                "lon": 2.12213
                            }
                        },
                        {
                            "city": "Le Mans",
                            "country": "France",
                            "geoPoint": {
                                "lat": 48.0,
                                "lon": 0.2
                            }
                        },
                        {
                            "city": "Lille Cedex",
                            "country": "France",
                            "geoPoint": {
                                "lat": 50.63297,
                                "lon": 3.05858
                            }
                        },
                        {
                            "city": "Lille",
                            "country": "France",
                            "geoPoint": {
                                "lat": 50.63297,
                                "lon": 3.05858
                            }
                        },
                        {
                            "city": "Limoges",
                            "country": "France",
                            "geoPoint": {
                                "lat": 45.83153,
                                "lon": 1.25781
                            }
                        },
                        {
                            "city": "Lyon, Pierre-Benite",
                            "country": "France"
                        },
                        {
                            "city": "Marseille Cedex 9",
                            "country": "France",
                            "geoPoint": {
                                "lat": 43.29551,
                                "lon": 5.38958
                            }
                        },
                        {
                            "city": "Metz-Tessy",
                            "country": "France",
                            "geoPoint": {
                                "lat": 45.93406,
                                "lon": 6.10826
                            }
                        },
                        {
                            "city": "Montivilliers",
                            "country": "France",
                            "geoPoint": {
                                "lat": 49.54518,
                                "lon": 0.18769
                            }
                        },
                        {
                            "city": "Montpellier",
                            "country": "France",
                            "geoPoint": {
                                "lat": 43.61092,
                                "lon": 3.87723
                            }
                        },
                        {
                            "city": "Mulhouse",
                            "country": "France",
                            "geoPoint": {
                                "lat": 47.75,
                                "lon": 7.33333
                            }
                        },
                        {
                            "city": "Nantes",
                            "country": "France",
                            "geoPoint": {
                                "lat": 47.21725,
                                "lon": -1.55336
                            }
                        },
                        {
                            "city": "Nice N/a",
                            "country": "France"
                        },
                        {
                            "city": "Paris Cedex 12",
                            "country": "France",
                            "geoPoint": {
                                "lat": 48.85341,
                                "lon": 2.3488
                            }
                        },
                        {
                            "city": "Paris, 75",
                            "country": "France",
                            "geoPoint": {
                                "lat": 48.85341,
                                "lon": 2.3488
                            }
                        },
                        {
                            "city": "Paris",
                            "country": "France",
                            "geoPoint": {
                                "lat": 48.85341,
                                "lon": 2.3488
                            }
                        },
                        {
                            "city": "PERIGUEUX cedex",
                            "country": "France",
                            "geoPoint": {
                                "lat": 45.18333,
                                "lon": 0.71667
                            }
                        },
                        {
                            "city": "Perpignan",
                            "country": "France",
                            "geoPoint": {
                                "lat": 42.69764,
                                "lon": 2.89541
                            }
                        },
                        {
                            "city": "Pessac",
                            "country": "France",
                            "geoPoint": {
                                "lat": 44.81011,
                                "lon": -0.64129
                            }
                        },
                        {
                            "city": "Poitiers",
                            "country": "France",
                            "geoPoint": {
                                "lat": 46.58333,
                                "lon": 0.33333
                            }
                        },
                        {
                            "city": "Reims",
                            "country": "France",
                            "geoPoint": {
                                "lat": 49.25,
                                "lon": 4.03333
                            }
                        },
                        {
                            "city": "Rennes",
                            "country": "France",
                            "geoPoint": {
                                "lat": 48.11198,
                                "lon": -1.67429
                            }
                        },
                        {
                            "city": "Rouen Cedex",
                            "country": "France",
                            "geoPoint": {
                                "lat": 49.44313,
                                "lon": 1.09932
                            }
                        },
                        {
                            "city": "Saint Brieuc Cedex 1",
                            "country": "France",
                            "geoPoint": {
                                "lat": 48.51513,
                                "lon": -2.76838
                            }
                        },
                        {
                            "city": "Saint Priest en Jarez",
                            "country": "France",
                            "geoPoint": {
                                "lat": 45.47501,
                                "lon": 4.37614
                            }
                        },
                        {
                            "city": "St Malo Cedex",
                            "country": "France",
                            "geoPoint": {
                                "lat": 48.65,
                                "lon": -2.01667
                            }
                        },
                        {
                            "city": "St Quentin Cedex",
                            "country": "France",
                            "geoPoint": {
                                "lat": 49.84889,
                                "lon": 3.28757
                            }
                        },
                        {
                            "city": "Strasbourg",
                            "country": "France",
                            "geoPoint": {
                                "lat": 48.58392,
                                "lon": 7.74553
                            }
                        },
                        {
                            "city": "Toulouse Cedex 9",
                            "country": "France",
                            "geoPoint": {
                                "lat": 43.60426,
                                "lon": 1.44367
                            }
                        },
                        {
                            "city": "TOURS Cedex 9",
                            "country": "France",
                            "geoPoint": {
                                "lat": 47.38333,
                                "lon": 0.68333
                            }
                        },
                        {
                            "city": "Vandoeuvre Les Nancy",
                            "country": "France",
                            "geoPoint": {
                                "lat": 48.65,
                                "lon": 6.18333
                            }
                        },
                        {
                            "city": "Aschaffenburg",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 49.97704,
                                "lon": 9.15214
                            }
                        },
                        {
                            "city": "Bad Berka",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 50.89982,
                                "lon": 11.28245
                            }
                        },
                        {
                            "city": "Bonn",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 50.73438,
                                "lon": 7.09549
                            }
                        },
                        {
                            "city": "Braunschweig",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 52.26594,
                                "lon": 10.52673
                            }
                        },
                        {
                            "city": "Dresden",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 51.05089,
                                "lon": 13.73832
                            }
                        },
                        {
                            "city": "Essen",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 51.45657,
                                "lon": 7.01228
                            }
                        },
                        {
                            "city": "Frankfurt",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 50.11552,
                                "lon": 8.68417
                            }
                        },
                        {
                            "city": "Hannover",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 52.37052,
                                "lon": 9.73322
                            }
                        },
                        {
                            "city": "Heidelberg",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 49.40768,
                                "lon": 8.69079
                            }
                        },
                        {
                            "city": "Hessen",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 52.01667,
                                "lon": 10.78333
                            }
                        },
                        {
                            "city": "Kiel",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 54.32133,
                                "lon": 10.13489
                            }
                        },
                        {
                            "city": "Koblenz",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 50.35357,
                                "lon": 7.57883
                            }
                        },
                        {
                            "city": "Mainz",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 49.98419,
                                "lon": 8.2791
                            }
                        },
                        {
                            "city": "Mannheim",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 49.4891,
                                "lon": 8.46694
                            }
                        },
                        {
                            "city": "Rostock",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 54.0887,
                                "lon": 12.14049
                            }
                        },
                        {
                            "city": "Schwerin",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 53.62937,
                                "lon": 11.41316
                            }
                        },
                        {
                            "city": "Stuttgart",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 48.78232,
                                "lon": 9.17702
                            }
                        },
                        {
                            "city": "Tuebingen",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 48.52266,
                                "lon": 9.05222
                            }
                        },
                        {
                            "city": "Ulm",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 48.39841,
                                "lon": 9.99155
                            }
                        },
                        {
                            "city": "Villingen-Schwenningen",
                            "country": "Germany",
                            "geoPoint": {
                                "lat": 48.06226,
                                "lon": 8.49358
                            }
                        },
                        {
                            "city": "Dublin",
                            "country": "Ireland",
                            "geoPoint": {
                                "lat": 53.33306,
                                "lon": -6.24889
                            }
                        },
                        {
                            "city": "Galway",
                            "country": "Ireland",
                            "geoPoint": {
                                "lat": 53.27194,
                                "lon": -9.04889
                            }
                        },
                        {
                            "city": "Hadera",
                            "country": "Israel",
                            "geoPoint": {
                                "lat": 32.44192,
                                "lon": 34.9039
                            }
                        },
                        {
                            "city": "Haifa",
                            "country": "Israel",
                            "geoPoint": {
                                "lat": 32.81841,
                                "lon": 34.9885
                            }
                        },
                        {
                            "city": "Jerusalem",
                            "country": "Israel",
                            "geoPoint": {
                                "lat": 31.76904,
                                "lon": 35.21633
                            }
                        },
                        {
                            "city": "Nahariya",
                            "country": "Israel",
                            "geoPoint": {
                                "lat": 33.00892,
                                "lon": 35.09814
                            }
                        },
                        {
                            "city": "Petah Tikva",
                            "country": "Israel",
                            "geoPoint": {
                                "lat": 32.08707,
                                "lon": 34.88747
                            }
                        },
                        {
                            "city": "Tel-Aviv",
                            "country": "Israel",
                            "geoPoint": {
                                "lat": 32.08088,
                                "lon": 34.78057
                            }
                        },
                        {
                            "city": "Hilversum",
                            "country": "Netherlands",
                            "geoPoint": {
                                "lat": 52.22333,
                                "lon": 5.17639
                            }
                        },
                        {
                            "city": "Hoofddorp",
                            "country": "Netherlands",
                            "geoPoint": {
                                "lat": 52.3025,
                                "lon": 4.68889
                            }
                        },
                        {
                            "city": "Rotterdam",
                            "country": "Netherlands",
                            "geoPoint": {
                                "lat": 51.9225,
                                "lon": 4.47917
                            }
                        },
                        {
                            "city": "Tilburg",
                            "country": "Netherlands",
                            "geoPoint": {
                                "lat": 51.55551,
                                "lon": 5.0913
                            }
                        },
                        {
                            "city": "Falun",
                            "country": "Sweden",
                            "geoPoint": {
                                "lat": 60.60357,
                                "lon": 15.62597
                            }
                        },
                        {
                            "city": "G\u00f6teborg",
                            "country": "Sweden",
                            "geoPoint": {
                                "lat": 57.70716,
                                "lon": 11.96679
                            }
                        },
                        {
                            "city": "Halmstad",
                            "country": "Sweden",
                            "geoPoint": {
                                "lat": 56.67446,
                                "lon": 12.85676
                            }
                        },
                        {
                            "city": "Helsingborg",
                            "country": "Sweden",
                            "geoPoint": {
                                "lat": 56.04673,
                                "lon": 12.69437
                            }
                        },
                        {
                            "city": "Huddinge",
                            "country": "Sweden",
                            "geoPoint": {
                                "lat": 59.23705,
                                "lon": 17.98192
                            }
                        },
                        {
                            "city": "Lulea",
                            "country": "Sweden",
                            "geoPoint": {
                                "lat": 65.58415,
                                "lon": 22.15465
                            }
                        },
                        {
                            "city": "Lund",
                            "country": "Sweden",
                            "geoPoint": {
                                "lat": 55.70584,
                                "lon": 13.19321
                            }
                        },
                        {
                            "city": "Stockholm",
                            "country": "Sweden",
                            "geoPoint": {
                                "lat": 59.33258,
                                "lon": 18.0649
                            }
                        },
                        {
                            "city": "\u00d6rebro",
                            "country": "Sweden",
                            "geoPoint": {
                                "lat": 59.27412,
                                "lon": 15.2066
                            }
                        },
                        {
                            "city": "Aberdeen",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 57.14369,
                                "lon": -2.09814
                            }
                        },
                        {
                            "city": "Canterbury",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 51.27904,
                                "lon": 1.07992
                            }
                        },
                        {
                            "city": "Dundee",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 56.46913,
                                "lon": -2.97489
                            }
                        },
                        {
                            "city": "Leeds",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 53.79648,
                                "lon": -1.54785
                            }
                        },
                        {
                            "city": "London",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 51.50853,
                                "lon": -0.12574
                            }
                        },
                        {
                            "city": "Manchester",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 53.48095,
                                "lon": -2.23743
                            }
                        },
                        {
                            "city": "Nottingham",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 52.9536,
                                "lon": -1.15047
                            }
                        },
                        {
                            "city": "Oxford",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 51.75222,
                                "lon": -1.25596
                            }
                        },
                        {
                            "city": "Plymouth, Devon",
                            "country": "United Kingdom"
                        },
                        {
                            "city": "Southampton",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 50.90395,
                                "lon": -1.40428
                            }
                        },
                        {
                            "city": "Truro",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 50.26526,
                                "lon": -5.05436
                            }
                        },
                        {
                            "city": "Wolverhampton",
                            "country": "United Kingdom",
                            "geoPoint": {
                                "lat": 52.58547,
                                "lon": -2.12296
                            }
                        }
                    ]
                },
                "referencesModule": {
                    "references": [
                        {
                            "pmid": "36067063",
                            "type": "DERIVED",
                            "citation": "Mateos MV, Rigaudeau S, Basu S, Spicka I, Schots R, Wrobel T, Cook G, Beksac M, Gries KS, Kudva A, Tromp B, Van Rampelbergh R, Pei H, Wroblewski S, Carson R, Delioukina M, White D. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. J Oncol Pharm Pract. 2023 Jul;29(5):1172-1177. doi: 10.1177/10781552221103551. Epub 2022 Sep 6."
                        },
                        {
                            "pmid": "34655533",
                            "type": "DERIVED",
                            "citation": "Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Wang J, Van Rampelbergh R, Uhlar CM, Tromp B, Delioukina M, Vermeulen J, Usmani SZ. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13."
                        },
                        {
                            "pmid": "34289038",
                            "type": "DERIVED",
                            "citation": "Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, Paiva B, Bahlis NJ, Plesner T, Hungria V, Moreau P, Mateos MV, Perrot A, Iida S, Facon T, Kumar S, van de Donk NWCJ, Sonneveld P, Spencer A, Krevvata M, Heuck C, Wang J, Ukropec J, Kobos R, Sun S, Qi M, Munshi N. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022 Feb 10;139(6):835-844. doi: 10.1182/blood.2021011101."
                        },
                        {
                            "pmid": "34269818",
                            "type": "DERIVED",
                            "citation": "San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, Mateos MV, Touzeau C, Jakubowiak A, Usmani SZ, Cook G, Cavo M, Quach H, Ukropec J, Ramaswami P, Pei H, Qi M, Sun S, Wang J, Krevvata M, DeAngelis N, Heuck C, Van Rampelbergh R, Kudva A, Kobos R, Qi M, Bahlis NJ. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022 Jan 27;139(4):492-501. doi: 10.1182/blood.2020010439."
                        },
                        {
                            "pmid": "33326255",
                            "type": "DERIVED",
                            "citation": "Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel K. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. J Clin Oncol. 2021 Jan 20;39(3):227-237. doi: 10.1200/JCO.20.01370. Epub 2020 Dec 16."
                        },
                        {
                            "pmid": "31141632",
                            "type": "DERIVED",
                            "citation": "Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249."
                        }
                    ]
                }
            },
            "resultsSection": {
                "participantFlowModule": {
                    "groups": [
                        {
                            "id": "FG000",
                            "title": "Lenalidomide + Dexamethasone (Rd)",
                            "description": "Participants received Lenalidomide 25 milligrams (mg) capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously (IV) once a week (QW) until disease progression or unacceptable toxicity."
                        },
                        {
                            "id": "FG001",
                            "title": "Daratumumab + Lenalidomide + Dexamethasone (DRd)",
                            "description": "Participants received Daratumumab 16 milligrams per kilograms (mg/kg) IV QW for the first 8 weeks (cycles 1-2) and then every 2 weeks (Q2W) for 16 weeks (Cycle 3-6), then every 4 weeks (Q4W) (from Cycle 7 and beyond) (each cycle of 28 days), Lenalidomide 25 mg capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or IV QW until disease progression or unacceptable toxicity."
                        }
                    ],
                    "periods": [
                        {
                            "title": "Overall Study",
                            "milestones": [
                                {
                                    "type": "STARTED",
                                    "achievements": [
                                        {
                                            "groupId": "FG000",
                                            "numSubjects": "369"
                                        },
                                        {
                                            "groupId": "FG001",
                                            "numSubjects": "368"
                                        }
                                    ]
                                },
                                {
                                    "type": "Treated",
                                    "achievements": [
                                        {
                                            "groupId": "FG000",
                                            "numSubjects": "365"
                                        },
                                        {
                                            "groupId": "FG001",
                                            "numSubjects": "364"
                                        }
                                    ]
                                },
                                {
                                    "type": "COMPLETED",
                                    "comment": "Participants who died or withdrew consent were considered as completed.",
                                    "achievements": [
                                        {
                                            "groupId": "FG000",
                                            "numSubjects": "90"
                                        },
                                        {
                                            "groupId": "FG001",
                                            "numSubjects": "69"
                                        }
                                    ]
                                },
                                {
                                    "type": "NOT COMPLETED",
                                    "achievements": [
                                        {
                                            "groupId": "FG000",
                                            "numSubjects": "279"
                                        },
                                        {
                                            "groupId": "FG001",
                                            "numSubjects": "299"
                                        }
                                    ]
                                }
                            ],
                            "dropWithdraws": [
                                {
                                    "type": "Lost to Follow-up",
                                    "reasons": [
                                        {
                                            "groupId": "FG000",
                                            "numSubjects": "3"
                                        },
                                        {
                                            "groupId": "FG001",
                                            "numSubjects": "1"
                                        }
                                    ]
                                },
                                {
                                    "type": "Ongoing",
                                    "reasons": [
                                        {
                                            "groupId": "FG000",
                                            "numSubjects": "276"
                                        },
                                        {
                                            "groupId": "FG001",
                                            "numSubjects": "298"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                "baselineCharacteristicsModule": {
                    "groups": [
                        {
                            "id": "BG000",
                            "title": "Lenalidomide + Dexamethasone (Rd)",
                            "description": "Participants received Lenalidomide 25 milligrams (mg) capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously (IV) once a week (QW) until disease progression or unacceptable toxicity."
                        },
                        {
                            "id": "BG001",
                            "title": "Daratumumab + Lenalidomide + Dexamethasone (DRd)",
                            "description": "Participants received Daratumumab 16 milligrams per kilograms (mg/kg) IV QW for the first 8 weeks (cycles 1-2) and then every 2 weeks (Q2W) for 16 weeks (Cycle 3-6), then every 4 weeks (Q4W) (from Cycle 7 and beyond) (each cycle of 28 days), Lenalidomide 25 mg capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or IV QW until disease progression or unacceptable toxicity."
                        },
                        {
                            "id": "BG002",
                            "title": "Total",
                            "description": "Total of all reporting groups"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "BG000",
                                    "value": "369"
                                },
                                {
                                    "groupId": "BG001",
                                    "value": "368"
                                },
                                {
                                    "groupId": "BG002",
                                    "value": "737"
                                }
                            ]
                        }
                    ],
                    "measures": [
                        {
                            "title": "Age, Continuous",
                            "paramType": "MEAN",
                            "dispersionType": "STANDARD_DEVIATION",
                            "unitOfMeasure": "years",
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "74.2",
                                                    "spread": "5.66"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "74.0",
                                                    "spread": "5.44"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "74.1",
                                                    "spread": "5.55"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Sex: Female, Male",
                            "paramType": "COUNT_OF_PARTICIPANTS",
                            "unitOfMeasure": "Participants",
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "title": "Female",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "174"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "179"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "353"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "Male",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "195"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "189"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "384"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Ethnicity (NIH/OMB)",
                            "paramType": "COUNT_OF_PARTICIPANTS",
                            "unitOfMeasure": "Participants",
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "title": "Hispanic or Latino",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "12"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "11"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "23"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "Not Hispanic or Latino",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "352"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "347"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "699"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "Unknown or Not Reported",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "5"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "10"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "15"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Race/Ethnicity, Customized",
                            "paramType": "COUNT_OF_PARTICIPANTS",
                            "unitOfMeasure": "Participants",
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "title": "American Indian or Alaska Native",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "0"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "Asian",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "2"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "3"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "5"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "Native Hawaiian or Other Pacific Islander",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "1"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "0"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "1"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "Black or African American",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "16"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "12"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "28"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "White",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "339"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "336"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "675"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "Other",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "6"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "6"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "12"
                                                }
                                            ]
                                        },
                                        {
                                            "title": "Unknown or Not Reported",
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "5"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "11"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "16"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Region of Enrollment",
                            "paramType": "COUNT_OF_PARTICIPANTS",
                            "unitOfMeasure": "Participants",
                            "classes": [
                                {
                                    "title": "AUSTRALIA",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "18"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "17"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "35"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "AUSTRIA",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "11"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "3"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "14"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "BELGIUM",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "5"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "2"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "7"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "CANADA",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "28"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "24"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "52"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "DENMARK",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "6"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "10"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "16"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "FRANCE",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "155"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "157"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "312"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "GERMANY",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "16"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "19"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "35"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "IRELAND",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "3"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "4"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "7"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "ISRAEL",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "3"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "5"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "8"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "ITALY",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "3"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "3"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "6"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "NETHERLANDS",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "1"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "4"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "5"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "SWEDEN",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "12"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "10"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "22"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "UNITED KINGDOM",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "34"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "33"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "67"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "UNITED STATES",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "74"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "77"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "151"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Stage of Disease (ISS)",
                            "description": "The International Staging System (ISS) consists of following 3 stages - Stage I: serum beta2-microglobulin less than (\\<) 3.5 milligram per liter (mg/L) and albumin greater than or equal to (\\>=) 3.5 gram per 100 Milliliter (g/100 mL); Stage II: neither stage I nor stage III and Stage III: serum beta2-microglobulin \\>= 5.5 mg/L.",
                            "paramType": "COUNT_OF_PARTICIPANTS",
                            "unitOfMeasure": "Participants",
                            "classes": [
                                {
                                    "title": "Stage I",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "103"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "98"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "201"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Stage II",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "156"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "163"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "319"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Stage III",
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "110"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "107"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "217"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Time from Multiple Myeloma (MM) diagnosis",
                            "description": "Time from MM diagnosis is the time from diagnosis of multiple myeloma to randomization in each treatment group.",
                            "paramType": "MEAN",
                            "dispersionType": "STANDARD_DEVIATION",
                            "unitOfMeasure": "months",
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "BG000",
                                                    "value": "1.3",
                                                    "spread": "1.4"
                                                },
                                                {
                                                    "groupId": "BG001",
                                                    "value": "1.4",
                                                    "spread": "1.5"
                                                },
                                                {
                                                    "groupId": "BG002",
                                                    "value": "1.3",
                                                    "spread": "1.5"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                "outcomeMeasuresModule": {
                    "outcomeMeasures": [
                        {
                            "type": "PRIMARY",
                            "title": "Primary: Progression-free Survival (PFS)",
                            "description": "PFS is defined as time from date of randomization to either progressive disease (PD) or death, whichever occurs first based on computerized algorithm as per International Myeloma Working Group (IMWG) criteria. PD is defined as an increase of 25 percent (%) from the lowest response value in one of the following: serum and urine M-component (absolute increase must be greater than or equal to \\[\\>=\\] 0.5 gram per deciliter \\[g/dL\\] and \\>=200 milligram \\[mg\\]/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be greater than \\[\\>\\]10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \\>11.5 mg/dL) that can be attributed solely to Plasma cell (PC) proliferative disorder.",
                            "populationDescription": "Intent-to-treat (ITT) population included all randomized participants.",
                            "reportingStatus": "POSTED",
                            "paramType": "MEDIAN",
                            "dispersionType": "95% Confidence Interval",
                            "unitOfMeasure": "Months",
                            "timeFrame": "From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "Lenalidomide + Dexamethasone (Rd)",
                                    "description": "Participants received Lenalidomide 25 milligrams (mg) capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously (IV) once a week (QW) until disease progression or unacceptable toxicity."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Daratumumab + Lenalidomide + Dexamethasone (DRd)",
                                    "description": "Participants received Daratumumab 16 milligrams per kilograms (mg/kg) IV QW for the first 8 weeks (cycles 1-2) and then every 2 weeks (Q2W) for 16 weeks (Cycle 3-6), then every 4 weeks (Q4W) (from Cycle 7 and beyond) (each cycle of 28 days), Lenalidomide 25 mg capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or IV QW until disease progression or unacceptable toxicity."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "369"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "368"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "31.87",
                                                    "lowerLimit": "28.94",
                                                    "upperLimit": "NA",
                                                    "comment": "Here NA signifies upper limit of confidence interval (CI) was not estimable due to an insufficient number of events."
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "NA",
                                                    "lowerLimit": "NA",
                                                    "upperLimit": "NA",
                                                    "comment": "Here NA signifies Median and CI was not estimable due to an insufficient number of events."
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ],
                            "analyses": [
                                {
                                    "groupIds": [
                                        "OG000",
                                        "OG001"
                                    ],
                                    "nonInferiorityType": "SUPERIORITY",
                                    "pValue": "<0.0001",
                                    "statisticalMethod": "Log Rank",
                                    "paramType": "Hazard Ratio (HR)",
                                    "paramValue": "0.56",
                                    "ciPctValue": "95",
                                    "ciNumSides": "TWO_SIDED",
                                    "ciLowerLimit": "0.43",
                                    "ciUpperLimit": "0.73"
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Percentage of Participants With Complete Response (CR) or Better",
                            "description": "CR or better is defined as percentage of participants with a CR or better (CR or stringent complete response \\[sCR\\]) based on computerized algorithm as per IMWG criteria. CR is defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and less than (\\<) 5 percent (%) PCs in bone marrow. In participants with only measurable disease by serum FLC levels a normal serum FLC ratio is required. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.",
                            "reportingStatus": "NOT_POSTED",
                            "anticipatedPostingDate": "2024-12",
                            "timeFrame": "From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)",
                            "denomUnitsSelected": "Participants"
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Percentage of Participants With Very Good Partial Response (VGPR) or Better",
                            "description": "VGPR or better is defined as the percentage of participants with a response of VGPR or better (VGPR, CR or sCR) based on computerized algorithm as per IMWG criteria. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis or \\>=90% reduction in serum M-protein plus urine M-protein \\<100 mg/24 hours. In participants with only measurable disease by serum FLC levels a \\>90% decrease in the difference between involved and uninvolved FLC levels is required.",
                            "reportingStatus": "NOT_POSTED",
                            "anticipatedPostingDate": "2024-12",
                            "timeFrame": "From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)",
                            "denomUnitsSelected": "Participants"
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Percentage of Participants With Negative Minimal Residual Disease (MRD)",
                            "description": "MRD negativity rate is defined as the percentage of participants who had negative MRD (detection of less than 1 malignant cell among 100,000 normal cells) assessment at any timepoint after the date of randomization by evaluation of bone marrow aspirates. MRD was assessed in participants who achieved CR or better.",
                            "reportingStatus": "NOT_POSTED",
                            "anticipatedPostingDate": "2024-12",
                            "timeFrame": "From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)",
                            "denomUnitsSelected": "Participants"
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Overall Response Rate (ORR)",
                            "description": "ORR is defined as the percentage of participants who achieved partial response (PR) or better (PR, VGPR, CR or sCR) based on computerized algorithm as per IMWG criteria. PR is defined as \\>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to \\<200 mg/24 hours. If the serum and urine M-protein are not measurable, a decrease of \\>=50% in the difference between involved and uninvolved FLC levels is required. A \\>=50% reduction in the size of soft tissue plasmacytomas is also required.",
                            "reportingStatus": "NOT_POSTED",
                            "anticipatedPostingDate": "2024-12",
                            "timeFrame": "From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)",
                            "denomUnitsSelected": "Participants"
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Overall Survival (OS)",
                            "description": "OS was measured from the date of randomization to the date of the death.",
                            "reportingStatus": "NOT_POSTED",
                            "anticipatedPostingDate": "2024-12",
                            "timeFrame": "From randomization to death, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)",
                            "denomUnitsSelected": "Participants"
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Time to Disease Progression (TTP)",
                            "description": "TTP is defined as the time from the date of randomization to the date of PD based on computerized algorithm as per IMWG criteria, or death due to PD.",
                            "reportingStatus": "NOT_POSTED",
                            "anticipatedPostingDate": "2024-12",
                            "timeFrame": "From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)",
                            "denomUnitsSelected": "Participants"
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Time to Response",
                            "description": "Time to response is defined as the time from the date of randomization to the first efficacy evaluation that met criteria for PR or better based on computerized algorithm as per IMWG criteria. PR: \\>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to \\<200 mg/24 hours. If the serum and urine M-protein are not measurable, a decrease of \\>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria; If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \\>=50% reduction in bone marrow PCs is required. A \\>=50% reduction in the size of soft tissue plasmacytomas is also required.",
                            "reportingStatus": "NOT_POSTED",
                            "anticipatedPostingDate": "2024-12",
                            "timeFrame": "From randomization to first response (PR or better) (up to 7.8 years)",
                            "denomUnitsSelected": "Participants"
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Duration of Response (DoR)",
                            "description": "DoR is defined as the time from the date of initial response (PR or better) to the date of PD, based on computerized algorithm as per IMWG criteria.",
                            "reportingStatus": "NOT_POSTED",
                            "anticipatedPostingDate": "2024-12",
                            "timeFrame": "From first response (PR of better) to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)",
                            "denomUnitsSelected": "Participants"
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Time to Subsequent Anti-myeloma Treatment",
                            "description": "Time to subsequent anti-myeloma treatment is defined as the time from randomization to the start of first line of subsequent anti-myeloma treatment or death, whichever occurs first.",
                            "reportingStatus": "NOT_POSTED",
                            "anticipatedPostingDate": "2024-12",
                            "timeFrame": "From randomization to start of first subsequent anti-myeloma treatment, death, withdrawal of consent to study participation or CCO whichever is first (up to 7.8 years)",
                            "denomUnitsSelected": "Participants"
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Progression-free Survival on Next Line of Therapy (PFS2)",
                            "description": "PFS2 is defined as the time from randomization to progression on the first line of subsequent anti-myeloma therapy or death, whichever occurs first. Disease progression on first line of subsequent anti-myeloma treatment was based on investigator judgment. Participants that were censored for PFS1 were also censored for PFS2.",
                            "reportingStatus": "NOT_POSTED",
                            "anticipatedPostingDate": "2024-12",
                            "timeFrame": "From randomization to disease progression on first line of subsequent anti-myeloma therapy, death, withdrawal of consent to study participation or CCO whichever occurs first (up to 7.8 years)",
                            "denomUnitsSelected": "Participants"
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 Global Health Status Score to Day 1 of Cycle 3, 6, 9 and 12",
                            "description": "EORTC QLQ-C30 is 30 items self-reporting questionnaire, with 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Questionnaire includes 28 items with 4-point Likert type responses from \"1-not at all\" to \"4-very much\" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall health related QoL. Scores are transformed to 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms. Negative change from baseline values shows deterioration in quality of life or functioning and reduction in symptom and positive values indicate improvement and worsening of symptoms.",
                            "populationDescription": "ITT population included all randomized participants. Here 'N' (overall number of participants analyzed) signifies number of participants who were evaluable in this outcome measure. Here 'n' (number analyzed) signifies number of participants analyzed at specified timepoints.",
                            "reportingStatus": "POSTED",
                            "paramType": "LEAST_SQUARES_MEAN",
                            "dispersionType": "95% Confidence Interval",
                            "unitOfMeasure": "Score on scale",
                            "timeFrame": "Baseline and Day 1 of Cycle 3, 6, 9 and 12 (each Cycle of 28 days)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "Lenalidomide + Dexamethasone (Rd)",
                                    "description": "Participants received Lenalidomide 25 milligrams (mg) capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously (IV) once a week (QW) until disease progression or unacceptable toxicity."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Daratumumab + Lenalidomide + Dexamethasone (DRd)",
                                    "description": "Participants received Daratumumab 16 milligrams per kilograms (mg/kg) IV QW for the first 8 weeks (cycles 1-2) and then every 2 weeks (Q2W) for 16 weeks (Cycle 3-6), then every 4 weeks (Q4W) (from Cycle 7 and beyond) (each cycle of 28 days), Lenalidomide 25 mg capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or IV QW until disease progression or unacceptable toxicity."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "348"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "354"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "title": "Global health status score: Cycle 3 Day 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "272"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "303"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "1.5",
                                                    "lowerLimit": "-0.7",
                                                    "upperLimit": "3.7"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "4.5",
                                                    "lowerLimit": "2.4",
                                                    "upperLimit": "6.6"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Global health status score: Cycle 6 Day 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "255"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "295"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "5.6",
                                                    "lowerLimit": "3.3",
                                                    "upperLimit": "7.9"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "6.4",
                                                    "lowerLimit": "4.3",
                                                    "upperLimit": "8.6"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Global health status score: Cycle 9 Day 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "214"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "268"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "7",
                                                    "lowerLimit": "4.6",
                                                    "upperLimit": "9.4"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "8.2",
                                                    "lowerLimit": "6",
                                                    "upperLimit": "10.4"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Global health status score: Cycle 12 Day 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "209"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "260"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "5.4",
                                                    "lowerLimit": "2.9",
                                                    "upperLimit": "7.9"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "8.4",
                                                    "lowerLimit": "6.1",
                                                    "upperLimit": "10.6"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) to Day 1 of Cycle 3, 6, 9 and 12",
                            "description": "EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.",
                            "populationDescription": "ITT population included all randomized participants. Here 'N' (overall number of participants analyzed) signifies number of participants who were evaluable in this outcome measure. Here 'n' signifies number of participants analyzed at specified timepoints.",
                            "reportingStatus": "POSTED",
                            "paramType": "LEAST_SQUARES_MEAN",
                            "dispersionType": "95% Confidence Interval",
                            "unitOfMeasure": "Score on scale",
                            "timeFrame": "Baseline and Day 1 of Cycle 3, 6, 9 and 12 (each Cycle of 28 days)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "Lenalidomide + Dexamethasone (Rd)",
                                    "description": "Participants received Lenalidomide 25 milligrams (mg) capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously (IV) once a week (QW) until disease progression or unacceptable toxicity."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Daratumumab + Lenalidomide + Dexamethasone (DRd)",
                                    "description": "Participants received Daratumumab 16 milligrams per kilograms (mg/kg) IV QW for the first 8 weeks (cycles 1-2) and then every 2 weeks (Q2W) for 16 weeks (Cycle 3-6), then every 4 weeks (Q4W) (from Cycle 7 and beyond) (each cycle of 28 days), Lenalidomide 25 mg capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or IV QW until disease progression or unacceptable toxicity."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "346"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "349"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "title": "Change at Cycle 3 Day 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "262"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "290"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "2.5",
                                                    "lowerLimit": "0.6",
                                                    "upperLimit": "4.4"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "4.9",
                                                    "lowerLimit": "3",
                                                    "upperLimit": "6.7"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Change at Cycle 6 Day 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "240"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "280"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "5.7",
                                                    "lowerLimit": "3.7",
                                                    "upperLimit": "7.7"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "8",
                                                    "lowerLimit": "6.1",
                                                    "upperLimit": "9.8"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Change at Cycle 9 Day 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "207"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "256"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "7.7",
                                                    "lowerLimit": "5.6",
                                                    "upperLimit": "9.8"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "10.2",
                                                    "lowerLimit": "8.2",
                                                    "upperLimit": "12.1"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Change at Cycle 12 Day 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "206"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "247"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "4.9",
                                                    "lowerLimit": "2.8",
                                                    "upperLimit": "7"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "10.1",
                                                    "lowerLimit": "8.1",
                                                    "upperLimit": "12.1"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "type": "SECONDARY",
                            "title": "Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Utility Score to Day 1 of Cycle 3, 6, 9 and 12",
                            "description": "EQ-5D-5L is standardized, participant-reported questionnaire to assess health-related quality of life. EQ-5D-5L includes 2 components: EQ-5D-5L health state profile (descriptive system) and EQ-5D-5L VAS. EQ-5D-5L descriptive system provides a profile of participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. Responses to the 5-dimension scores were combined and converted into single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of individual (but allows for values less than 0 by United kingdom \\[UK\\] scoring algorithm).",
                            "populationDescription": "ITT population included all randomized participants. Here 'N' (overall number of participants analyzed) signifies number of participants who were evaluable in this outcome measure. Here 'n' signifies number of participants analyzed at specified timepoints.",
                            "reportingStatus": "POSTED",
                            "paramType": "LEAST_SQUARES_MEAN",
                            "dispersionType": "95% Confidence Interval",
                            "unitOfMeasure": "Score on scale",
                            "timeFrame": "Baseline and Day 1 of Cycle 3, 6, 9 and 12 (each Cycle of 28 days)",
                            "groups": [
                                {
                                    "id": "OG000",
                                    "title": "Lenalidomide + Dexamethasone (Rd)",
                                    "description": "Participants received Lenalidomide 25 milligrams (mg) capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously (IV) once a week (QW) until disease progression or unacceptable toxicity."
                                },
                                {
                                    "id": "OG001",
                                    "title": "Daratumumab + Lenalidomide + Dexamethasone (DRd)",
                                    "description": "Participants received Daratumumab 16 milligrams per kilograms (mg/kg) IV QW for the first 8 weeks (cycles 1-2) and then every 2 weeks (Q2W) for 16 weeks (Cycle 3-6), then every 4 weeks (Q4W) (from Cycle 7 and beyond) (each cycle of 28 days), Lenalidomide 25 mg capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or IV QW until disease progression or unacceptable toxicity."
                                }
                            ],
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "OG000",
                                            "value": "346"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "349"
                                        }
                                    ]
                                }
                            ],
                            "classes": [
                                {
                                    "title": "Change at Cycle 3 Day 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "262"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "291"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0.08",
                                                    "lowerLimit": "0.057",
                                                    "upperLimit": "0.102"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0.107",
                                                    "lowerLimit": "0.085",
                                                    "upperLimit": "0.128"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Change at Cycle 6 Day 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "240"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "280"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0.116",
                                                    "lowerLimit": "0.092",
                                                    "upperLimit": "0.139"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0.136",
                                                    "lowerLimit": "0.114",
                                                    "upperLimit": "0.158"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Change at Cycle 9 Day 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "207"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "256"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0.124",
                                                    "lowerLimit": "0.1",
                                                    "upperLimit": "0.149"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0.124",
                                                    "lowerLimit": "0.101",
                                                    "upperLimit": "0.146"
                                                }
                                            ]
                                        }
                                    ]
                                },
                                {
                                    "title": "Change at Cycle 12 Day 1",
                                    "denoms": [
                                        {
                                            "units": "Participants",
                                            "counts": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "206"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "247"
                                                }
                                            ]
                                        }
                                    ],
                                    "categories": [
                                        {
                                            "measurements": [
                                                {
                                                    "groupId": "OG000",
                                                    "value": "0.113",
                                                    "lowerLimit": "0.088",
                                                    "upperLimit": "0.138"
                                                },
                                                {
                                                    "groupId": "OG001",
                                                    "value": "0.141",
                                                    "lowerLimit": "0.118",
                                                    "upperLimit": "0.164"
                                                }
                                            ]
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                "adverseEventsModule": {
                    "frequencyThreshold": "5",
                    "timeFrame": "Up to 3.5 years",
                    "description": "Safety population was defined as participants who have received at least 1 administration of any study treatment (partial or complete).",
                    "eventGroups": [
                        {
                            "id": "EG000",
                            "title": "Lenalidomide + Dexamethasone (Rd)",
                            "description": "Participants received Lenalidomide 25 milligrams (mg) capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously (IV) once a week (QW) until disease progression or unacceptable toxicity.",
                            "deathsNumAffected": 76,
                            "deathsNumAtRisk": 365,
                            "seriousNumAffected": 229,
                            "seriousNumAtRisk": 365,
                            "otherNumAffected": 355,
                            "otherNumAtRisk": 365
                        },
                        {
                            "id": "EG001",
                            "title": "Daratumumab + Lenalidomide + Dexamethasone (DRd)",
                            "description": "Participants received Daratumumab 16 milligrams per kilograms (mg/kg) IV QW for the first 8 weeks (cycles 1-2) and then every 2 weeks (Q2W) for 16 weeks (Cycle 3-6), then every 4 weeks (Q4W) (from Cycle 7 and beyond) (each cycle of 28 days), Lenalidomide 25 mg capsule orally daily on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or IV QW until disease progression or unacceptable toxicity.",
                            "deathsNumAffected": 62,
                            "deathsNumAtRisk": 364,
                            "seriousNumAffected": 229,
                            "seriousNumAtRisk": 364,
                            "otherNumAffected": 362,
                            "otherNumAtRisk": 364
                        }
                    ],
                    "seriousEvents": [
                        {
                            "term": "Anaemia",
                            "organSystem": "Blood and lymphatic system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 12,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 6,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Anaemia Macrocytic",
                            "organSystem": "Blood and lymphatic system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Disseminated Intravascular Coagulation",
                            "organSystem": "Blood and lymphatic system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Febrile Neutropenia",
                            "organSystem": "Blood and lymphatic system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 9,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 9,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Heparin-Induced Thrombocytopenia",
                            "organSystem": "Blood and lymphatic system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Leukopenia",
                            "organSystem": "Blood and lymphatic system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Neutropenia",
                            "organSystem": "Blood and lymphatic system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Thrombocytopenia",
                            "organSystem": "Blood and lymphatic system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Acute Coronary Syndrome",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 5,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Acute Myocardial Infarction",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Angina Pectoris",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Arrhythmia",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Arteriosclerosis Coronary Artery",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Atrial Fibrillation",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 12,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 8,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Atrial Flutter",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Atrial Tachycardia",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Atrioventricular Block",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Atrioventricular Block Complete",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bradycardia",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cardiac Amyloidosis",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cardiac Arrest",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cardiac Failure",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 9,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 5,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cardiac Failure Acute",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cardiac Failure Chronic",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cardiac Failure Congestive",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 5,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cardio-Respiratory Arrest",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cardiogenic Shock",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Coronary Artery Disease",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Coronary Artery Stenosis",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypertensive Heart Disease",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Myocardial Infarction",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 5,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Myocardial Ischaemia",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Myocarditis",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pericardial Effusion",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Stress Cardiomyopathy",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Ventricular Tachycardia",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Corneal Dystrophy",
                            "organSystem": "Congenital, familial and genetic disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Deafness Bilateral",
                            "organSystem": "Ear and labyrinth disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Vertigo",
                            "organSystem": "Ear and labyrinth disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Adrenal Insufficiency",
                            "organSystem": "Endocrine disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypothyroidism",
                            "organSystem": "Endocrine disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Blepharitis",
                            "organSystem": "Eye disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cataract",
                            "organSystem": "Eye disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 5,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Retinal Artery Occlusion",
                            "organSystem": "Eye disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Retinal Detachment",
                            "organSystem": "Eye disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Retinal Vein Thrombosis",
                            "organSystem": "Eye disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Abdominal Pain",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Abdominal Pain Upper",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Ascites",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Colitis",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Colitis Ischaemic",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Constipation",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Diarrhoea",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 6,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 9,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Diarrhoea Haemorrhagic",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Diverticular Perforation",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Diverticulum",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Diverticulum Intestinal Haemorrhagic",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dyspepsia",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dysphagia",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Enterovesical Fistula",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Faecaloma",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Gastric Haemorrhage",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Gastric Ulcer",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Gastrointestinal Haemorrhage",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Inguinal Hernia",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Inguinal Hernia Strangulated",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Intestinal Ischaemia",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Intestinal Obstruction",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Large Intestinal Obstruction",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Large Intestine Perforation",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Melaena",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Nausea",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Oesophageal Achalasia",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Oesophagitis",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pancreatitis",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pancreatitis Acute",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pneumoperitoneum",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Rectal Haemorrhage",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Small Intestinal Obstruction",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Subileus",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Upper Gastrointestinal Haemorrhage",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Vomiting",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Asthenia",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 7,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Chest Discomfort",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Chest Pain",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Chills",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Extravasation",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Fatigue",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "General Physical Health Deterioration",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 10,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Granuloma",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Malaise",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Multiple Organ Dysfunction Syndrome",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Non-Cardiac Chest Pain",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Oedema Peripheral",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pain",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Peripheral Swelling",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pyrexia",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 11,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 16,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Sudden Cardiac Death",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Sudden Death",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Systemic Inflammatory Response Syndrome",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Acute Hepatic Failure",
                            "organSystem": "Hepatobiliary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bile Duct Stone",
                            "organSystem": "Hepatobiliary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cholecystitis",
                            "organSystem": "Hepatobiliary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cholecystitis Acute",
                            "organSystem": "Hepatobiliary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cholestasis",
                            "organSystem": "Hepatobiliary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hepatic Failure",
                            "organSystem": "Hepatobiliary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hepatocellular Injury",
                            "organSystem": "Hepatobiliary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hyperbilirubinaemia",
                            "organSystem": "Hepatobiliary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Abdominal Sepsis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Anal Abscess",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Appendicitis Perforated",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Arthritis Bacterial",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Arthritis Infective",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bacteraemia",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bacterial Diarrhoea",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bronchiolitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bronchitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 5,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 12,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Campylobacter Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cellulitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 4,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Clostridium Difficile Colitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Colonic Abscess",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Corona Virus Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cystitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Device Related Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Diverticulitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 6,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Endocarditis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Endocarditis Staphylococcal",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Erysipelas",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Escherichia Pyelonephritis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Escherichia Sepsis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Escherichia Urinary Tract Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Gastroenteritis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Gastrointestinal Viral Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Groin Abscess",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Haematoma Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Infected Cyst",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Influenza",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 6,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 11,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Klebsiella Bacteraemia",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Klebsiella Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Laryngitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Lower Respiratory Tract Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 11,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 10,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Lower Respiratory Tract Infection Bacterial",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Lower Respiratory Tract Infection Viral",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Lung Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 7,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Metapneumovirus Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Myocarditis Infectious",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Neutropenic Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Neutropenic Sepsis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Nocardiosis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Oesophageal Candidiasis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Osteomyelitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Otitis Externa",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Peritonitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pharyngitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pleural Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pneumocystis Jirovecii Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pneumocystis Jirovecii Pneumonia",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pneumonia",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 27,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 48,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pulmonary Mycosis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pyelonephritis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Respiratory Syncytial Virus Bronchiolitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Respiratory Syncytial Virus Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Respiratory Tract Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Salmonellosis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Sepsis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 7,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 9,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Sepsis Syndrome",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Septic Arthritis Staphylococcal",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Septic Embolus",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Septic Shock",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Skin Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Soft Tissue Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Spinal Cord Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Staphylococcal Sepsis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Subcutaneous Abscess",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Upper Respiratory Tract Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 4,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 5,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Ureteritis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Urinary Tract Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 5,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 8,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Urinary Tract Infection Bacterial",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Urosepsis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Varicella Zoster Virus Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Vascular Stent Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Vestibular Neuronitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Viral Upper Respiratory Tract Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Accident",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Accidental Overdose",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Acetabulum Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Clavicle Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Concussion",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Craniocerebral Injury",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Face Injury",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Facial Bones Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Fall",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Femoral Neck Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Femur Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Foot Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Head Injury",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hip Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Humerus Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Limb Injury",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Open Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pelvic Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Periorbital Haemorrhage",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Postoperative Fever",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pubis Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Rib Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Spinal Compression Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 6,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Spinal Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Sternal Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Subdural Haematoma",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Tendon Rupture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Upper Limb Fracture",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Blood Creatinine Increased",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "C-Reactive Protein Increased",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "International Normalised Ratio Increased",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Lipase Increased",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Occult Blood Positive",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Oxygen Saturation Decreased",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Transaminases Increased",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Troponin I Increased",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Decreased Appetite",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dehydration",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 6,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Diabetes Mellitus Inadequate Control",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Failure to Thrive",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Gout",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypercalcaemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hyperglycaemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hyperkalaemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypocalcaemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypokalaemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 5,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypomagnesaemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hyponatraemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypovolaemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Type 1 Diabetes Mellitus",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Arthralgia",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Arthritis",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Back Pain",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 8,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 12,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bone Lesion",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bone Pain",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 4,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bursitis",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Chondrocalcinosis",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Chondrocalcinosis Pyrophosphate",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Crystal Arthropathy",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Intervertebral Disc Compression",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Intervertebral Disc Protrusion",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Jaw Fistula",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Lumbar Spinal Stenosis",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Muscle Spasms",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Muscular Weakness",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Musculoskeletal Chest Pain",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Musculoskeletal Pain",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Neck Pain",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Osteoarthritis",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Osteolysis",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Osteonecrosis",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Osteonecrosis of Jaw",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Osteoporosis",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pain in Extremity",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pathological Fracture",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Primary Sequestrum",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Spinal Pain",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 4,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Adenocarcinoma Gastric",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Adrenal Adenoma",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Basal Cell Carcinoma",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Breast Cancer",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cancer Pain",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Colorectal Adenocarcinoma",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Diffuse Large B-Cell Lymphoma",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Gastrointestinal Neoplasm",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Gastrointestinal Stromal Tumour",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Invasive Lobular Breast Carcinoma",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Keratoacanthoma",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Leiomyosarcoma",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Lung Neoplasm Malignant",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Mantle Cell Lymphoma",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Meningioma",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Neuroendocrine Carcinoma of the Skin",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Porocarcinoma",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Prostate Cancer",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Prostatic Adenoma",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Small Cell Lung Cancer",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Squamous Cell Carcinoma of Skin",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Transitional Cell Carcinoma",
                            "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Brain Stem Infarction",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cerebral Infarction",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cerebrovascular Accident",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 5,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 5,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cognitive Disorder",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dementia Alzheimer's Type",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dizziness",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Epilepsy",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Focal Dyscognitive Seizures",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Generalised Tonic-Clonic Seizure",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Haemorrhage Intracranial",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Haemorrhagic Stroke",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Headache",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hepatic Encephalopathy",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hyperaesthesia",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypoaesthesia",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Ischaemic Stroke",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Nervous System Disorder",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Neuralgia",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Orthostatic Intolerance",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Peripheral Motor Neuropathy",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Post Herpetic Neuralgia",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Presyncope",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Sciatica",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Seizure",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Spinal Cord Compression",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Syncope",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Transient Ischaemic Attack",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Vith Nerve Paralysis",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Device Dislocation",
                            "organSystem": "Product Issues",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Confusional State",
                            "organSystem": "Psychiatric disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Depression",
                            "organSystem": "Psychiatric disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Eating Disorder",
                            "organSystem": "Psychiatric disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Major Depression",
                            "organSystem": "Psychiatric disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Mental Status Changes",
                            "organSystem": "Psychiatric disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Personality Change",
                            "organSystem": "Psychiatric disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Psychotic Disorder",
                            "organSystem": "Psychiatric disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Acute Kidney Injury",
                            "organSystem": "Renal and urinary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 14,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 11,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bladder Stenosis",
                            "organSystem": "Renal and urinary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Chronic Kidney Disease",
                            "organSystem": "Renal and urinary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dysuria",
                            "organSystem": "Renal and urinary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Haematuria",
                            "organSystem": "Renal and urinary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Renal Disorder",
                            "organSystem": "Renal and urinary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Renal Failure",
                            "organSystem": "Renal and urinary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 5,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Renal Impairment",
                            "organSystem": "Renal and urinary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Urethral Caruncle",
                            "organSystem": "Renal and urinary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Urinary Retention",
                            "organSystem": "Renal and urinary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Benign Prostatic Hyperplasia",
                            "organSystem": "Reproductive system and breast disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Genital Prolapse",
                            "organSystem": "Reproductive system and breast disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pelvic Pain",
                            "organSystem": "Reproductive system and breast disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Vaginal Haemorrhage",
                            "organSystem": "Reproductive system and breast disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Acute Pulmonary Oedema",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Asthma",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bronchiectasis",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bronchopneumopathy",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bronchospasm",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Chronic Obstructive Pulmonary Disease",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dyspnoea",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 4,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 6,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Epistaxis",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Haemoptysis",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hiccups",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypoxia",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 4,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Lung Disorder",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pleural Effusion",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pleurisy",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pleuritic Pain",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pneumonitis",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pulmonary Embolism",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 14,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 11,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pulmonary Thrombosis",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Respiratory Distress",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Respiratory Failure",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Acute Febrile Neutrophilic Dermatosis",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dermatitis Exfoliative",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Drug Reaction with Eosinophilia and Systemic Symptoms",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 4,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Ecchymosis",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Purpura",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Rash",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Rash Generalised",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 5,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Rash Maculo-Papular",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Skin Ulcer",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Stevens-Johnson Syndrome",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Air Embolism",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Aortic Aneurysm",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Aortic Aneurysm Rupture",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Arteritis",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Deep Vein Thrombosis",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 8,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 5,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Embolism",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Haematoma",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 3,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Haemorrhage",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypertension",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 3,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypotension",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Orthostatic Hypotension",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Peripheral Arterial Occlusive Disease",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 1,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Peripheral Artery Stenosis",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Peripheral Ischaemia",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 2,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Phlebitis",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Superior Vena Cava Occlusion",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 0,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 1,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Venous Thrombosis",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 2,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 0,
                                    "numAtRisk": 364
                                }
                            ]
                        }
                    ],
                    "otherEvents": [
                        {
                            "term": "Anaemia",
                            "organSystem": "Blood and lymphatic system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 136,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 126,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Leukopenia",
                            "organSystem": "Blood and lymphatic system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 34,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 68,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Lymphopenia",
                            "organSystem": "Blood and lymphatic system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 45,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 66,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Neutropenia",
                            "organSystem": "Blood and lymphatic system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 154,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 207,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Thrombocytopenia",
                            "organSystem": "Blood and lymphatic system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 68,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 68,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Atrial Fibrillation",
                            "organSystem": "Cardiac disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 29,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 19,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cataract",
                            "organSystem": "Eye disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 55,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 52,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Vision Blurred",
                            "organSystem": "Eye disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 16,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 26,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Abdominal Pain",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 33,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 40,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Abdominal Pain Upper",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 28,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 33,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Constipation",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 129,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 148,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Diarrhoea",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 166,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 204,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dry Mouth",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 19,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 12,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dyspepsia",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 27,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 26,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Nausea",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 83,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 115,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Stomatitis",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 13,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 22,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Vomiting",
                            "organSystem": "Gastrointestinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 43,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 60,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Asthenia",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 85,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 116,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Chills",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 6,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 45,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Fatigue",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 104,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 145,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Oedema Peripheral",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 107,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 140,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Peripheral Swelling",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 19,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 10,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pyrexia",
                            "organSystem": "General disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 58,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 70,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bronchitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 73,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 100,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Influenza",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 15,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 23,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Nasopharyngitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 11,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 26,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Oral Candidiasis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 19,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 15,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pneumonia",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 25,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 41,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Rhinitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 21,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 29,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Sinusitis",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 14,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 20,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Upper Respiratory Tract Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 50,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 81,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Urinary Tract Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 34,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 60,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Viral Upper Respiratory Tract Infection",
                            "organSystem": "Infections and infestations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 46,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 55,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Contusion",
                            "organSystem": "Injury, poisoning and procedural complications",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 22,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 27,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Blood Creatinine Increased",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 13,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 24,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Weight Decreased",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 63,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 101,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Weight Increased",
                            "organSystem": "Investigations",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 6,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 25,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Decreased Appetite",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 54,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 78,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dehydration",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 16,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 19,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hyperglycaemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 28,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 50,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypocalcaemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 31,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 49,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypokalaemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 60,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 72,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypomagnesaemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 29,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 18,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hyponatraemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 11,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 19,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypophosphataemia",
                            "organSystem": "Metabolism and nutrition disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 7,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 19,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Arthralgia",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 63,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 69,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Back Pain",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 93,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 114,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Bone Pain",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 33,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 34,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Muscle Spasms",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 79,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 106,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Muscular Weakness",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 22,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 30,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Musculoskeletal Chest Pain",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 41,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 27,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Musculoskeletal Pain",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 40,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 49,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Myalgia",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 25,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 25,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Neck Pain",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 26,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 21,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pain in Extremity",
                            "organSystem": "Musculoskeletal and connective tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 50,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 59,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dizziness",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 57,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 69,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dysgeusia",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 35,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 40,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Headache",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 39,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 68,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Paraesthesia",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 30,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 58,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Peripheral Sensory Neuropathy",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 54,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 87,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Tremor",
                            "organSystem": "Nervous system disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 51,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 57,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Anxiety",
                            "organSystem": "Psychiatric disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 34,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 32,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Confusional State",
                            "organSystem": "Psychiatric disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 19,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 22,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Depression",
                            "organSystem": "Psychiatric disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 32,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 29,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Insomnia",
                            "organSystem": "Psychiatric disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 107,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 109,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Acute Kidney Injury",
                            "organSystem": "Renal and urinary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 15,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 23,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Chronic Kidney Disease",
                            "organSystem": "Renal and urinary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 18,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 21,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Renal Impairment",
                            "organSystem": "Renal and urinary disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 27,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 26,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Cough",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 59,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 100,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dysphonia",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 18,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 27,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dyspnoea",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 56,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 97,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dyspnoea Exertional",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 21,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 23,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Epistaxis",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 20,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 17,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Oropharyngeal Pain",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 9,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 24,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Rhinorrhoea",
                            "organSystem": "Respiratory, thoracic and mediastinal disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 11,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 25,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Dry Skin",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 14,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 25,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Erythema",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 18,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 23,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hyperhidrosis",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 5,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 19,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Pruritus",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 29,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 32,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Rash",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 43,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 57,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Rash Generalised",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 23,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 16,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Rash Maculo-Papular",
                            "organSystem": "Skin and subcutaneous tissue disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 9,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 20,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Deep Vein Thrombosis",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 27,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 26,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypertension",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 26,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 46,
                                    "numAtRisk": 364
                                }
                            ]
                        },
                        {
                            "term": "Hypotension",
                            "organSystem": "Vascular disorders",
                            "sourceVocabulary": "MedDRA Version 20.0",
                            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                            "stats": [
                                {
                                    "groupId": "EG000",
                                    "numAffected": 32,
                                    "numAtRisk": 365
                                },
                                {
                                    "groupId": "EG001",
                                    "numAffected": 34,
                                    "numAtRisk": 364
                                }
                            ]
                        }
                    ]
                },
                "moreInfoModule": {
                    "certainAgreement": {
                        "piSponsorEmployee": false,
                        "restrictionType": "OTHER",
                        "restrictiveAgreement": true,
                        "otherDetails": "If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days."
                    },
                    "pointOfContact": {
                        "title": "Director",
                        "organization": "Janssen Research & Development, LLC",
                        "email": "ClinicalTrialDisclosure@its.jnj.com",
                        "phone": "844-434-4210"
                    }
                }
            },
            "documentSection": {
                "largeDocumentModule": {
                    "largeDocs": [
                        {
                            "typeAbbrev": "Prot",
                            "hasProtocol": true,
                            "hasSap": false,
                            "hasIcf": false,
                            "label": "Study Protocol",
                            "date": "2019-06-12",
                            "uploadDate": "2019-09-24T08:56",
                            "filename": "Prot_001.pdf",
                            "size": 2915470
                        },
                        {
                            "typeAbbrev": "SAP",
                            "hasProtocol": false,
                            "hasSap": true,
                            "hasIcf": false,
                            "label": "Statistical Analysis Plan",
                            "date": "2018-10-03",
                            "uploadDate": "2019-09-24T08:56",
                            "filename": "SAP_000.pdf",
                            "size": 1206211
                        }
                    ]
                }
            },
            "derivedSection": {
                "miscInfoModule": {
                    "versionHolder": "2024-11-18",
                    "removedCountries": [
                        "New Zealand"
                    ]
                },
                "conditionBrowseModule": {
                    "meshes": [
                        {
                            "id": "D009101",
                            "term": "Multiple Myeloma"
                        },
                        {
                            "id": "D054219",
                            "term": "Neoplasms, Plasma Cell"
                        }
                    ],
                    "ancestors": [
                        {
                            "id": "D009370",
                            "term": "Neoplasms by Histologic Type"
                        },
                        {
                            "id": "D009369",
                            "term": "Neoplasms"
                        },
                        {
                            "id": "D020141",
                            "term": "Hemostatic Disorders"
                        },
                        {
                            "id": "D014652",
                            "term": "Vascular Diseases"
                        },
                        {
                            "id": "D002318",
                            "term": "Cardiovascular Diseases"
                        },
                        {
                            "id": "D010265",
                            "term": "Paraproteinemias"
                        },
                        {
                            "id": "D001796",
                            "term": "Blood Protein Disorders"
                        },
                        {
                            "id": "D006402",
                            "term": "Hematologic Diseases"
                        },
                        {
                            "id": "D006474",
                            "term": "Hemorrhagic Disorders"
                        },
                        {
                            "id": "D008232",
                            "term": "Lymphoproliferative Disorders"
                        },
                        {
                            "id": "D007160",
                            "term": "Immunoproliferative Disorders"
                        },
                        {
                            "id": "D007154",
                            "term": "Immune System Diseases"
                        }
                    ],
                    "browseLeaves": [
                        {
                            "id": "M12058",
                            "name": "Multiple Myeloma",
                            "asFound": "Multiple Myeloma",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M27588",
                            "name": "Neoplasms, Plasma Cell",
                            "asFound": "Multiple Myeloma",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M12315",
                            "name": "Neoplasms by Histologic Type",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M21977",
                            "name": "Hemostatic Disorders",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M5059",
                            "name": "Blood Coagulation Disorders",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M17400",
                            "name": "Vascular Diseases",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M13178",
                            "name": "Paraproteinemias",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M5077",
                            "name": "Blood Protein Disorders",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M9490",
                            "name": "Hematologic Diseases",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M9560",
                            "name": "Hemorrhagic Disorders",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M11225",
                            "name": "Lymphoproliferative Disorders",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M10206",
                            "name": "Immunoproliferative Disorders",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M10200",
                            "name": "Immune System Diseases",
                            "relevance": "LOW"
                        },
                        {
                            "id": "T3947",
                            "name": "Multiple Myeloma",
                            "asFound": "Multiple Myeloma",
                            "relevance": "HIGH"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "BC04",
                            "name": "Neoplasms"
                        },
                        {
                            "abbrev": "BC14",
                            "name": "Heart and Blood Diseases"
                        },
                        {
                            "abbrev": "BC15",
                            "name": "Blood and Lymph Conditions"
                        },
                        {
                            "abbrev": "BC20",
                            "name": "Immune System Diseases"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Conditions"
                        },
                        {
                            "abbrev": "Rare",
                            "name": "Rare Diseases"
                        }
                    ]
                },
                "interventionBrowseModule": {
                    "meshes": [
                        {
                            "id": "D003907",
                            "term": "Dexamethasone"
                        },
                        {
                            "id": "D000077269",
                            "term": "Lenalidomide"
                        },
                        {
                            "id": "C556306",
                            "term": "Daratumumab"
                        },
                        {
                            "id": "D000911",
                            "term": "Antibodies, Monoclonal"
                        }
                    ],
                    "ancestors": [
                        {
                            "id": "D000893",
                            "term": "Anti-Inflammatory Agents"
                        },
                        {
                            "id": "D000932",
                            "term": "Antiemetics"
                        },
                        {
                            "id": "D001337",
                            "term": "Autonomic Agents"
                        },
                        {
                            "id": "D018373",
                            "term": "Peripheral Nervous System Agents"
                        },
                        {
                            "id": "D045505",
                            "term": "Physiological Effects of Drugs"
                        },
                        {
                            "id": "D005765",
                            "term": "Gastrointestinal Agents"
                        },
                        {
                            "id": "D005938",
                            "term": "Glucocorticoids"
                        },
                        {
                            "id": "D006728",
                            "term": "Hormones"
                        },
                        {
                            "id": "D006730",
                            "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                        },
                        {
                            "id": "D018931",
                            "term": "Antineoplastic Agents, Hormonal"
                        },
                        {
                            "id": "D000970",
                            "term": "Antineoplastic Agents"
                        },
                        {
                            "id": "D007155",
                            "term": "Immunologic Factors"
                        },
                        {
                            "id": "D020533",
                            "term": "Angiogenesis Inhibitors"
                        },
                        {
                            "id": "D043924",
                            "term": "Angiogenesis Modulating Agents"
                        },
                        {
                            "id": "D006133",
                            "term": "Growth Substances"
                        },
                        {
                            "id": "D006131",
                            "term": "Growth Inhibitors"
                        }
                    ],
                    "browseLeaves": [
                        {
                            "id": "M7102",
                            "name": "Dexamethasone",
                            "asFound": "First",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M1725",
                            "name": "Lenalidomide",
                            "asFound": "Per week",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M272211",
                            "name": "Daratumumab",
                            "asFound": "50%",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M235549",
                            "name": "Dexamethasone acetate",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M4225",
                            "name": "Antibodies",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M4230",
                            "name": "Antibodies, Monoclonal",
                            "asFound": "50%",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M10184",
                            "name": "Immunoglobulins",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M4217",
                            "name": "Anti-Inflammatory Agents",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M4251",
                            "name": "Antiemetics",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M8881",
                            "name": "Gastrointestinal Agents",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M9047",
                            "name": "Glucocorticoids",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M9789",
                            "name": "Hormones",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M9788",
                            "name": "Hormone Antagonists",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M20966",
                            "name": "Antineoplastic Agents, Hormonal",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M10201",
                            "name": "Immunologic Factors",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M22318",
                            "name": "Angiogenesis Inhibitors",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M9231",
                            "name": "Growth Inhibitors",
                            "relevance": "LOW"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "Infl",
                            "name": "Anti-Inflammatory Agents"
                        },
                        {
                            "abbrev": "ANeo",
                            "name": "Antineoplastic Agents"
                        },
                        {
                            "abbrev": "AnEm",
                            "name": "Antiemetics"
                        },
                        {
                            "abbrev": "Gast",
                            "name": "Gastrointestinal Agents"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Drugs and Chemicals"
                        }
                    ]
                }
            },
            "hasResults": true
        },
        {
            "protocolSection": {
                "identificationModule": {
                    "nctId": "NCT00233272",
                    "orgStudyIdInfo": {
                        "id": "030325"
                    },
                    "secondaryIdInfos": [
                        {
                            "id": "03-AG-0325"
                        }
                    ],
                    "organization": {
                        "fullName": "National Institutes of Health Clinical Center (CC)",
                        "class": "NIH"
                    },
                    "briefTitle": "Baltimore Longitudinal Study of Aging",
                    "officialTitle": "The Baltimore Longitudinal Study of Aging(BLSA)"
                },
                "statusModule": {
                    "statusVerifiedDate": "2024-10-17",
                    "overallStatus": "RECRUITING",
                    "expandedAccessInfo": {
                        "hasExpandedAccess": false
                    },
                    "startDateStruct": {
                        "date": "2014-02-03",
                        "type": "ACTUAL"
                    },
                    "studyFirstSubmitDate": "2005-10-03",
                    "studyFirstSubmitQcDate": "2005-10-03",
                    "studyFirstPostDateStruct": {
                        "date": "2005-10-05",
                        "type": "ESTIMATED"
                    },
                    "lastUpdateSubmitDate": "2024-10-18",
                    "lastUpdatePostDateStruct": {
                        "date": "2024-10-21",
                        "type": "ACTUAL"
                    }
                },
                "sponsorCollaboratorsModule": {
                    "responsibleParty": {
                        "type": "SPONSOR"
                    },
                    "leadSponsor": {
                        "name": "National Institute on Aging (NIA)",
                        "class": "NIH"
                    }
                },
                "oversightModule": {
                    "isFdaRegulatedDrug": false,
                    "isFdaRegulatedDevice": false
                },
                "descriptionModule": {
                    "briefSummary": "Background:\n\n- The Baltimore Longitudinal Study of Aging (BLSA) is a clinical research program on human aging that began in 1958. Volunteers of different ages join the study when they are healthy, and have follow-up visits for life. Visits last for multiple days. Participants are evaluated for many physical elements as well as for brain function. Physical tests are given. Information on mood, personality, and social aspects of life is also collected. This program has contributed more than any other research project to our understanding of aging.\n\nObjectives:\n\n- To characterize the many aspects of the aging process and learn how people can successfully adapt to aging.\n\nEligibility:\n\n- Healthy individuals at least 20 years old.\n\nDesign:\n\n* Participants will receive a booklet and video describing the tests they will take.\n* During a 3-day visit at the study hospital, participants will take the following tests:\n* Urine will be collected for 24 hours. Blood samples will be taken. A small piece of muscle tissue may be collected by a needle.\n* A medical questionnaire and a physical exam will be given.\n* Participants hearts will be tested, including with blood pressure tests and electronic monitors. They will breathe into a tube to test their lungs.\n* Participants will perform several exercises, including treadmill walking.\n* Vision, hearing, and taste will be tested.\n* Bone and joint X-rays may be taken.\n* Imaging tests will be given, such as an MRI.\n* Participants will answer questions to test their mental abilities.\n* Participants will return for follow-up visits every few years for life. The tests listed above will be given at every visit.",
                    "detailedDescription": "The Baltimore Longitudinal Study of Aging (BLSA) is the NIA s major clinical research program in human aging that has been conducted in Baltimore since 1958. The study population is a series of healthy volunteers of different ages followed indefinitely with serial evaluations over time. The major aim of the study is to characterize the aging process in its multifaceted aspects. To accomplish this task, a large cohort of volunteers dispersed over a wide age range are enrolled in the study when they are healthy, and then followed with regular follow-up visits for life. Since the aging process involves the whole range of physiological domains, participants receive an extensive evaluation of physiological parameters, biomarkers, risk factors, disease-related measures, impairments, and physical and cognitive function over follow-up visits that last for multiple days. Blood samples and other specimens are collected to obtain part of these measures and/or to be stored for future use. Information on mood, personality, psychological and social aspects of life that are relevant to the study of aging is also collected. Information collected in the BLSA represents a unique source of longitudinal data on aging. Historically the BLSA has contributed more than any other research project to our understanding of aging. More recently, the BLSA has begun to focus on factors associated with exceptionally healthy aging."
                },
                "conditionsModule": {
                    "conditions": [
                        "Aging"
                    ],
                    "keywords": [
                        "Frailty",
                        "Disease Processes",
                        "Natural History"
                    ]
                },
                "designModule": {
                    "studyType": "OBSERVATIONAL",
                    "designInfo": {
                        "observationalModel": "COHORT",
                        "timePerspective": "PROSPECTIVE"
                    },
                    "enrollmentInfo": {
                        "count": 10000,
                        "type": "ESTIMATED"
                    }
                },
                "armsInterventionsModule": {
                    "armGroups": [
                        {
                            "label": "Healthy Volunteers",
                            "description": "Healthy volunteers over a wide age-range"
                        }
                    ]
                },
                "outcomesModule": {
                    "primaryOutcomes": [
                        {
                            "measure": "The major aim of the BLSA is to characterize the aging process in its multifaceted aspects.",
                            "description": "Characterization of the aging process",
                            "timeFrame": "Ongoing"
                        }
                    ]
                },
                "eligibilityModule": {
                    "eligibilityCriteria": "* INCLUSION CRITERIA:\n\nThese criteria pertain to the Screening Visit and Visit 1. If any of these conditions develop after this time, the participant remains in the study. In particular, participants who develop cognitive, motor or psychiatric conditions are retained in the study, although they are excluded from specific testing in which their underlying health condition is an exclusion criteria. Participants that refuse genetic testing and storage at Visit 1 will not be eligible to participate in the study.\n\n* Age greater than or equal to 20 years of age\n* Weigh less than or equal to 300lbs and/or body mass index (BMI) is less than or equal to 40\n* Do not have established genetic diseases\n* Are able to perform daily self- care without assistance\n* Are able to walk independently for at least 400 meters without assistance and without developing symptoms\n* Are able to perform normal activities of daily living without shortness of breath (walking or climbing stairs)\n* Do not have cognitive impairment based on screening tests and in the absence of any drug treatment\n* Do not have a history of cardiovascular disease (including angina, myocardial infarction, congestive heart failure, cerebrovascular diseases, uncontrolled hypertension)\n* Do not have a history of diabetes (requiring any medical treatment other than diet and exercise)\n* Do not have active (any activity in the last 10 years) cancer, except for locally limited basal or squamous cell cancer\n* Do not have clinically significant hormonal dysfunction (Laboratory values out of range despite supplementation and/or drug treatment)\n* Do not have a history of neurological diseases or birth defects (other than minor anatomical abnormalities, which do not affect physical and/or cognitive function)\n* Do not have a history of kidney or liver disease (associated with reduced kidney or liver function)\n* Do not have a history of severe gastrointestinal (G.I.) diseases\n* Do not have muscle-skeletal conditions due to diseases or traumas (that cause pathological weakness and/or chronic pain)\n* Do not have a history of severe psychiatric conditions (associated with behavioral problems or requiring chronic medical treatment)\n* Do not have any medical condition that requires absolute and continuous need for long term treatment with antibiotics, corticosteroids, immunosuppressors, H2 blockers and/or proton pump inhibitors, or pain medications\n* Do not have important sensory deficits (legally blind and/or any condition that precludes the participant from being tested with standard neuropsychological tests or providing informed consent)\n* Able to read and speak English\n* Do not have joint replacements due to arthritic changes (joint replacements due to previous trauma are ok) or do not have 2 or more joint replacements for any reason.\n* Do not meet any exclusionary criteria for MRI and agrees to perform the test\n* Agree to genetic (DNA/RNA) sample collection, analysis, and storage at Visit 1\n\nEXCLUSION CRITERIA:\n\nThese criteria pertain to the Screening Visit and Visit 1. If conditions considered as exclusion criteria for study entry develop any time after the this, the participant remains in the study.\n\nExclusion Criteria Based on Laboratory Assessment:\n\n* HIV virus infection\n* Hepatitis B or C\n* Syphilis\n* WBC \\> 12,000/mcrL;\n* Platelets \\< 100,000 or \\>600,000 /mcrL;\n* Hemoglobin \\< 11 g/dL;\n* Creatinine \\>1.5 mg/dl or calculated creatinine clearance \\< 50 cc/min;\n* Bilirubin \\> 1.5 mg/dl unless higher levels can be ascribed to Gilbert s disease;\n* ALT, AST or alkaline phosphatase twice the normal serum concentration\n* Corrected calcium \\< 8.5 or \\> 10.7 mg/dl\n* Albumin \\< 3.1 g/dl",
                    "healthyVolunteers": true,
                    "sex": "ALL",
                    "minimumAge": "20 Years",
                    "maximumAge": "120 Years",
                    "stdAges": [
                        "ADULT",
                        "OLDER_ADULT"
                    ],
                    "studyPopulation": "Healthy volunteers 20 years of age or older.",
                    "samplingMethod": "PROBABILITY_SAMPLE"
                },
                "contactsLocationsModule": {
                    "centralContacts": [
                        {
                            "name": "Linda M Zukley, Ph.D.",
                            "role": "CONTACT",
                            "phone": "(410) 350-3983",
                            "email": "zukleylm@mail.nih.gov"
                        },
                        {
                            "name": "Luigi Ferrucci, M.D.",
                            "role": "CONTACT",
                            "phone": "(410) 558-8110",
                            "email": "ferruccilu@grc.nia.nih.gov"
                        }
                    ],
                    "overallOfficials": [
                        {
                            "name": "Luigi Ferrucci, M.D.",
                            "affiliation": "National Institute on Aging (NIA)",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "locations": [
                        {
                            "facility": "National Institute of Aging, Clinical Research Unit",
                            "status": "RECRUITING",
                            "city": "Baltimore",
                            "state": "Maryland",
                            "zip": "21224",
                            "country": "United States",
                            "contacts": [
                                {
                                    "name": "NIA Studies Recruitment",
                                    "role": "CONTACT",
                                    "phone": "410-350-3941",
                                    "email": "niastudiesrecruitment@mail.nih.gov"
                                }
                            ],
                            "geoPoint": {
                                "lat": 39.29038,
                                "lon": -76.61219
                            }
                        }
                    ]
                },
                "referencesModule": {
                    "references": [
                        {
                            "pmid": "24712564",
                            "type": "DERIVED",
                            "citation": "Chia CW, Odetunde JO, Kim W, Carlson OD, Ferrucci L, Egan JM. GIP contributes to islet trihormonal abnormalities in type 2 diabetes. J Clin Endocrinol Metab. 2014 Jul;99(7):2477-85. doi: 10.1210/jc.2013-3994. Epub 2014 Apr 8."
                        }
                    ],
                    "seeAlsoLinks": [
                        {
                            "label": "NIH Clinical Center Detailed Web Page",
                            "url": "https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2003-AG-0325.html"
                        }
                    ]
                },
                "ipdSharingStatementModule": {
                    "ipdSharing": "UNDECIDED",
                    "description": "There is ongoing discussion within the NIA IRP and a plan has not been finalized yet."
                }
            },
            "derivedSection": {
                "miscInfoModule": {
                    "versionHolder": "2024-11-18"
                },
                "conditionBrowseModule": {
                    "browseLeaves": [
                        {
                            "id": "M1175",
                            "name": "Frailty",
                            "relevance": "LOW"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "BC23",
                            "name": "Symptoms and General Pathology"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Conditions"
                        }
                    ]
                }
            },
            "hasResults": false
        },
        {
            "protocolSection": {
                "identificationModule": {
                    "nctId": "NCT06150872",
                    "orgStudyIdInfo": {
                        "id": "DUR-001"
                    },
                    "organization": {
                        "fullName": "DurVena, Inc.",
                        "class": "INDUSTRY"
                    },
                    "briefTitle": "Photochemical Tissue Passivation Treatment of Saphenous Vein Grafts in CABG",
                    "officialTitle": "Early Feasibility Study to Evaluate the Safety of Photochemical Tissue Passivation (PTP) Treatment of Saphenous Vein Grafts in Participants Undergoing Elective CABG"
                },
                "statusModule": {
                    "statusVerifiedDate": "2024-10",
                    "overallStatus": "ACTIVE_NOT_RECRUITING",
                    "expandedAccessInfo": {
                        "hasExpandedAccess": false
                    },
                    "startDateStruct": {
                        "date": "2024-01-08",
                        "type": "ACTUAL"
                    },
                    "primaryCompletionDateStruct": {
                        "date": "2025-01-30",
                        "type": "ESTIMATED"
                    },
                    "completionDateStruct": {
                        "date": "2025-03-30",
                        "type": "ESTIMATED"
                    },
                    "studyFirstSubmitDate": "2023-11-20",
                    "studyFirstSubmitQcDate": "2023-11-27",
                    "studyFirstPostDateStruct": {
                        "date": "2023-11-29",
                        "type": "ACTUAL"
                    },
                    "lastUpdateSubmitDate": "2024-10-17",
                    "lastUpdatePostDateStruct": {
                        "date": "2024-10-21",
                        "type": "ACTUAL"
                    }
                },
                "sponsorCollaboratorsModule": {
                    "responsibleParty": {
                        "type": "SPONSOR"
                    },
                    "leadSponsor": {
                        "name": "DurVena, Inc.",
                        "class": "INDUSTRY"
                    }
                },
                "oversightModule": {
                    "oversightHasDmc": false,
                    "isFdaRegulatedDrug": false,
                    "isFdaRegulatedDevice": true,
                    "isUnapprovedDevice": true,
                    "isUsExport": true
                },
                "descriptionModule": {
                    "briefSummary": "Early feasibility study of the DurVena Photochemical Tissue Passivation (PTP) device for treatment of saphenous vein grafts in participants undergoing elective coronary artery bypass graft (CABG) surgery. Study to be conducted outside the U.S.",
                    "detailedDescription": "The Photochemical Tissue Passivation (PTP) treatment of a saphenous vein graft (SVG) is indicated for the reduction of intimal hyperplasia and graft failure rate in SVGs after coronary bypass graft (CABG) surgery. The primary study objective, in this early feasibility study outside the US, is to characterize the safety profile of the PTP device when used during CABG surgery in participants with multivessel atherosclerotic coronary artery disease (CAD).\n\nThis is a prospective, randomized, within-subject controlled early feasibility study.\n\nUp to 15 participants with multivessel CAD will be recruited for this study and followed for a minimum of 1 year."
                },
                "conditionsModule": {
                    "conditions": [
                        "Coronary Artery Disease"
                    ],
                    "keywords": [
                        "saphenous vein grafts",
                        "CABG surgery"
                    ]
                },
                "designModule": {
                    "studyType": "INTERVENTIONAL",
                    "phases": [
                        "NA"
                    ],
                    "designInfo": {
                        "allocation": "RANDOMIZED",
                        "interventionModel": "PARALLEL",
                        "primaryPurpose": "TREATMENT",
                        "maskingInfo": {
                            "masking": "SINGLE",
                            "maskingDescription": "Each subject will have at least 2 saphenous vein grafts. One graft will be randomized to treatment and one graft will be randomized to control. The outcomes assessor will be blinded to which graft has been treated.",
                            "whoMasked": [
                                "OUTCOMES_ASSESSOR"
                            ]
                        }
                    },
                    "enrollmentInfo": {
                        "count": 4,
                        "type": "ESTIMATED"
                    }
                },
                "armsInterventionsModule": {
                    "armGroups": [
                        {
                            "label": "Photochemical tissue passivation group",
                            "type": "EXPERIMENTAL",
                            "description": "Photochemical tissue passivation of a saphenous vein graft",
                            "interventionNames": [
                                "Device: DurVena Photochemical Tissue Passivation"
                            ]
                        },
                        {
                            "label": "Standard of care group",
                            "type": "NO_INTERVENTION",
                            "description": "Standard of care treatment of a saphenous vein graft"
                        }
                    ],
                    "interventions": [
                        {
                            "type": "DEVICE",
                            "name": "DurVena Photochemical Tissue Passivation",
                            "description": "Treatment of a saphenous vein graft with the DurVena Photochemical Tissue Passivation device.",
                            "armGroupLabels": [
                                "Photochemical tissue passivation group"
                            ]
                        }
                    ]
                },
                "outcomesModule": {
                    "primaryOutcomes": [
                        {
                            "measure": "Major cardiac adverse events (MACCE)",
                            "description": "Major adverse cardiac and cerebral events (MACCE) including all-cause mortality, MI, stroke, and revascularization",
                            "timeFrame": "30-days"
                        }
                    ],
                    "secondaryOutcomes": [
                        {
                            "measure": "Major cardiac adverse events (MACCE)",
                            "description": "Major adverse cardiac and cerebral events (MACCE) including all-cause mortality, MI, stroke, and revascularization",
                            "timeFrame": "6-months"
                        },
                        {
                            "measure": "Major cardiac adverse events (MACCE)",
                            "description": "Major adverse cardiac and cerebral events (MACCE) including all-cause mortality, MI, stroke, and revascularization",
                            "timeFrame": "1-year"
                        }
                    ]
                },
                "eligibilityModule": {
                    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Signed informed consent, inclusive of release of medical information, and Health Insurance Portability and Accountability Act (HIPAA) documentation.\n2. Age 21 years or older.\n3. Planned and scheduled on-pump, arrested heart CABG.\n4. Two or more vein grafts to native vessels having at least 75% stenosis and comparable runoff.\n5. IMA graft indicated for the LAD.\n6. Appropriately sized and accessible target coronary arteries, with a minimum diameter of 2 mm and adequate vascular bed (without significant distal stenosis), as assessed by pre-operative cardiac angiography and verified by diameter gauging intraoperatively.\n\n   -\n\nExclusion Criteria:\n\n1. Concomitant non-CABG cardiac surgical procedure.\n2. Prior cardiac surgery.\n3. Emergency CABG surgery (e.g., cardiogenic shock, inotropic pressure support, intraaortic balloon pump, ECMO).\n4. Contraindication for on-pump CABG with cardioplegic arrest (e.g., severely calcified aorta).\n5. Calcification at the intended anastomotic sites, as assessed upon opening of the chest and before randomization.\n6. Platelets \\< 50,000/mm3 or other evidence of coagulopathy, INR greater than 1.5 in the absence of anticoagulation therapy.\n7. Infection (WBC \u226512.5 x 103/ml and or temperature \u2265100.5\u00b0F/38\u00b0C).\n8. History of cerebral vascular accident (CVA) or transient ischemic attacks (TIA) within the last 3 months.\n9. Unwilling or unable to receive blood transfusion.\n10. Inability to undergo treatment with heparin.\n11. Participants on dialysis or GFR of \\<30 ml/min/1.73m2.\n12. Primary liver disease with bilirubin, SGOT, or SGPT \\> 4X upper limit of normal.\n13. Prior history of allergic reaction to contrast media with anaphylaxis or severe peripheral edema.\n14. Any medical condition that, in the opinion of the investigator, would compromise the safety of the participant or quality of the study data.\n15. Pregnancy and nursing or lactating.\n16. Current, or past participation in a clinical trial within the past 30 days.",
                    "healthyVolunteers": false,
                    "sex": "ALL",
                    "minimumAge": "21 Years",
                    "stdAges": [
                        "ADULT",
                        "OLDER_ADULT"
                    ]
                },
                "contactsLocationsModule": {
                    "overallOfficials": [
                        {
                            "name": "Abdusalom Abdurakhmanov, MD",
                            "affiliation": "Republican Scientific Center of Emergency Medical Care, Uzbekistan",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "locations": [
                        {
                            "facility": "Republican Scientific Center of Emergency Medical Care",
                            "city": "Tashkent",
                            "country": "Uzbekistan",
                            "geoPoint": {
                                "lat": 41.26465,
                                "lon": 69.21627
                            }
                        }
                    ]
                },
                "ipdSharingStatementModule": {
                    "ipdSharing": "NO"
                }
            },
            "derivedSection": {
                "miscInfoModule": {
                    "versionHolder": "2024-11-18"
                },
                "conditionBrowseModule": {
                    "meshes": [
                        {
                            "id": "D003324",
                            "term": "Coronary Artery Disease"
                        }
                    ],
                    "ancestors": [
                        {
                            "id": "D003327",
                            "term": "Coronary Disease"
                        },
                        {
                            "id": "D017202",
                            "term": "Myocardial Ischemia"
                        },
                        {
                            "id": "D006331",
                            "term": "Heart Diseases"
                        },
                        {
                            "id": "D002318",
                            "term": "Cardiovascular Diseases"
                        },
                        {
                            "id": "D001161",
                            "term": "Arteriosclerosis"
                        },
                        {
                            "id": "D001157",
                            "term": "Arterial Occlusive Diseases"
                        },
                        {
                            "id": "D014652",
                            "term": "Vascular Diseases"
                        }
                    ],
                    "browseLeaves": [
                        {
                            "id": "M6546",
                            "name": "Coronary Artery Disease",
                            "asFound": "Coronary Artery Disease",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M19506",
                            "name": "Myocardial Ischemia",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M6549",
                            "name": "Coronary Disease",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M10543",
                            "name": "Ischemia",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M9419",
                            "name": "Heart Diseases",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M4469",
                            "name": "Arteriosclerosis",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M4465",
                            "name": "Arterial Occlusive Diseases",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M17400",
                            "name": "Vascular Diseases",
                            "relevance": "LOW"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "BC14",
                            "name": "Heart and Blood Diseases"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Conditions"
                        },
                        {
                            "abbrev": "BC23",
                            "name": "Symptoms and General Pathology"
                        }
                    ]
                }
            },
            "hasResults": false
        },
        {
            "protocolSection": {
                "identificationModule": {
                    "nctId": "NCT05909904",
                    "orgStudyIdInfo": {
                        "id": "BGB-HNSCC-201"
                    },
                    "secondaryIdInfos": [
                        {
                            "id": "CTR20232123",
                            "type": "OTHER",
                            "domain": "ChinaDrugTrials"
                        }
                    ],
                    "organization": {
                        "fullName": "BeiGene",
                        "class": "INDUSTRY"
                    },
                    "briefTitle": "Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma",
                    "officialTitle": "A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma"
                },
                "statusModule": {
                    "statusVerifiedDate": "2024-10",
                    "overallStatus": "RECRUITING",
                    "expandedAccessInfo": {
                        "hasExpandedAccess": false
                    },
                    "startDateStruct": {
                        "date": "2023-07-21",
                        "type": "ACTUAL"
                    },
                    "primaryCompletionDateStruct": {
                        "date": "2027-01",
                        "type": "ESTIMATED"
                    },
                    "completionDateStruct": {
                        "date": "2027-01",
                        "type": "ESTIMATED"
                    },
                    "studyFirstSubmitDate": "2023-06-09",
                    "studyFirstSubmitQcDate": "2023-06-09",
                    "studyFirstPostDateStruct": {
                        "date": "2023-06-18",
                        "type": "ACTUAL"
                    },
                    "lastUpdateSubmitDate": "2024-10-18",
                    "lastUpdatePostDateStruct": {
                        "date": "2024-10-21",
                        "type": "ACTUAL"
                    }
                },
                "sponsorCollaboratorsModule": {
                    "responsibleParty": {
                        "type": "SPONSOR"
                    },
                    "leadSponsor": {
                        "name": "BeiGene",
                        "class": "INDUSTRY"
                    }
                },
                "oversightModule": {
                    "oversightHasDmc": true,
                    "isFdaRegulatedDrug": true,
                    "isFdaRegulatedDevice": false
                },
                "descriptionModule": {
                    "briefSummary": "This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).",
                    "detailedDescription": "This study will test whether tislelizumab alone and combined with other investigational agents can be used to improve treatment outcomes in participants with head and neck squamous cell carcinoma. The main goals of the study are to determine how many participants may no longer have evidence of cancer or have some improvement in the signs and symptoms of cancer after treatment and to determine what adverse events, or side effects, participants might experience.\n\nTislelizumab is used to block the programmed cell death protein-1 pathway so that immune system cells (T-cells) can better protect the body from infection and find tumor cells to attack. Tislelizumab may be used in combination with other therapies as a promising approach with potential therapeutic benefits to treat participants with cancer. The study will enroll approximately 160 participants. Participants will be randomly assigned (by chance, similar to flipping a coin) to one of the various treatment groups. Tislelizumab and investigational agents will be administered as an infusion through a vein at regularly scheduled intervals.\n\nThe study will take place at multiple centers worldwide. Treatments will continue until participants experience no benefits, too many side effects, or withdraw consent."
                },
                "conditionsModule": {
                    "conditions": [
                        "Head and Neck Squamous Cell Carcinoma",
                        "Head and Neck Cancer"
                    ]
                },
                "designModule": {
                    "studyType": "INTERVENTIONAL",
                    "phases": [
                        "PHASE2"
                    ],
                    "designInfo": {
                        "allocation": "RANDOMIZED",
                        "interventionModel": "PARALLEL",
                        "primaryPurpose": "TREATMENT",
                        "maskingInfo": {
                            "masking": "NONE"
                        }
                    },
                    "enrollmentInfo": {
                        "count": 160,
                        "type": "ESTIMATED"
                    }
                },
                "armsInterventionsModule": {
                    "armGroups": [
                        {
                            "label": "Tislelizumab",
                            "type": "ACTIVE_COMPARATOR",
                            "description": "Tislelizumab 200 milligrams (mg) administered once every 3 weeks",
                            "interventionNames": [
                                "Drug: Tislelizumab"
                            ]
                        },
                        {
                            "label": "Tislelizumab + BGB-A425",
                            "type": "EXPERIMENTAL",
                            "description": "Tislelizumab 200 mg administered once every 3 weeks with BGB-A425",
                            "interventionNames": [
                                "Drug: Tislelizumab",
                                "Drug: BGB-A425"
                            ]
                        },
                        {
                            "label": "Tislelizumab + LBL-007",
                            "type": "EXPERIMENTAL",
                            "description": "Tislelizumab 200 mg administered once every 3 weeks with LBL-007",
                            "interventionNames": [
                                "Drug: Tislelizumab",
                                "Drug: LBL-007"
                            ]
                        },
                        {
                            "label": "Tislelizumab + BGB-A425 + LBL-007",
                            "type": "EXPERIMENTAL",
                            "description": "Tislelizumab 200 mg administered once every 3 weeks with BGB-A425 and LBL-007",
                            "interventionNames": [
                                "Drug: Tislelizumab",
                                "Drug: BGB-A425",
                                "Drug: LBL-007"
                            ]
                        }
                    ],
                    "interventions": [
                        {
                            "type": "DRUG",
                            "name": "Tislelizumab",
                            "description": "Administered intravenously",
                            "armGroupLabels": [
                                "Tislelizumab",
                                "Tislelizumab + BGB-A425",
                                "Tislelizumab + BGB-A425 + LBL-007",
                                "Tislelizumab + LBL-007"
                            ],
                            "otherNames": [
                                "BGB-A317"
                            ]
                        },
                        {
                            "type": "DRUG",
                            "name": "BGB-A425",
                            "description": "Administered intravenously",
                            "armGroupLabels": [
                                "Tislelizumab + BGB-A425",
                                "Tislelizumab + BGB-A425 + LBL-007"
                            ]
                        },
                        {
                            "type": "DRUG",
                            "name": "LBL-007",
                            "description": "Administered intravenously",
                            "armGroupLabels": [
                                "Tislelizumab + BGB-A425 + LBL-007",
                                "Tislelizumab + LBL-007"
                            ]
                        }
                    ]
                },
                "outcomesModule": {
                    "primaryOutcomes": [
                        {
                            "measure": "Objective Response Rate (ORR)",
                            "description": "ORR is defined as percentage of participants who have a confirmed complete response (CR) or a confirmed partial response (PR) as assessed by the investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",
                            "timeFrame": "Up to approximately 3 years and 6 months"
                        }
                    ],
                    "secondaryOutcomes": [
                        {
                            "measure": "Progression-free Survival (PFS)",
                            "description": "PFS is defined as the time from the date of randomization to the date of the first documentation of progressive disease assessed by the investigators per RECIST v1.1 or death, whichever occurs first",
                            "timeFrame": "Up to approximately 3 years and 6 months"
                        },
                        {
                            "measure": "Duration of Response (DOR)",
                            "description": "DOR is defined as the time from the first determination of a confirmed response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first",
                            "timeFrame": "Up to approximately 3 years and 6 months"
                        },
                        {
                            "measure": "Clinical Benefit Rate (CBR)",
                            "description": "CBR is defined as the percentage of participants with a best overall response of a confirmed CR, a confirmed PR, or a durable stable disease (SD) (SD duration \u2265 24 weeks)",
                            "timeFrame": "Up to approximately 3 years and 6 months"
                        },
                        {
                            "measure": "Disease Control Rate (DCR)",
                            "description": "DCR is defined as the percentage of participants with a best overall response of a confirmed CR, a confirmed PR, or SD",
                            "timeFrame": "Up to approximately 3 years and 6 months"
                        },
                        {
                            "measure": "Number of Participants with Adverse Events",
                            "description": "Number of participants with adverse events, including laboratory values, vital signs, physical examinations, and electrocardiogram findings",
                            "timeFrame": "Up to approximately 3 years and 6 months"
                        },
                        {
                            "measure": "Overall Survival (OS)",
                            "description": "OS is defined as the time from the date of randomization to the date of death due to any cause",
                            "timeFrame": "Up to approximately 3 years and 6 months"
                        },
                        {
                            "measure": "Number of Participants with Anti-Drug Antibodies (ADAs)",
                            "description": "Number of participants with detectable ADAs",
                            "timeFrame": "Up to approximately 3 years and 6 months"
                        }
                    ]
                },
                "eligibilityModule": {
                    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants with histologically or cytologically confirmed R/M HNSCC that is considered incurable by local therapies\n\n  1. The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx\n  2. Participants should not have had prior systemic therapy administered in the R/M setting; systemic therapy which was completed prior to randomization/enrollment if given as part of multimodal treatment for locally or locoregionally advanced disease is allowed\n* Participants must have positive PD-L1 expression (Combined Positive Score \\[CPS\\] \u2265 1)\n* Have at least 1 measurable lesion as defined per RECIST v1.1\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1\n* Adequate hematologic and organ function as indicated by specific laboratory values within 7 days of first dose of study drug\n* Willing to use a highly effective method of birth control for the duration of the study and for \u2265 120 days after the last dose of study drug(s)\n\nExclusion Criteria:\n\n* Recurrent or metastatic carcinoma of the nasopharynx (any histology), squamous cell carcinoma of unknown primary, squamous cell carcinoma that originated from the skin and salivary gland primary tumor or non-squamous histologies (eg, mucosal melanoma)\n* Prior therapy with an anti-PD-1, anti-PD-L1, PD-L2, T-cell immunoglobulin and mucin domain containing-3 (TIM-3), LAG-3, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways\n* Any active malignancy \u2264 2 years before randomization/enrollment except for the specific cancer under investigation in this study, those with a negligible risk of metastasis or death, and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, localized prostate cancer, and carcinoma in situ of the cervix or breast)\n* History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including pulmonary fibrosis, and acute lung diseases\n* A history of severe hypersensitivity reactions to other monoclonal antibodies or has experienced a severe immune-mediated adverse event (imAE), an imAE that led to treatment discontinuation, or a cardiac or ocular imAE of any grade with prior immunotherapy\n\nNote: Other inclusion and exclusion criteria may apply",
                    "healthyVolunteers": false,
                    "sex": "ALL",
                    "minimumAge": "18 Years",
                    "stdAges": [
                        "ADULT",
                        "OLDER_ADULT"
                    ]
                },
                "contactsLocationsModule": {
                    "centralContacts": [
                        {
                            "name": "Study Director",
                            "role": "CONTACT",
                            "phone": "1-877-828-5568",
                            "email": "clinicaltrials@beigene.com"
                        }
                    ],
                    "overallOfficials": [
                        {
                            "name": "Study Director",
                            "affiliation": "BeiGene",
                            "role": "STUDY_DIRECTOR"
                        }
                    ],
                    "locations": [
                        {
                            "facility": "Stanford Medicine",
                            "status": "RECRUITING",
                            "city": "Stanford",
                            "state": "California",
                            "zip": "94305",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 37.42411,
                                "lon": -122.16608
                            }
                        },
                        {
                            "facility": "Rocky Mountain Cancer Centers, Llp(Us Oncology Research)",
                            "status": "RECRUITING",
                            "city": "Lone Tree",
                            "state": "Colorado",
                            "zip": "80124",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 39.55171,
                                "lon": -104.8863
                            }
                        },
                        {
                            "facility": "Florida Cancer Specialist Research Institute Lake Nona",
                            "status": "RECRUITING",
                            "city": "Orlando",
                            "state": "Florida",
                            "zip": "32827",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 28.53834,
                                "lon": -81.37924
                            }
                        },
                        {
                            "facility": "Florida Cancer Specialist Research Institute Panhandle",
                            "status": "RECRUITING",
                            "city": "Tallahassee",
                            "state": "Florida",
                            "zip": "32308",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 30.43826,
                                "lon": -84.28073
                            }
                        },
                        {
                            "facility": "University of Kentucky Markey Cancer Center",
                            "status": "RECRUITING",
                            "city": "Lexington",
                            "state": "Kentucky",
                            "zip": "40536",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 37.98869,
                                "lon": -84.47772
                            }
                        },
                        {
                            "facility": "Oncology and Hematology Associates of Southwest Virginia, Inc (Us Oncology Research)",
                            "status": "RECRUITING",
                            "city": "Blacksburg",
                            "state": "Virginia",
                            "zip": "24060",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 37.22957,
                                "lon": -80.41394
                            }
                        },
                        {
                            "facility": "Cancer Care Northwest",
                            "status": "RECRUITING",
                            "city": "Spokane Valley",
                            "state": "Washington",
                            "zip": "99216",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 47.67323,
                                "lon": -117.23937
                            }
                        },
                        {
                            "facility": "Northwest Cancer Specialist, Pc(Us Oncology Research)",
                            "status": "RECRUITING",
                            "city": "Vancouver",
                            "state": "Washington",
                            "zip": "98684",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 45.63873,
                                "lon": -122.66149
                            }
                        },
                        {
                            "facility": "Nepean Hospital",
                            "status": "RECRUITING",
                            "city": "Kingswood",
                            "state": "New South Wales",
                            "zip": "2747",
                            "country": "Australia"
                        },
                        {
                            "facility": "North Shore Private Hospital",
                            "status": "RECRUITING",
                            "city": "St Leonards",
                            "state": "New South Wales",
                            "zip": "2065",
                            "country": "Australia",
                            "geoPoint": {
                                "lat": -33.82344,
                                "lon": 151.19836
                            }
                        },
                        {
                            "facility": "Greenslopes Private Hospital",
                            "status": "RECRUITING",
                            "city": "Greenslopes",
                            "state": "Queensland",
                            "zip": "4120",
                            "country": "Australia",
                            "geoPoint": {
                                "lat": -27.50815,
                                "lon": 153.04951
                            }
                        },
                        {
                            "facility": "Cancer Research South Australia",
                            "status": "RECRUITING",
                            "city": "Adelaide",
                            "state": "South Australia",
                            "zip": "5000",
                            "country": "Australia",
                            "geoPoint": {
                                "lat": -34.92866,
                                "lon": 138.59863
                            }
                        },
                        {
                            "facility": "Northeast Health Wangaratta",
                            "status": "RECRUITING",
                            "city": "Wangaratta",
                            "state": "Victoria",
                            "zip": "3677",
                            "country": "Australia",
                            "geoPoint": {
                                "lat": -36.35846,
                                "lon": 146.32056
                            }
                        },
                        {
                            "facility": "St John of God, Murdoch",
                            "status": "RECRUITING",
                            "city": "Murdoch",
                            "state": "Western Australia",
                            "zip": "6150",
                            "country": "Australia",
                            "geoPoint": {
                                "lat": -32.06987,
                                "lon": 115.83757
                            }
                        },
                        {
                            "facility": "British Columbia Cancer Agency the Vancouver Centre",
                            "status": "RECRUITING",
                            "city": "Vancouver",
                            "state": "British Columbia",
                            "zip": "V5Z 4E6",
                            "country": "Canada",
                            "geoPoint": {
                                "lat": 49.24966,
                                "lon": -123.11934
                            }
                        },
                        {
                            "facility": "The Ottawa Hospital Cancer Centre",
                            "status": "RECRUITING",
                            "city": "Ottawa",
                            "state": "Ontario",
                            "zip": "K1H 8L6",
                            "country": "Canada",
                            "geoPoint": {
                                "lat": 45.41117,
                                "lon": -75.69812
                            }
                        },
                        {
                            "facility": "Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital",
                            "status": "RECRUITING",
                            "city": "Hefei",
                            "state": "Anhui",
                            "zip": "230088",
                            "country": "China",
                            "geoPoint": {
                                "lat": 31.86389,
                                "lon": 117.28083
                            }
                        },
                        {
                            "facility": "Beijing Tongren Hospital, Cmu",
                            "status": "RECRUITING",
                            "city": "Beijing",
                            "state": "Beijing",
                            "zip": "100010",
                            "country": "China",
                            "geoPoint": {
                                "lat": 39.9075,
                                "lon": 116.39723
                            }
                        },
                        {
                            "facility": "Beijing Cancer Hospital",
                            "status": "RECRUITING",
                            "city": "Beijing",
                            "state": "Beijing",
                            "zip": "100142",
                            "country": "China",
                            "geoPoint": {
                                "lat": 39.9075,
                                "lon": 116.39723
                            }
                        },
                        {
                            "facility": "The First Affiliated Hospital of Chongqing Medical University",
                            "status": "RECRUITING",
                            "city": "Chongqing",
                            "state": "Chongqing",
                            "zip": "630014",
                            "country": "China",
                            "geoPoint": {
                                "lat": 29.56278,
                                "lon": 106.55278
                            }
                        },
                        {
                            "facility": "Fujian Cancer Hospital",
                            "status": "RECRUITING",
                            "city": "Fuzhou",
                            "state": "Fujian",
                            "zip": "350014",
                            "country": "China",
                            "geoPoint": {
                                "lat": 26.06139,
                                "lon": 119.30611
                            }
                        },
                        {
                            "facility": "The First Affiliated Hospital of Xiamen University",
                            "status": "RECRUITING",
                            "city": "Xiamen",
                            "state": "Fujian",
                            "zip": "361003",
                            "country": "China",
                            "geoPoint": {
                                "lat": 24.47979,
                                "lon": 118.08187
                            }
                        },
                        {
                            "facility": "Sun Yat Sen University Cancer Center",
                            "status": "RECRUITING",
                            "city": "Guangzhou",
                            "state": "Guangdong",
                            "zip": "510060",
                            "country": "China",
                            "geoPoint": {
                                "lat": 23.11667,
                                "lon": 113.25
                            }
                        },
                        {
                            "facility": "The Tumor Hospital Affiliated to Guangxi Medical University",
                            "status": "RECRUITING",
                            "city": "Nanning",
                            "state": "Guangxi",
                            "zip": "530021",
                            "country": "China",
                            "geoPoint": {
                                "lat": 22.81667,
                                "lon": 108.31667
                            }
                        },
                        {
                            "facility": "Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology",
                            "status": "RECRUITING",
                            "city": "Wuhan",
                            "state": "Hubei",
                            "zip": "430030",
                            "country": "China",
                            "geoPoint": {
                                "lat": 30.58333,
                                "lon": 114.26667
                            }
                        },
                        {
                            "facility": "Xiangya Hospital of Central South University",
                            "status": "RECRUITING",
                            "city": "Changsha",
                            "state": "Hunan",
                            "zip": "410008",
                            "country": "China",
                            "geoPoint": {
                                "lat": 28.19874,
                                "lon": 112.97087
                            }
                        },
                        {
                            "facility": "The Second Xiangya Hospital of Central South University",
                            "status": "RECRUITING",
                            "city": "Changsha",
                            "state": "Hunan",
                            "zip": "410011",
                            "country": "China",
                            "geoPoint": {
                                "lat": 28.19874,
                                "lon": 112.97087
                            }
                        },
                        {
                            "facility": "Hunan Cancer Hospital",
                            "status": "RECRUITING",
                            "city": "Changsha",
                            "state": "Hunan",
                            "zip": "410013",
                            "country": "China",
                            "geoPoint": {
                                "lat": 28.19874,
                                "lon": 112.97087
                            }
                        },
                        {
                            "facility": "The First Affiliated Hospital of Nanchang University Branch Donghu",
                            "status": "RECRUITING",
                            "city": "Nanchang",
                            "state": "Jiangxi",
                            "zip": "330006",
                            "country": "China",
                            "geoPoint": {
                                "lat": 28.68396,
                                "lon": 115.85306
                            }
                        },
                        {
                            "facility": "The First Hospital of Jilin University",
                            "status": "RECRUITING",
                            "city": "Changchun",
                            "state": "Jilin",
                            "zip": "130021",
                            "country": "China",
                            "geoPoint": {
                                "lat": 43.88,
                                "lon": 125.32278
                            }
                        },
                        {
                            "facility": "Shandong Cancer Hospital",
                            "status": "RECRUITING",
                            "city": "Jinan",
                            "state": "Shandong",
                            "zip": "250117",
                            "country": "China",
                            "geoPoint": {
                                "lat": 36.66833,
                                "lon": 116.99722
                            }
                        },
                        {
                            "facility": "Shanghai East Hospital",
                            "status": "RECRUITING",
                            "city": "Shanghai",
                            "state": "Shanghai",
                            "zip": "200120",
                            "country": "China",
                            "geoPoint": {
                                "lat": 31.22222,
                                "lon": 121.45806
                            }
                        },
                        {
                            "facility": "Sichuan Cancer Hospital and Institute",
                            "status": "RECRUITING",
                            "city": "Chengdu",
                            "state": "Sichuan",
                            "zip": "610041",
                            "country": "China",
                            "geoPoint": {
                                "lat": 30.66667,
                                "lon": 104.06667
                            }
                        },
                        {
                            "facility": "West China Hospital, Sichuan University",
                            "status": "RECRUITING",
                            "city": "Chengdu",
                            "state": "Sichuan",
                            "zip": "610041",
                            "country": "China",
                            "geoPoint": {
                                "lat": 30.66667,
                                "lon": 104.06667
                            }
                        },
                        {
                            "facility": "Tianjin Medical University Cancer Institute and Hospital",
                            "status": "RECRUITING",
                            "city": "Tianjin",
                            "state": "Tianjin",
                            "zip": "300060",
                            "country": "China",
                            "geoPoint": {
                                "lat": 39.14222,
                                "lon": 117.17667
                            }
                        },
                        {
                            "facility": "Zhejiang University College of Medicine Second Affiliated Hospital",
                            "status": "RECRUITING",
                            "city": "Hangzhou",
                            "state": "Zhejiang",
                            "zip": "310009",
                            "country": "China",
                            "geoPoint": {
                                "lat": 30.29365,
                                "lon": 120.16142
                            }
                        },
                        {
                            "facility": "Zhejiang Cancer Hospital",
                            "status": "RECRUITING",
                            "city": "Hangzhou",
                            "state": "Zhejiang",
                            "zip": "310022",
                            "country": "China",
                            "geoPoint": {
                                "lat": 30.29365,
                                "lon": 120.16142
                            }
                        },
                        {
                            "facility": "Keimyung University Dongsan Hospital",
                            "status": "RECRUITING",
                            "city": "Dalseogu",
                            "state": "Daegu Gwang'yeogsi",
                            "zip": "42601",
                            "country": "Korea, Republic of"
                        },
                        {
                            "facility": "National Cancer Center",
                            "status": "RECRUITING",
                            "city": "Goyangsi",
                            "state": "Gyeonggido",
                            "zip": "10408",
                            "country": "Korea, Republic of"
                        },
                        {
                            "facility": "Seoul National University Bundang Hospital",
                            "status": "RECRUITING",
                            "city": "Seongnamsi",
                            "state": "Gyeonggido",
                            "zip": "13620",
                            "country": "Korea, Republic of"
                        },
                        {
                            "facility": "Seoul National University Hospital",
                            "status": "RECRUITING",
                            "city": "Seoul",
                            "state": "Seoul Teugbyeolsi",
                            "zip": "03080",
                            "country": "Korea, Republic of",
                            "geoPoint": {
                                "lat": 37.566,
                                "lon": 126.9784
                            }
                        },
                        {
                            "facility": "Severance Hospital Yonsei University Health System",
                            "status": "RECRUITING",
                            "city": "Seoul",
                            "state": "Seoul Teugbyeolsi",
                            "zip": "03722",
                            "country": "Korea, Republic of",
                            "geoPoint": {
                                "lat": 37.566,
                                "lon": 126.9784
                            }
                        },
                        {
                            "facility": "Asan Medical Center",
                            "status": "RECRUITING",
                            "city": "Seoul",
                            "state": "Seoul Teugbyeolsi",
                            "zip": "05505",
                            "country": "Korea, Republic of",
                            "geoPoint": {
                                "lat": 37.566,
                                "lon": 126.9784
                            }
                        },
                        {
                            "facility": "Samsung Medical Center",
                            "status": "RECRUITING",
                            "city": "Seoul",
                            "state": "Seoul Teugbyeolsi",
                            "zip": "06351",
                            "country": "Korea, Republic of",
                            "geoPoint": {
                                "lat": 37.566,
                                "lon": 126.9784
                            }
                        },
                        {
                            "facility": "National Cancer Centre Singapore",
                            "status": "RECRUITING",
                            "city": "Singapore",
                            "zip": "168583",
                            "country": "Singapore",
                            "geoPoint": {
                                "lat": 1.28967,
                                "lon": 103.85007
                            }
                        },
                        {
                            "facility": "Changhua Christian Hospital",
                            "status": "RECRUITING",
                            "city": "Changhua",
                            "zip": "50006",
                            "country": "Taiwan",
                            "geoPoint": {
                                "lat": 24.07327,
                                "lon": 120.56276
                            }
                        },
                        {
                            "facility": "China Medical University Hospital",
                            "status": "RECRUITING",
                            "city": "Taichung",
                            "zip": "40447",
                            "country": "Taiwan",
                            "geoPoint": {
                                "lat": 24.1469,
                                "lon": 120.6839
                            }
                        },
                        {
                            "facility": "National Cheng Kung University Hospital",
                            "status": "RECRUITING",
                            "city": "Tainan",
                            "zip": "704",
                            "country": "Taiwan",
                            "geoPoint": {
                                "lat": 22.99083,
                                "lon": 120.21333
                            }
                        },
                        {
                            "facility": "Taipei Veterans General Hospital",
                            "status": "RECRUITING",
                            "city": "Taipei",
                            "zip": "11217",
                            "country": "Taiwan",
                            "geoPoint": {
                                "lat": 25.04776,
                                "lon": 121.53185
                            }
                        },
                        {
                            "facility": "Ramathibodi Hospital Mahidol University",
                            "status": "RECRUITING",
                            "city": "Bangkok",
                            "zip": "10400",
                            "country": "Thailand",
                            "geoPoint": {
                                "lat": 13.75398,
                                "lon": 100.50144
                            }
                        },
                        {
                            "facility": "Siriraj Hospital",
                            "status": "RECRUITING",
                            "city": "Bangkok",
                            "zip": "10700",
                            "country": "Thailand",
                            "geoPoint": {
                                "lat": 13.75398,
                                "lon": 100.50144
                            }
                        },
                        {
                            "facility": "Songklanagarind Hospital (Prince of Songkhla University)",
                            "status": "RECRUITING",
                            "city": "Hat Yai",
                            "zip": "90110",
                            "country": "Thailand",
                            "geoPoint": {
                                "lat": 7.00836,
                                "lon": 100.47668
                            }
                        },
                        {
                            "facility": "Srinagarind Hospital (Khon Kaen University)",
                            "status": "RECRUITING",
                            "city": "Muang",
                            "zip": "40002",
                            "country": "Thailand"
                        }
                    ]
                }
            },
            "derivedSection": {
                "miscInfoModule": {
                    "versionHolder": "2024-11-18",
                    "removedCountries": [
                        "France",
                        "Georgia",
                        "Italy",
                        "Spain",
                        "Turkey",
                        "United Kingdom"
                    ]
                },
                "conditionBrowseModule": {
                    "meshes": [
                        {
                            "id": "D002277",
                            "term": "Carcinoma"
                        },
                        {
                            "id": "D002294",
                            "term": "Carcinoma, Squamous Cell"
                        },
                        {
                            "id": "D000077195",
                            "term": "Squamous Cell Carcinoma of Head and Neck"
                        }
                    ],
                    "ancestors": [
                        {
                            "id": "D009375",
                            "term": "Neoplasms, Glandular and Epithelial"
                        },
                        {
                            "id": "D009370",
                            "term": "Neoplasms by Histologic Type"
                        },
                        {
                            "id": "D009369",
                            "term": "Neoplasms"
                        },
                        {
                            "id": "D018307",
                            "term": "Neoplasms, Squamous Cell"
                        },
                        {
                            "id": "D006258",
                            "term": "Head and Neck Neoplasms"
                        },
                        {
                            "id": "D009371",
                            "term": "Neoplasms by Site"
                        }
                    ],
                    "browseLeaves": [
                        {
                            "id": "M5534",
                            "name": "Carcinoma",
                            "asFound": "Carcinoma",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M5550",
                            "name": "Carcinoma, Squamous Cell",
                            "asFound": "Squamous Cell Carcinoma",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M14850",
                            "name": "Recurrence",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M9348",
                            "name": "Head and Neck Neoplasms",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M1689",
                            "name": "Squamous Cell Carcinoma of Head and Neck",
                            "asFound": "Head and Neck Squamous Cell Carcinoma",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M12320",
                            "name": "Neoplasms, Glandular and Epithelial",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M12315",
                            "name": "Neoplasms by Histologic Type",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M20451",
                            "name": "Neoplasms, Squamous Cell",
                            "relevance": "LOW"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "BC04",
                            "name": "Neoplasms"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Conditions"
                        },
                        {
                            "abbrev": "BC23",
                            "name": "Symptoms and General Pathology"
                        }
                    ]
                },
                "interventionBrowseModule": {
                    "meshes": [
                        {
                            "id": "C000707970",
                            "term": "Tislelizumab"
                        }
                    ],
                    "ancestors": [
                        {
                            "id": "D000074322",
                            "term": "Antineoplastic Agents, Immunological"
                        },
                        {
                            "id": "D000970",
                            "term": "Antineoplastic Agents"
                        }
                    ],
                    "browseLeaves": [
                        {
                            "id": "M137899",
                            "name": "Tislelizumab",
                            "asFound": "Healthy Adult",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M1346",
                            "name": "Antineoplastic Agents, Immunological",
                            "relevance": "LOW"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "ANeo",
                            "name": "Antineoplastic Agents"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Drugs and Chemicals"
                        }
                    ]
                }
            },
            "hasResults": false
        },
        {
            "protocolSection": {
                "identificationModule": {
                    "nctId": "NCT06649604",
                    "orgStudyIdInfo": {
                        "id": "Pro00144813"
                    },
                    "organization": {
                        "fullName": "University of Alberta",
                        "class": "OTHER"
                    },
                    "briefTitle": "Reducing Pain From Retinal Laser With Vibrational Stimulation",
                    "officialTitle": "Alleviating Panretinal Photocoagulation Associated Ocular Pain With Vibratory Stimulation"
                },
                "statusModule": {
                    "statusVerifiedDate": "2024-10",
                    "overallStatus": "NOT_YET_RECRUITING",
                    "expandedAccessInfo": {
                        "hasExpandedAccess": false
                    },
                    "startDateStruct": {
                        "date": "2024-11-01",
                        "type": "ESTIMATED"
                    },
                    "primaryCompletionDateStruct": {
                        "date": "2025-04-01",
                        "type": "ESTIMATED"
                    },
                    "completionDateStruct": {
                        "date": "2025-05-01",
                        "type": "ESTIMATED"
                    },
                    "studyFirstSubmitDate": "2024-10-07",
                    "studyFirstSubmitQcDate": "2024-10-14",
                    "studyFirstPostDateStruct": {
                        "date": "2024-10-21",
                        "type": "ACTUAL"
                    },
                    "lastUpdateSubmitDate": "2024-10-14",
                    "lastUpdatePostDateStruct": {
                        "date": "2024-10-21",
                        "type": "ACTUAL"
                    }
                },
                "sponsorCollaboratorsModule": {
                    "responsibleParty": {
                        "type": "SPONSOR"
                    },
                    "leadSponsor": {
                        "name": "University of Alberta",
                        "class": "OTHER"
                    },
                    "collaborators": [
                        {
                            "name": "Alberta Retina Consultant",
                            "class": "UNKNOWN"
                        }
                    ]
                },
                "oversightModule": {
                    "isFdaRegulatedDrug": false,
                    "isFdaRegulatedDevice": true,
                    "isUsExport": true
                },
                "descriptionModule": {
                    "briefSummary": "The goal of this clinical trial is to learn if Vibration Anesthesia Device works to reduce pain during retinal laser for diabetic retinopathy. The main question it aims to answer is:\n\nDoes the Vibration Anesthesia Device reduces the pain felt by patients during the laser treatment? Researchers will compare the standard method (no vibration device) to the standard method with the Vibration Anesthesia Device to see if the device works to reduce discomfort during treatment.\n\nEligible participants will have both eyes treated as required, one eye with the device and the other one without. Both the side that will be treated with the device in place and the first side to be treated will be decided by random sequence.",
                    "detailedDescription": "Background:\n\nPanretinal photocoagulation (PRP) is a widely used laser treatment for proliferative diabetic retinopathy (PDR). However, the associated ocular pain can make the procedure uncomfortable, leading to increased treatment visits or missed appointments. This pain is multifactorial and can be exacerbated by factors such as anxiety and hypervigilance. Traditional pain management techniques, such as regional anesthesia, are effective but invasive and carry potential complications. Oral medications have largely proven ineffective in alleviating PRP-related pain.\n\nThe Gate-Control Theory of pain posits that non-noxious stimuli can inhibit pain signals by activating A-\u03b2 fibers, effectively \"closing the gate\" to pain transmission through A-\u03b4 and C fibers. The most relatable example is the mother rubbing a child's knee after an impact injury in the affected region. Transcutaneous electrical nerve stimulation (TENS) which utilizes the Gate-Control Theory of pain, has been shown to reduce ocular pain during PRP. However, its use raises practical concerns, including the need to carefully adjust pulse width, intensity, and frequency for effective pain relief. Additionally, some patients may find the muscular contractions or paresthesia uncomfortable. TENS is also contraindicated in individuals who are pregnant, have epilepsy, or have pacemakers. Vibratory stimulation activates cutaneous mechanoreceptors to reduce pain during intramuscular and subcutaneous injections. This technique is safer and less invasive than TENS and is therefore an ideal candidate for evaluating its effect in pain reduction during PRP. This study has the potential for an innovative concept by utilizing a vibratory device integrated within the PRP machine headrest.\n\nHypothesis:\n\nVibratory stimulation is expected to reduce ocular pain during PRP by activating cutaneous mechanoreceptors and inhibiting pain transmission, as suggested by the Gate-Control Theory. Its non-invasive nature makes it a practical alternative to traditional pain management methods, potentially enhancing patient comfort during the procedure.\n\nObjective:\n\nTo evaluate the effectiveness of vibratory stimulation in reducing ocular pain during PRP treatments\n\nMethod:\n\nSubjects will be recruited at a single tertiary referral center (Alberta Retina Consultants, Edmonton, Alberta). Matriculation will be established upon obtainment of consent, and patients will have the autonomy to withdraw from the study at any stage. The enrollment period will be from October 2024 to March 2025, with a total of 50 patients.\n\nLaser settings will be tailored to each patient based on individual differences in pigmentation and tissue uptake. The threshold for treatment will be determined by observing an opacified photothermic response. For each patient, one eye will be treated without vibratory stimulation, while the contralateral eye will receive stimulation using the Blaine Labs Vibration Anesthesia Device. The assignment of which eye receives which treatment will be randomized using Python programming, ensuring a balanced allocation. To minimize variability, the time taken to perform PRP on both eyes will be kept as equal as possible. A no-treatment zone of 1 clock hour from the horizontal meridian will be maintained to avoid the long ciliary nerves. After treatment, patients will complete a validated survey based on the numeric rating scale (NRS) to assess pain levels for each eye treated."
                },
                "conditionsModule": {
                    "conditions": [
                        "Pain, Perioperative"
                    ],
                    "keywords": [
                        "Vibration Anesthesia Device",
                        "Perioperative Pain Alleviation",
                        "Panretinal Photocoagulation",
                        "Diabetic retinopathy treatment"
                    ]
                },
                "designModule": {
                    "studyType": "INTERVENTIONAL",
                    "phases": [
                        "NA"
                    ],
                    "designInfo": {
                        "allocation": "RANDOMIZED",
                        "interventionModel": "CROSSOVER",
                        "interventionModelDescription": "All patient are their own control, using laser in both eyes, but only one using the Vibration Anesthesia Device.",
                        "primaryPurpose": "SUPPORTIVE_CARE",
                        "maskingInfo": {
                            "masking": "SINGLE",
                            "maskingDescription": "Only the collaborator who will analyse the data will be masked, due to the manifest presence or absence of the vibratory device for both the clinician and the patient.",
                            "whoMasked": [
                                "OUTCOMES_ASSESSOR"
                            ]
                        }
                    },
                    "enrollmentInfo": {
                        "count": 50,
                        "type": "ESTIMATED"
                    }
                },
                "armsInterventionsModule": {
                    "armGroups": [
                        {
                            "label": "PRP with the Vibration Anesthesia Device",
                            "type": "EXPERIMENTAL",
                            "description": "Laser for PRP treatment as usual, but with the addition of the Vibration Device in one of the two eyes of a patient (The other eye receiving the same laser treatment without the device).",
                            "interventionNames": [
                                "Device: Vibration Anesthesia Device",
                                "Procedure: Panretinal Photocoagulation"
                            ]
                        },
                        {
                            "label": "PRP without the Vibration Anesthesia Device",
                            "type": "ACTIVE_COMPARATOR",
                            "description": "Laser for PRP treatment as usual in one of the two eyes of a patient (other eye receiving the same treatment, but with the Vibration Device).",
                            "interventionNames": [
                                "Procedure: Panretinal Photocoagulation"
                            ]
                        }
                    ],
                    "interventions": [
                        {
                            "type": "DEVICE",
                            "name": "Vibration Anesthesia Device",
                            "description": "The intervention arm of this study is distinguished by way of the use of the Vibration Anesthesia Device",
                            "armGroupLabels": [
                                "PRP with the Vibration Anesthesia Device"
                            ]
                        },
                        {
                            "type": "PROCEDURE",
                            "name": "Panretinal Photocoagulation",
                            "description": "Laser treatment for diabetic retinopathy done in a standard fashion",
                            "armGroupLabels": [
                                "PRP with the Vibration Anesthesia Device",
                                "PRP without the Vibration Anesthesia Device"
                            ]
                        }
                    ]
                },
                "outcomesModule": {
                    "primaryOutcomes": [
                        {
                            "measure": "Pain Rating Scale",
                            "description": "Patient are enrolled on the same day as the study treatment. Patients will rate their pain sensation. They will have their first eye (left or right and with or without the Anesthesia Vibration Device based on randomization) treated, then they will assess their pain sensation. After this assessment, during the same session, their second eye will be treated and they will be asked to complete the same assessment for this second eye. The provided form to assess this outcome is a numeric scale from 0 (no pain) to 10 (worst possible pain) using the Wong-Baker Faces scale.",
                            "timeFrame": "At time of enrolment"
                        }
                    ]
                },
                "eligibilityModule": {
                    "eligibilityCriteria": "Inclusion Criteria:\n\n* Treatment na\u00efve patients\n* Bilateral PRP for proliferative diabetic retinopathy required\n* \\>500 applications to each eye\n* \\< 51 applications difference between each eye, in the superior or inferior hemisphere.\n\nExclusion Criteria:\n\n* Poor pupil dilation \\< 5mm\n* Media opacity preventing laser",
                    "healthyVolunteers": false,
                    "sex": "ALL",
                    "minimumAge": "18 Years",
                    "stdAges": [
                        "ADULT",
                        "OLDER_ADULT"
                    ]
                },
                "contactsLocationsModule": {
                    "centralContacts": [
                        {
                            "name": "Mathieu Carri\u00e8re, MD, FRCSC",
                            "role": "CONTACT",
                            "phone": "(780) 448-1801",
                            "email": "mcarrie2@ualberta.ca"
                        }
                    ],
                    "overallOfficials": [
                        {
                            "name": "Matthew Tennant, MD, FRCSC",
                            "affiliation": "University of Alberta",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "locations": [
                        {
                            "facility": "Alberta Retina Consultant",
                            "city": "Edmonton",
                            "state": "Alberta",
                            "zip": "T5H 0X5",
                            "country": "Canada",
                            "contacts": [
                                {
                                    "name": "Mathieu Carri\u00e8re, MD, FRCSC",
                                    "role": "CONTACT",
                                    "phone": "(780) 448-1801",
                                    "email": "mcarrie2@ualberta.ca"
                                }
                            ],
                            "geoPoint": {
                                "lat": 53.55014,
                                "lon": -113.46871
                            }
                        }
                    ]
                },
                "ipdSharingStatementModule": {
                    "ipdSharing": "NO"
                }
            },
            "derivedSection": {
                "miscInfoModule": {
                    "versionHolder": "2024-11-18"
                },
                "conditionBrowseModule": {
                    "browseLeaves": [
                        {
                            "id": "M14999",
                            "name": "Retinal Diseases",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M13066",
                            "name": "Pain",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M7125",
                            "name": "Diabetic Retinopathy",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M29070",
                            "name": "Eye Pain",
                            "relevance": "LOW"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "BC11",
                            "name": "Eye Diseases"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Conditions"
                        },
                        {
                            "abbrev": "BC23",
                            "name": "Symptoms and General Pathology"
                        },
                        {
                            "abbrev": "BC14",
                            "name": "Heart and Blood Diseases"
                        },
                        {
                            "abbrev": "BC19",
                            "name": "Gland and Hormone Related Diseases"
                        }
                    ]
                },
                "interventionBrowseModule": {
                    "meshes": [
                        {
                            "id": "D000777",
                            "term": "Anesthetics"
                        }
                    ],
                    "ancestors": [
                        {
                            "id": "D002492",
                            "term": "Central Nervous System Depressants"
                        },
                        {
                            "id": "D045505",
                            "term": "Physiological Effects of Drugs"
                        }
                    ],
                    "browseLeaves": [
                        {
                            "id": "M4107",
                            "name": "Anesthetics",
                            "asFound": "Saline",
                            "relevance": "HIGH"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "CNSDep",
                            "name": "Central Nervous System Depressants"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Drugs and Chemicals"
                        }
                    ]
                }
            },
            "hasResults": false
        },
        {
            "protocolSection": {
                "identificationModule": {
                    "nctId": "NCT05480904",
                    "orgStudyIdInfo": {
                        "id": "CSALTS"
                    },
                    "secondaryIdInfos": [
                        {
                            "id": "NCI-2022-08555",
                            "type": "REGISTRY",
                            "domain": "NCI"
                        }
                    ],
                    "organization": {
                        "fullName": "St. Jude Children's Research Hospital",
                        "class": "OTHER"
                    },
                    "briefTitle": "Characterizing Sleep Among Long-term Survivors of Childhood Cancer",
                    "officialTitle": "Characterizing Sleep Among Long-term Survivors of Childhood Cancer"
                },
                "statusModule": {
                    "statusVerifiedDate": "2024-10",
                    "overallStatus": "RECRUITING",
                    "expandedAccessInfo": {
                        "hasExpandedAccess": false
                    },
                    "startDateStruct": {
                        "date": "2023-04-17",
                        "type": "ACTUAL"
                    },
                    "primaryCompletionDateStruct": {
                        "date": "2025-03",
                        "type": "ESTIMATED"
                    },
                    "completionDateStruct": {
                        "date": "2025-12",
                        "type": "ESTIMATED"
                    },
                    "studyFirstSubmitDate": "2022-07-19",
                    "studyFirstSubmitQcDate": "2022-07-27",
                    "studyFirstPostDateStruct": {
                        "date": "2022-07-29",
                        "type": "ACTUAL"
                    },
                    "lastUpdateSubmitDate": "2024-10-18",
                    "lastUpdatePostDateStruct": {
                        "date": "2024-10-21",
                        "type": "ACTUAL"
                    }
                },
                "sponsorCollaboratorsModule": {
                    "responsibleParty": {
                        "type": "SPONSOR"
                    },
                    "leadSponsor": {
                        "name": "St. Jude Children's Research Hospital",
                        "class": "OTHER"
                    }
                },
                "oversightModule": {
                    "isFdaRegulatedDrug": false,
                    "isFdaRegulatedDevice": false,
                    "isUsExport": true
                },
                "descriptionModule": {
                    "briefSummary": "The patients are being asked to take part in this clinical trial because they received cancer treatment as a child at St. Jude. The study comprehensively examines sleep among three distinct diagnostic groups of survivors in the SJLIFE cohort: ALL, CNS tumors, and non-CNS solid tumors.\n\nPrimary Objective\n\nThe primary aim of this protocol is to estimate the prevalence of various sleep disorders among long-term survivors of childhood ALL, CNS tumors, and non- CNS solid tumors.\n\nExploratory Objective\n\nThe exploratory objective of the study is to explore associations between the prevalence of sleep disorders and clinical outcomes collected in SJLIFE.",
                    "detailedDescription": "A cross-sectional pilot study that will enroll participants for on-campus or remote study activities. The investigators anticipate a targeted evaluable accrual of 120, 40 within each of the three groups identified above. The plan is to employ remote polysomnography and surveys to assess patterns of sleep disorders. These assessments could be done in the homes of survivors or during campus visits."
                },
                "conditionsModule": {
                    "conditions": [
                        "ALL, Adult",
                        "CNS Tumor",
                        "Solid Tumor"
                    ]
                },
                "designModule": {
                    "studyType": "OBSERVATIONAL",
                    "patientRegistry": false,
                    "designInfo": {
                        "observationalModel": "COHORT",
                        "timePerspective": "PROSPECTIVE"
                    },
                    "enrollmentInfo": {
                        "count": 120,
                        "type": "ESTIMATED"
                    }
                },
                "armsInterventionsModule": {
                    "armGroups": [
                        {
                            "label": "On campus",
                            "description": "SJLIFE Study Campus Visit",
                            "interventionNames": [
                                "Other: Neurocognitive (Thinking) Testing",
                                "Other: Health Questionnaires, Sleep Surveys & Sleep Diary",
                                "Diagnostic Test: Echocardiography/EKG",
                                "Diagnostic Test: Pulmonary Function",
                                "Device: Remote Polysomnography",
                                "Diagnostic Test: Physical Function"
                            ]
                        },
                        {
                            "label": "Remote",
                            "description": "SJLIFE cohort: ALL, CNS tumors, and non-CNS solid tumors",
                            "interventionNames": [
                                "Diagnostic Test: CNS Vital Signs (Thinking) Testing",
                                "Other: Health Questionnaires, Sleep Surveys & Sleep Diary",
                                "Device: Remote Polysomnography"
                            ]
                        }
                    ],
                    "interventions": [
                        {
                            "type": "OTHER",
                            "name": "Neurocognitive (Thinking) Testing",
                            "description": "Intelligence: WASI-II 20 min; Sustained Attention:\n\nConners Continuous Performance Test 3rd ED. 15 min; Memory: California Verbal Learning Test 2nd Ed. 20 min; Visual Selective Reminding 7 min; Processing Speed:Coding/Digit Symbol 3 min; Grooved Pegboard 5 min; Executive Function: Trail Making Test 5 min; Verbal Fluency Test 3 min; Digit Span 5 min; Visuospatial: Rey Complex Figure 10 min; Functional Behavior: CCSS Neurocognitive Questionnaire 5 min.",
                            "armGroupLabels": [
                                "On campus"
                            ]
                        },
                        {
                            "type": "DIAGNOSTIC_TEST",
                            "name": "CNS Vital Signs (Thinking) Testing",
                            "description": "Attention: Continuous Performance Task 5 mins Processing Speed: Symbol Digit Test 4 mins Executive Function: Shifting Attention 3 min and Stroop Test 5 mins",
                            "armGroupLabels": [
                                "Remote"
                            ]
                        },
                        {
                            "type": "OTHER",
                            "name": "Health Questionnaires, Sleep Surveys & Sleep Diary",
                            "description": "The participant will be asked to complete the sleep surveys and sleep diary, FACIT fatigue, and CSALTS Pain Survey These questionnaires will take about 29 minutes to complete. The sleep diary is completed at the time the participant wears the sleep device.",
                            "armGroupLabels": [
                                "On campus",
                                "Remote"
                            ]
                        },
                        {
                            "type": "DIAGNOSTIC_TEST",
                            "name": "Echocardiography/EKG",
                            "description": "All echocardiograms will be performed using a General Electric VIVID-7. The LV volume, mass and EF will be calculated using the recommendations of the American Society of Echocardiography",
                            "armGroupLabels": [
                                "On campus"
                            ]
                        },
                        {
                            "type": "DIAGNOSTIC_TEST",
                            "name": "Pulmonary Function",
                            "description": "PFTs will include spirometry, lung volume measurements by body plethysmography and single breath carbon monoxide-diffusion capacity (DLCO).",
                            "armGroupLabels": [
                                "On campus"
                            ]
                        },
                        {
                            "type": "DEVICE",
                            "name": "Remote Polysomnography",
                            "description": "The Sleep Profiler PSG2/WatchPat device will be used to assess nighttime sleep disorders.",
                            "armGroupLabels": [
                                "On campus",
                                "Remote"
                            ],
                            "otherNames": [
                                "Sleep Profiler PSG2-Overnight Sleep Study"
                            ]
                        },
                        {
                            "type": "DIAGNOSTIC_TEST",
                            "name": "Physical Function",
                            "description": "This is a test of how your heart and lungs respond to exercise.",
                            "armGroupLabels": [
                                "On campus"
                            ]
                        }
                    ]
                },
                "outcomesModule": {
                    "primaryOutcomes": [
                        {
                            "measure": "Insomnia Severity Index (ISI)",
                            "description": "ISI is a seven-item questionnaire that looks at symptoms of clinical insomnia. The ISI assesses insomnia symptoms over the past 14 days and has demonstrated good reliability and validity. The total ISI score ranges from 0 to 28, with scores \\< 8 indicating no significant insomnia.",
                            "timeFrame": "Baseline"
                        },
                        {
                            "measure": "CSALTS Sleep Survey",
                            "description": "CSALTS Sleep Survey incorporating Epworth Sleepiness Scale (EPS) and Pittsburg Sleep Quality Index (PSQI) The CSALTS Sleep Survey assesses sleep quality, patterns, and daytime sleepiness. It incorporates 19 questions from the PSQI and 8 questions of the ESS. The PSQI and ESS total scores will be reported.",
                            "timeFrame": "Baseline"
                        },
                        {
                            "measure": "Morningness-Eveningness Questionnaire (MEQ)",
                            "description": "The MEQ is a 19-question measure that assesses the degree to which respondents are active and alert at certain times of the day. Each item is rated using a Likert-type scale with lower scales reflecting a more evening-type characterization of alertness. Global scores range from 16 to 86 and these values are used to define 'definitely morning type' (70-86), 'moderately morning type' (59-69), 'neither type' (42-58), 'moderately evening type' (31-41), and 'definitely evening type' (16-30).",
                            "timeFrame": "Baseline"
                        },
                        {
                            "measure": "Circadian Type Inventory (CTI)",
                            "description": "CTI is an 11-item questionnaire that looks at rigidity/flexibility of sleeping habits and ability/inability to overcome drowsiness (i.e., circadian rhythm disorders). Respondents use a 5-item, Likert-type scale to answer questions regarding their sleep habits and preferences. Scales range from 1 (\"almost never\") to 5 (\"almost always\"). Higher scores on the rigidity subscales indicate a greater flexibility in circadian rhythm, while lower scores on the overcoming-drowsiness subscale indicate a greater ability to manage on less sleep.",
                            "timeFrame": "Baseline"
                        },
                        {
                            "measure": "Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT)",
                            "description": "fatigue scale is a short 13-item tool that provides a single measure of an individual's level of fatigue during a usual day.",
                            "timeFrame": "Baseline"
                        },
                        {
                            "measure": "CSALTS Pain Survey",
                            "description": "The 7-item pain survey will include pain interference questions from the SJLIFE Behavioral Survey and one pain intensity question. The six items that measures amount of pain interference in daily activities in last 7 days is measured from \"not at all\" to \"very much.\" The pain intensity question is measured 1-10 with 10 \"worst imaginable pain.\"",
                            "timeFrame": "Baseline for 2 nights"
                        },
                        {
                            "measure": "Polysomnography Evaluation (Sleep Profiler PSG2 or WatchPAT)",
                            "description": "The Sleep Profiler PSG2 measures brain waves during sleep, blood oxygen levels, heart rate, and breathing and will measure different patterns of sleep stages. Two nights of data collection will be requested though one night will be sufficient if the participant sleeps at least 4 hours. The apnea hypopnea index and sleep efficiency scores will be reported.\n\nThe WatchPAT device assesses sleep timing, sleep staging, and sleep apnea events via a device worn on the wrist that measures limb movement, peripheral arterial tone and connects to an EKG electrode. Two nights of data collection will be requested though one night will be sufficient if the participant sleeps at least 4 hours. The apnea hypopnea index and sleep efficiency scores will be reported",
                            "timeFrame": "Baseline"
                        }
                    ],
                    "secondaryOutcomes": [
                        {
                            "measure": "Sustained Attention -Conners Continuous Performance Test 3rd Ed or CNS-VS CPT.",
                            "description": "Computerized test of omissions, variability, and reaction time, requiring participants to respond to letter stimuli on the screen quickly and accurately, while avoiding targets. These three scores will be reported in T scores.",
                            "timeFrame": "Baseline"
                        },
                        {
                            "measure": "Memory-California Verbal Learning Test 2nd Ed.",
                            "description": "Orally administered test of verbal learning, short-term and long-term verbal free-recall memory, requiring participant to learn and remember a list of words, measured in T-score and z-scores.",
                            "timeFrame": "Baseline"
                        },
                        {
                            "measure": "Executive Functions -Trail Making Test or CNS-VS Shifting Attention Test",
                            "description": "The Trail Making Test is a timed task that requires a participant to shift his/her attention adaptively and flexibly. Considered a measure of cognitive flexibility. Standard score for Trail Making Letter-Word Switching will be reported.\n\nShifting Attention Test (SAT) measure cognitive flexibility with a single standard score.",
                            "timeFrame": "Baseline"
                        },
                        {
                            "measure": "Executive Functions- Verbal Fluency Test Controlled Oral Word Association (COWA) or CNS-VS Stroop Test",
                            "description": "This is a task of cognitive/verbal fluency. Participants are given a letter and must say as many words that start with that letter within 60 seconds. A single age-adjusted z-score will be reported.\n\nStroop Test (ST) measures cognitive control and fluency with a single standard score",
                            "timeFrame": "Baseline"
                        },
                        {
                            "measure": "Executive Functions -Digit Span Backward",
                            "description": "Digit Span Backward: Digit Span Backward (DSB), from the Digit Span subtest on the WAIS-IV, is a measure of working memory. The number of digits recalled in the longest span is converted to a standard score using age-based norms. Considered a process score on the WAIS-IV DSB is found to have acceptable reliability and validity parameters.",
                            "timeFrame": "Baseline"
                        }
                    ],
                    "otherOutcomes": [
                        {
                            "measure": "Intelligence",
                            "description": "WASI-II assessment of intelligence that provides composite scores that estimate verbal comprehension and perceptual reasoning abilities, requiring participants to define words and complete visual puzzles, measured in T scores converted to Standard Scores for Full Scale IQ.",
                            "timeFrame": "Baseline"
                        },
                        {
                            "measure": "Processing Speed - Coding/Digit Symbol or CNS-VS Symbol Digit Test",
                            "description": "Written timed test of processing speed, requiring participant to copy abstract symbols matched with numbers, measured in a single scaled score",
                            "timeFrame": "Baseline"
                        },
                        {
                            "measure": "Processing Speed-Grooved Pegboard",
                            "description": "Timed test of fine motor dexterity and speed, requiring participant to put small metal pegs into pegboard, using dominant hand, measured in a single standard score.",
                            "timeFrame": "Baseline"
                        },
                        {
                            "measure": "Pulmonary Function",
                            "description": "Participants will complete pulmonary function tests (PFTs) as part of their standard on-campus SJLIFE visit. PFTs will be performed in a single laboratory according to the American Thoracic Society task force guidelines. PFTs will include spirometry, lung volume measurements by body plethysmography and single breath carbon monoxide-diffusion capacity (DLCO). The observed values of each survivor for forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), total lung capacity (TLC), and DLCOcorr will be compared with those predicted for the patient's age, race, gender, and height based on reference equations.",
                            "timeFrame": "Baseline"
                        },
                        {
                            "measure": "Echocardiogram",
                            "description": "Participants will complete an echocardiogram as part of their standard SJLIFE visit. All echocardiograms will be performed using a General Electric VIVID-7. The LV volume, mass and EF will be calculated using the recommendations of the American Society of Echocardiography.",
                            "timeFrame": "Baseline"
                        }
                    ]
                },
                "eligibilityModule": {
                    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant in SJLIFE and \\> 5 years from diagnosis.\n* \\>18 years of age at time of enrollment.\n* Diagnosed with ALL (treated with CRT or chemotherapy only) or CNS tumors (posterior fossa tumors or supratentorial tumors) or non-CNS solid tumors (with abdominal or chest radiation or bilateral retinoblastoma survivors).\n* Participant was less than 21 years of age at time of diagnosis.\n* Speaks and understands English (polysomnography device speaks to patients only in English).\n* Remote participant must have Wi-Fi access\n\nExclusion Criteria:\n\n* Estimated intelligence score \\<80.\n* Currently prescribed an intervention for a sleep disorder.\n* Survivor of craniopharyngioma.\n* Survivor of Hodgkin Lymphoma.\n* Relapsed or treated with hematopoietic stem cell therapy.\n* Brain injury unrelated to cancer diagnosis or therapy.\n* Pulmonary injury unrelated to cancer diagnosis or therapy.",
                    "healthyVolunteers": false,
                    "sex": "ALL",
                    "minimumAge": "18 Years",
                    "stdAges": [
                        "ADULT",
                        "OLDER_ADULT"
                    ],
                    "studyPopulation": "All participants who meet eligibility criteria and consent to enrollment on the study.",
                    "samplingMethod": "NON_PROBABILITY_SAMPLE"
                },
                "contactsLocationsModule": {
                    "centralContacts": [
                        {
                            "name": "Kevin Krull, PhD",
                            "role": "CONTACT",
                            "phone": "866-278-5833",
                            "email": "referralinfo@stjude.org"
                        }
                    ],
                    "overallOfficials": [
                        {
                            "name": "Kevin Krull, PhD",
                            "affiliation": "St. Jude Children's Research Hospital",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "locations": [
                        {
                            "facility": "St. Jude Children's Research Hospital",
                            "status": "RECRUITING",
                            "city": "Memphis",
                            "state": "Tennessee",
                            "zip": "38105",
                            "country": "United States",
                            "contacts": [
                                {
                                    "name": "Kevin Krull, PhD",
                                    "role": "CONTACT",
                                    "phone": "866-278-5833",
                                    "email": "referralinfo@stjude.org"
                                },
                                {
                                    "name": "Kevin Krull, PhD",
                                    "role": "PRINCIPAL_INVESTIGATOR"
                                }
                            ],
                            "geoPoint": {
                                "lat": 35.14953,
                                "lon": -90.04898
                            }
                        }
                    ]
                },
                "referencesModule": {
                    "seeAlsoLinks": [
                        {
                            "label": "St. Jude Children's Research Hospital",
                            "url": "http://www.stjude.org"
                        },
                        {
                            "label": "Clinical Trials Open at St. Jude",
                            "url": "http://www.stjude.org/protocols"
                        }
                    ]
                },
                "ipdSharingStatementModule": {
                    "ipdSharing": "NO"
                }
            },
            "derivedSection": {
                "miscInfoModule": {
                    "versionHolder": "2024-11-18"
                },
                "conditionBrowseModule": {
                    "meshes": [
                        {
                            "id": "D009369",
                            "term": "Neoplasms"
                        },
                        {
                            "id": "D016543",
                            "term": "Central Nervous System Neoplasms"
                        }
                    ],
                    "ancestors": [
                        {
                            "id": "D009423",
                            "term": "Nervous System Neoplasms"
                        },
                        {
                            "id": "D009371",
                            "term": "Neoplasms by Site"
                        },
                        {
                            "id": "D009422",
                            "term": "Nervous System Diseases"
                        }
                    ],
                    "browseLeaves": [
                        {
                            "id": "M18937",
                            "name": "Central Nervous System Neoplasms",
                            "asFound": "CNS Tumors",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M12367",
                            "name": "Nervous System Neoplasms",
                            "relevance": "LOW"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "BC04",
                            "name": "Neoplasms"
                        },
                        {
                            "abbrev": "BC10",
                            "name": "Nervous System Diseases"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Conditions"
                        }
                    ]
                },
                "interventionBrowseModule": {
                    "browseLeaves": [
                        {
                            "id": "M5506",
                            "name": "Carbon Monoxide",
                            "relevance": "LOW"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "All",
                            "name": "All Drugs and Chemicals"
                        }
                    ]
                }
            },
            "hasResults": false
        },
        {
            "protocolSection": {
                "identificationModule": {
                    "nctId": "NCT06065631",
                    "orgStudyIdInfo": {
                        "id": "Glewwe Transfer"
                    },
                    "organization": {
                        "fullName": "University of Minnesota",
                        "class": "OTHER"
                    },
                    "briefTitle": "Seeing to Learn in Sierra Leone",
                    "officialTitle": "Seeing to Learn in Sierra Leone: Impact of Spectacle Correction on Children's Academic Performance and Mental Health Wellbeing",
                    "acronym": "SLII"
                },
                "statusModule": {
                    "statusVerifiedDate": "2024-10",
                    "overallStatus": "RECRUITING",
                    "expandedAccessInfo": {
                        "hasExpandedAccess": false
                    },
                    "startDateStruct": {
                        "date": "2023-10-25",
                        "type": "ACTUAL"
                    },
                    "primaryCompletionDateStruct": {
                        "date": "2024-12",
                        "type": "ESTIMATED"
                    },
                    "completionDateStruct": {
                        "date": "2025-01",
                        "type": "ESTIMATED"
                    },
                    "studyFirstSubmitDate": "2023-09-21",
                    "studyFirstSubmitQcDate": "2023-09-29",
                    "studyFirstPostDateStruct": {
                        "date": "2023-10-04",
                        "type": "ACTUAL"
                    },
                    "lastUpdateSubmitDate": "2024-10-17",
                    "lastUpdatePostDateStruct": {
                        "date": "2024-10-21",
                        "type": "ACTUAL"
                    }
                },
                "sponsorCollaboratorsModule": {
                    "responsibleParty": {
                        "type": "SPONSOR"
                    },
                    "leadSponsor": {
                        "name": "University of Minnesota",
                        "class": "OTHER"
                    },
                    "collaborators": [
                        {
                            "name": "Innovations for Poverty Action",
                            "class": "OTHER"
                        },
                        {
                            "name": "Peek Vision",
                            "class": "UNKNOWN"
                        },
                        {
                            "name": "Vision Action",
                            "class": "UNKNOWN"
                        }
                    ]
                },
                "oversightModule": {
                    "oversightHasDmc": true,
                    "isFdaRegulatedDrug": false,
                    "isFdaRegulatedDevice": false
                },
                "descriptionModule": {
                    "briefSummary": "The main objective of the Sierra Leone Sees to Learn (SL2) trial is to assess the educational impact of providing free eyeglasses to students aged 12-15 years with uncorrected refractive error in Sierra Leone. The procedures include baseline questionnaires and educational assessments to collect data on students and schools, and then the provision of free eyeglasses to students who have uncorrected (or undercorrected) refractive error (URE). The questionnaires and student assessments will take 1-2 hours. The duration of the study timeframe is one school year. The end-line questionnaires and student assessments will be administered at the end of the school year.",
                    "detailedDescription": "Objective: The main objective of the Sierra Leone Sees to Learn (SL2) trial is to assess the educational impact of providing free eyeglasses to students aged 12-15 years with uncorrected refractive error in Sierra Leone.\n\nSample frame: Approximately 2400 children with uncorrected (or undercorrected) refractive error (URE) at 160 randomly-selected schools in Freetown and Bo City. A similar number of children from the same schools but without vision problems will also be included, at baseline only, to compare their basic demographic characteristics and daily activities to those of the children with URE. The sample size may vary depending on the percentage of children with URE obtained from screening a total of 40,000 children. All children with URE as specified in the enrolment criteria below will be part of the study.\n\nDesign: Cluster-randomized control trial (cluster RCT), with schools as clusters.\n\nRandomization, interventions and balancing: All eligible children will be randomized by school to receive at the start of the school year either: free ready-made or custom eyeglasses (Intervention), or an eyeglasses prescription and letter to parents, with free eyeglasses at end-line (Control). The clusters (schools) will be stratified into groups based on the prevalence of refractive error and on the score on the baseline mathematics and reading exams. The division of the sample into schools in the two cities (Bo and Freetown) will be in the same proportion as the proportion of the number of public schools in those two cities.\n\nPower calculations (reading and math exams): Setting power = 0.8, statistical precision = 0.05, intracluster correlation = 0.2 (from 2019 Sierra Leone grade 8 learning assessment), 80 treated schools, 80 control schools, 15 students/school with uncorrected error, yields the following minimal detectable effect (MDE) sizes as a function of correlation between baseline and end-line tests:\n\nMDE Correlation of baseline and end-line tests 0.101 0.7 0.127 0.6 0.148 0.5\n\nA nested focus-group study will explore children's, parents' and teachers' attitudes towards vision, student learning, and wearing of eyeglasses, in order to design a locally-tailored intervention to promote wearing of eyeglasses.\n\nRegression Framework:\n\nThe investigators will estimate the effect of the program using a single difference cross-sectional ordinary least squares regression (OLS), and a difference-in-difference (DID) OLS regression that includes observations at both end-line and baseline. The investigators will report two types of effects: the intent-to-treat (ITT) effects and local average treatment effects (LATE), using treatment assignment as an instrumental variable for participation. Analysis will use the observed baseline characteristics as control variables and account for school-level variation through a fixed effect."
                },
                "conditionsModule": {
                    "conditions": [
                        "Refractive Errors"
                    ],
                    "keywords": [
                        "Myopia",
                        "Hyperopia",
                        "Spectacle correction",
                        "Educational outcomes"
                    ]
                },
                "designModule": {
                    "studyType": "INTERVENTIONAL",
                    "phases": [
                        "NA"
                    ],
                    "designInfo": {
                        "allocation": "RANDOMIZED",
                        "interventionModel": "PARALLEL",
                        "interventionModelDescription": "All eligible children will be randomized by school to receive at the start of the school year either: free ready-made or custom eyeglasses (Intervention), or an eyeglasses prescription and letter to parents, with free eyeglasses at endline (Control). The clusters (schools) will be stratified into groups based on the prevalence of refractive error and on the score on the baseline mathematics and reading exams. The division of the sample into schools in the two cities (Bo and Freetown) will be in the same proportion as the proportion of the number of public schools in those two cities.",
                        "primaryPurpose": "TREATMENT",
                        "maskingInfo": {
                            "masking": "DOUBLE",
                            "maskingDescription": "Participants will be given either glasses or a prescription. Hence, they could not be masked.\n\nThe Care Provider, in our case, screening and examination team will be providing either glasses or prescriptions to the participants. Hence, they could not masked.\n\nInvestigators and Outcome assessor will only analyse the data at the end of the trial and they will not be",
                            "whoMasked": [
                                "INVESTIGATOR",
                                "OUTCOMES_ASSESSOR"
                            ]
                        }
                    },
                    "enrollmentInfo": {
                        "count": 2400,
                        "type": "ESTIMATED"
                    }
                },
                "armsInterventionsModule": {
                    "armGroups": [
                        {
                            "label": "Control",
                            "type": "OTHER",
                            "description": "An eyeglasses prescription and letter to parents, with free eyeglasses at endline.",
                            "interventionNames": [
                                "Other: Prescription slip"
                            ]
                        },
                        {
                            "label": "Intervention",
                            "type": "EXPERIMENTAL",
                            "description": "free ready-made or custom eyeglasses",
                            "interventionNames": [
                                "Device: Eyeglasses"
                            ]
                        }
                    ],
                    "interventions": [
                        {
                            "type": "DEVICE",
                            "name": "Eyeglasses",
                            "description": "Children with uncorrected/under-corrected refractive error will be provided with either ready made or custom eyeglasses based on their magnitude and types of refractive errors.",
                            "armGroupLabels": [
                                "Intervention"
                            ],
                            "otherNames": [
                                "Glasses",
                                "Spectacle"
                            ]
                        },
                        {
                            "type": "OTHER",
                            "name": "Prescription slip",
                            "description": "Children with uncorrected/under-corrected refractive error will be provided with an eyeglasses prescription and letter to parents, but all of them will get eyeglasses at the end of the trial",
                            "armGroupLabels": [
                                "Control"
                            ]
                        }
                    ]
                },
                "outcomesModule": {
                    "primaryOutcomes": [
                        {
                            "measure": "Foundational mathematic and literacy skills",
                            "description": "Item Response Theory to estimate a student's ability on a continuous scale and subsequently standardize students' scores on a continuous scale with respect to the control-group distribution at baseline (mean zero, standard deviation of one). Lower scores will indicate lower performance, and higher scores will indicate higher performance. A -1 would indicate a student's performance is 1 standard deviation below the mean of the control-group performance distribution at baseline. A zero would mean the student performed like the mean student in the control group at baseline.",
                            "timeFrame": "Month 1 and 9 months after glasses are provided"
                        },
                        {
                            "measure": "Anxiety",
                            "description": "Measured using Generalized Anxiety Disorder 2-item (GAD-2) questionnaire, the highest score is 8 and the lowest score is 2. Higher scores indicated more severe anxiety disorders.",
                            "timeFrame": "Month 1 and 9 months after glasses are provided"
                        },
                        {
                            "measure": "Prosocial",
                            "description": "Measured using Strengths \\& Difficulties Questionnaire with the prosocial score ranges from 0 to 10 and higher scores indicate more prosocial behaviour.",
                            "timeFrame": "Month 1 and 9 months after glasses are provided"
                        },
                        {
                            "measure": "Social and emotional problems",
                            "description": "Measured using Strengths \\& Difficulties Questionnaire with the score ranges from 0 to 40. Higher scores indicate more social and emotional problems.",
                            "timeFrame": "Month 1 and 9 months after glasses are provided"
                        }
                    ],
                    "secondaryOutcomes": [
                        {
                            "measure": "Teacher-observed wearing of eyeglasses of children",
                            "description": "Proportion of children observed wear across all children at daily assessments",
                            "timeFrame": "Month 1 to Month 9 after glasses are provided"
                        },
                        {
                            "measure": "Self-reported wearing of eyeglasses compliance",
                            "description": "Proportion of children who reported to be wearing their eyeglasses 1. Not at all 2. Sometimes 3. Most of the time 4. All the time",
                            "timeFrame": "Month 9 after glasses are provided"
                        },
                        {
                            "measure": "Enumerator-observed wearing of eyeglasses",
                            "description": "Actual presence of spectacles on the child's face (rather than having glasses at school) at the time of an unannounced examination",
                            "timeFrame": "At Months 3, 6 and 9 after glasses are provided"
                        },
                        {
                            "measure": "Cost-effectiveness 1",
                            "description": "Total eyeglasses distribution cost (excluding study cost) per child receiving, and wearing, eyeglasses at endline",
                            "timeFrame": "Through study completion, an average of 9 months"
                        },
                        {
                            "measure": "Cost-effectiveness 2",
                            "description": "Total eyeglasses distribution cost (excluding study cost) per 0.1 standard deviation test score gain",
                            "timeFrame": "Through study completion, an average of 9 months"
                        },
                        {
                            "measure": "School attendance",
                            "description": "Attendance data will be collected from attendance registry at school. This will be expressed in percentage. Lowest attendance being 0%, highest being 100%.",
                            "timeFrame": "Daily from Month 1 to Month 9"
                        }
                    ]
                },
                "eligibilityModule": {
                    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Presenting (with or without glasses) distance visual acuity of 6/12 or worse in the better-seeing eye;\n2. Refractive error of at least 0.75 diopters (D) of myopia, 2.00 D of hyperopia or 1.00 D of astigmatism;\n3. Visual acuity is correctable to 6/7.5 or better with eyeglasses.\n\nExclusion Criteria:\n\n1. Other ocular problems preventing visual acuity \\> 6/12 in both eyes.",
                    "healthyVolunteers": false,
                    "sex": "ALL",
                    "minimumAge": "12 Years",
                    "maximumAge": "15 Years",
                    "stdAges": [
                        "CHILD"
                    ]
                },
                "contactsLocationsModule": {
                    "centralContacts": [
                        {
                            "name": "Paul Glewwe, PhD",
                            "role": "CONTACT",
                            "phone": "+1 612 625 0225",
                            "email": "pglewwe@umn.edu"
                        },
                        {
                            "name": "Nathan Congdon, MD",
                            "role": "CONTACT",
                            "phone": "+44 7748751393",
                            "email": "ncongdon1@gmail.com"
                        }
                    ],
                    "overallOfficials": [
                        {
                            "name": "Nathan Congdon, MD",
                            "affiliation": "Queen's University, Belfast",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "locations": [
                        {
                            "facility": "Innovations for Poverty Action (IPA)",
                            "status": "RECRUITING",
                            "city": "Freetown",
                            "country": "Sierra Leone",
                            "contacts": [
                                {
                                    "name": "Agnes Lahai",
                                    "role": "CONTACT",
                                    "phone": "+232 76513647",
                                    "email": "alahai@poverty-action.org"
                                },
                                {
                                    "name": "Amos Ahabwe",
                                    "role": "CONTACT",
                                    "phone": "+256704887317",
                                    "email": "aahabwe@poverty-action.org"
                                }
                            ],
                            "geoPoint": {
                                "lat": 8.484,
                                "lon": -13.22994
                            }
                        }
                    ]
                },
                "referencesModule": {
                    "references": [
                        {
                            "pmid": "33275950",
                            "type": "RESULT",
                            "citation": "GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021 Feb;9(2):e130-e143. doi: 10.1016/S2214-109X(20)30425-3. Epub 2020 Dec 1."
                        },
                        {
                            "pmid": "33607016",
                            "type": "RESULT",
                            "citation": "Burton MJ, Ramke J, Marques AP, Bourne RRA, Congdon N, Jones I, Ah Tong BAM, Arunga S, Bachani D, Bascaran C, Bastawrous A, Blanchet K, Braithwaite T, Buchan JC, Cairns J, Cama A, Chagunda M, Chuluunkhuu C, Cooper A, Crofts-Lawrence J, Dean WH, Denniston AK, Ehrlich JR, Emerson PM, Evans JR, Frick KD, Friedman DS, Furtado JM, Gichangi MM, Gichuhi S, Gilbert SS, Gurung R, Habtamu E, Holland P, Jonas JB, Keane PA, Keay L, Khanna RC, Khaw PT, Kuper H, Kyari F, Lansingh VC, Mactaggart I, Mafwiri MM, Mathenge W, McCormick I, Morjaria P, Mowatt L, Muirhead D, Murthy GVS, Mwangi N, Patel DB, Peto T, Qureshi BM, Salomao SR, Sarah V, Shilio BR, Solomon AW, Swenor BK, Taylor HR, Wang N, Webson A, West SK, Wong TY, Wormald R, Yasmin S, Yusufu M, Silva JC, Resnikoff S, Ravilla T, Gilbert CE, Foster A, Faal HB. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021 Apr;9(4):e489-e551. doi: 10.1016/S2214-109X(20)30488-5. Epub 2021 Feb 16. No abstract available."
                        },
                        {
                            "pmid": "16539747",
                            "type": "RESULT",
                            "citation": "Dandona L, Dandona R. What is the global burden of visual impairment? BMC Med. 2006 Mar 16;4:6. doi: 10.1186/1741-7015-4-6."
                        },
                        {
                            "pmid": "29693366",
                            "type": "RESULT",
                            "citation": "Glewwe P, West KL, Lee J. The Impact of Providing Vision Screening and Free Eyeglasses on Academic Outcomes: Evidence from a Randomized Trial in Title I Elementary Schools in Florida. J Policy Anal Manage. 2018;37(2):265-300. doi: 10.1002/pam.22043."
                        },
                        {
                            "pmid": "27852581",
                            "type": "RESULT",
                            "citation": "Keil S, Fielder A, Sargent J. Management of children and young people with vision impairment: diagnosis, developmental challenges and outcomes. Arch Dis Child. 2017 Jun;102(6):566-571. doi: 10.1136/archdischild-2016-311775. Epub 2016 Nov 16."
                        },
                        {
                            "pmid": "25249453",
                            "type": "RESULT",
                            "citation": "Ma X, Zhou Z, Yi H, Pang X, Shi Y, Chen Q, Meltzer ME, le Cessie S, He M, Rozelle S, Liu Y, Congdon N. Effect of providing free glasses on children's educational outcomes in China: cluster randomized controlled trial. BMJ. 2014 Sep 23;349:g5740. doi: 10.1136/bmj.g5740."
                        },
                        {
                            "pmid": "12939289",
                            "type": "RESULT",
                            "citation": "Naidoo KS, Raghunandan A, Mashige KP, Govender P, Holden BA, Pokharel GP, Ellwein LB. Refractive error and visual impairment in African children in South Africa. Invest Ophthalmol Vis Sci. 2003 Sep;44(9):3764-70. doi: 10.1167/iovs.03-0283."
                        },
                        {
                            "pmid": "29801081",
                            "type": "RESULT",
                            "citation": "Ma Y, Congdon N, Shi Y, Hogg R, Medina A, Boswell M, Rozelle S, Iyer M. Effect of a Local Vision Care Center on Eyeglasses Use and School Performance in Rural China: A Cluster Randomized Clinical Trial. JAMA Ophthalmol. 2018 Jul 1;136(7):731-737. doi: 10.1001/jamaophthalmol.2018.1329."
                        },
                        {
                            "pmid": "26426113",
                            "type": "RESULT",
                            "citation": "Wang X, Yi H, Lu L, Zhang L, Ma X, Jin L, Zhang H, Naidoo KS, Minto H, Zou H, Rozelle S, Congdon N. Population Prevalence of Need for Spectacles and Spectacle Ownership Among Urban Migrant Children in Eastern China. JAMA Ophthalmol. 2015 Dec;133(12):1399-406. doi: 10.1001/jamaophthalmol.2015.3513."
                        },
                        {
                            "pmid": "15665167",
                            "type": "RESULT",
                            "citation": "Williams WR, Latif AH, Hannington L, Watkins DR. Hyperopia and educational attainment in a primary school cohort. Arch Dis Child. 2005 Feb;90(2):150-3. doi: 10.1136/adc.2003.046755."
                        }
                    ]
                },
                "ipdSharingStatementModule": {
                    "ipdSharing": "YES",
                    "description": "Only deidentified data will be shared, on request.",
                    "infoTypes": [
                        "SAP"
                    ],
                    "timeFrame": "Data will be available once they are cleaned and de-identified, kept for at least 10 years after study completion",
                    "accessCriteria": "Those who wish to access the de-identified data will need to request formally with the research team."
                }
            },
            "derivedSection": {
                "miscInfoModule": {
                    "versionHolder": "2024-11-18"
                },
                "conditionBrowseModule": {
                    "meshes": [
                        {
                            "id": "D012030",
                            "term": "Refractive Errors"
                        }
                    ],
                    "ancestors": [
                        {
                            "id": "D005128",
                            "term": "Eye Diseases"
                        }
                    ],
                    "browseLeaves": [
                        {
                            "id": "M12168",
                            "name": "Myopia",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M14872",
                            "name": "Refractive Errors",
                            "asFound": "Refractive Errors",
                            "relevance": "HIGH"
                        },
                        {
                            "id": "M10007",
                            "name": "Hyperopia",
                            "relevance": "LOW"
                        },
                        {
                            "id": "M8271",
                            "name": "Eye Diseases",
                            "relevance": "LOW"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "BC11",
                            "name": "Eye Diseases"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Conditions"
                        }
                    ]
                }
            },
            "hasResults": false
        },
        {
            "protocolSection": {
                "identificationModule": {
                    "nctId": "NCT04060927",
                    "orgStudyIdInfo": {
                        "id": "IRB00081383"
                    },
                    "secondaryIdInfos": [
                        {
                            "id": "00036616",
                            "type": "OTHER",
                            "domain": "Advarra IRB"
                        },
                        {
                            "id": "LCI-LUN-SBRT-002",
                            "type": "OTHER",
                            "domain": "Atrium"
                        }
                    ],
                    "organization": {
                        "fullName": "Wake Forest University Health Sciences",
                        "class": "OTHER"
                    },
                    "briefTitle": "Pilot Study of SGRT Alone vs. SGRT With Fiducials for Breath Hold SBRT tx of the Lung",
                    "officialTitle": "LCI-LUN-SBRT-002: Pilot Study of SGRT Alone vs. SGRT in Combination With Fiducials for Breath Hold SBRT Treatments of the Lung"
                },
                "statusModule": {
                    "statusVerifiedDate": "2024-10",
                    "overallStatus": "ACTIVE_NOT_RECRUITING",
                    "expandedAccessInfo": {
                        "hasExpandedAccess": false
                    },
                    "startDateStruct": {
                        "date": "2019-09-25",
                        "type": "ACTUAL"
                    },
                    "primaryCompletionDateStruct": {
                        "date": "2025-10",
                        "type": "ESTIMATED"
                    },
                    "completionDateStruct": {
                        "date": "2026-10",
                        "type": "ESTIMATED"
                    },
                    "studyFirstSubmitDate": "2019-08-16",
                    "studyFirstSubmitQcDate": "2019-08-16",
                    "studyFirstPostDateStruct": {
                        "date": "2019-08-19",
                        "type": "ACTUAL"
                    },
                    "lastUpdateSubmitDate": "2024-10-17",
                    "lastUpdatePostDateStruct": {
                        "date": "2024-10-21",
                        "type": "ACTUAL"
                    }
                },
                "sponsorCollaboratorsModule": {
                    "responsibleParty": {
                        "type": "SPONSOR"
                    },
                    "leadSponsor": {
                        "name": "Wake Forest University Health Sciences",
                        "class": "OTHER"
                    },
                    "collaborators": [
                        {
                            "name": "Atrium Health Levine Cancer Institute",
                            "class": "OTHER"
                        }
                    ]
                },
                "oversightModule": {
                    "oversightHasDmc": true,
                    "isFdaRegulatedDrug": false,
                    "isFdaRegulatedDevice": true,
                    "isUsExport": false
                },
                "descriptionModule": {
                    "briefSummary": "This is a pilot study designed to to provide data and experience comparing two different techniques of breath hold SBRT treatments. The first technique will include SGRT, but with the assistance of implanted fiducials. Subjects will be treated with a breath hold technique utilizing SGRT, but will also be imaged during treatment with fiducial match. The second technique will utilize SGRT for breath hold treatments without the assistance of implanted fiducials/continuous imaging.",
                    "detailedDescription": "The study's primary objective is estimate the incidence of SBRT and fiducial-related pulmonary toxicities for subjects treated with SBRT who have tumors that move \u2265 1 cm in 3 different cohorts: 1) free breathing with SGRT 2) breath hold utilizing SGRT only; 3) breath hold utilizing SGRT in combination with implanted fiducials. Secondary objectives also include Estimate reliability of gated SBRT treatments utilizing SGRT vs. SGRT with fiducials estimating local control for SBRT in subjects treated in the three different cohorts, estimating overall survival, and evaluating quality of life. A safety objective of estimating acute and long-term grade 2 or higher non-hematologic toxicities attributed to SBRT/fiducial implantation in subjects treated in the three different cohorts will also be explored."
                },
                "conditionsModule": {
                    "conditions": [
                        "Lung Cancer"
                    ],
                    "keywords": [
                        "NSCLC",
                        "Lung",
                        "Radiation Therapy"
                    ]
                },
                "designModule": {
                    "studyType": "INTERVENTIONAL",
                    "phases": [
                        "NA"
                    ],
                    "designInfo": {
                        "allocation": "NON_RANDOMIZED",
                        "interventionModel": "PARALLEL",
                        "primaryPurpose": "TREATMENT",
                        "maskingInfo": {
                            "masking": "NONE"
                        }
                    },
                    "enrollmentInfo": {
                        "count": 45,
                        "type": "ACTUAL"
                    }
                },
                "armsInterventionsModule": {
                    "armGroups": [
                        {
                            "label": "Group 1",
                            "type": "EXPERIMENTAL",
                            "description": "Freebreathing SBRT with SGRT",
                            "interventionNames": [
                                "Device: SGRT"
                            ]
                        },
                        {
                            "label": "Group 2",
                            "type": "EXPERIMENTAL",
                            "description": "Breath hold SBRT with SGRT",
                            "interventionNames": [
                                "Device: SGRT"
                            ]
                        },
                        {
                            "label": "Group 3",
                            "type": "EXPERIMENTAL",
                            "description": "Breath hold SBRT with SGRT in combination with implanted fiducials",
                            "interventionNames": [
                                "Device: SGRT"
                            ]
                        }
                    ],
                    "interventions": [
                        {
                            "type": "DEVICE",
                            "name": "SGRT",
                            "description": "Surface Guided Radiation Therapy",
                            "armGroupLabels": [
                                "Group 1",
                                "Group 2",
                                "Group 3"
                            ]
                        }
                    ]
                },
                "outcomesModule": {
                    "primaryOutcomes": [
                        {
                            "measure": "Incidence of SBRT and fiducial-related pulmonary toxicities as assessed by NCI CTCAE v.5.0",
                            "description": "The outcome will be recorded as a binary variable determined for each subject indicating whether or not the subject had at least one grade 2 or higher pulmonary toxicity related to SBRT or implantation of fiducials.",
                            "timeFrame": "12 months"
                        }
                    ],
                    "secondaryOutcomes": [
                        {
                            "measure": "Reliability of gated SBRT treatments utilizing SGRT vs. SGRT with fiducials",
                            "description": "This will be recorded as numerical values for each of the shift/rotational directions and the vector composites of the directional shifts at the time of verification imaging.",
                            "timeFrame": "approx. 2 weeks"
                        },
                        {
                            "measure": "Local control of treated tumor(s)",
                            "description": "The outcome will be measured as the duration of time from enrollment to progression of the subject's treated tumor(s)",
                            "timeFrame": "up to 24 months"
                        },
                        {
                            "measure": "Overall Survival",
                            "description": "This outcome will be measured as the duration of time from the date of enrollment to the study to the date of death from any cause.",
                            "timeFrame": "approx. 5 years"
                        },
                        {
                            "measure": "Change from Baseline in MD Anderson Symptom Inventory - Lung Cancer (MDASI-LC) Score",
                            "description": "The MDASI-LC Module includes 22 questions to assess the severity of multiple lung cancer-related symptoms and the impact of these symptoms on daily functioning. Scores for each item range from 0 to 10, where 0 indicates no symptoms and 10 indicates worst possible symptoms.",
                            "timeFrame": "pre-SBRT and 1, 3, 6, and 12 months after the last treatment of SBRT"
                        }
                    ],
                    "otherOutcomes": [
                        {
                            "measure": "Incidence of Grade 2 or higher non-hematologic toxicities attributed to SBRT and fiducial implantation",
                            "description": "Incidence rates for acute and long-term adverse events of special interest, SAEs, and deaths from the time of initiation of SBRT until 12 months after the last treatment of SBRT will be summarized as counts and proportions.",
                            "timeFrame": "up to 12 months after the last treatment of SBRT"
                        }
                    ]
                },
                "eligibilityModule": {
                    "eligibilityCriteria": "Inclusion Criteria\n\nSubject must meet all of the following applicable inclusion criteria to participate in this study:\n\n1. Written informed consent with HIPAA authorization for release of personal health information.\n2. Age \u226518 years at the time of consent. Because no dosing or adverse event data are currently available on the use of fiducials in combination with SBRT in subjects \\<18 years of age, children are excluded from this study.\n3. ECOG Performance Status of \u2264 2.\n4. Stage IA-IIB (T1a-T3bN0) presumed non-small cell lung cancer, carcinoid tumors, or lung metastasis that have \u2265 1 cm of respiratory associated motion measured on 4DCT at time of simulation for SBRT with or without respiratory motion suppression techniques. Histologic confirmation of malignancy is encouraged but not required. Primary or metastatic tumor \u2264 7 cm.\n5. Subjects may be receiving systemic chemotherapy or other systemic agents prior to enrollment, but these agents must be stopped during SBRT treatments.\n6. Females of childbearing potential (FCBP) must have a negative serum pregnancy test within 14 days prior to day 1 of treatment. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are postmenopausal (at least 12 consecutive months with no menses without an alternative medical cause).\n7. The effects of radiation on the developing human fetus are not well described. For this reason, women of child-bearing potential and non-sterilized men who are sexually active with a woman of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. FCBP must be willing to use a highly effective contraceptive method (i.e., achieves a failure rate of \\<1% per year when used consistently and correctly) from the time of informed consent until 5 days after last dose of SBRT. Contraceptive methods with low user dependency are preferable but not required.\n8. As determined by the enrolling physician, ability of the subject to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria\n\nSubjects meeting any of the criteria below may not participate in the study:\n\n1. Prior radiation to the chest that would overlap with the current radiation fields and determined by the treating physician to impede the treatment of the study malignancy.\n2. Active ongoing pulmonary infection or pneumonitis that is requiring active treatment with antibiotics or steroids. Prior pneumonitis from drug or other therapies that has been treated within 15 days of first day of treatment.",
                    "healthyVolunteers": false,
                    "sex": "ALL",
                    "minimumAge": "18 Years",
                    "stdAges": [
                        "ADULT",
                        "OLDER_ADULT"
                    ]
                },
                "contactsLocationsModule": {
                    "overallOfficials": [
                        {
                            "name": "John Heinzerling, MD",
                            "affiliation": "Wake Forest University Health Sciences",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "locations": [
                        {
                            "facility": "Levine Cancer Institute",
                            "city": "Charlotte",
                            "state": "North Carolina",
                            "zip": "28204",
                            "country": "United States",
                            "geoPoint": {
                                "lat": 35.22709,
                                "lon": -80.84313
                            }
                        }
                    ]
                },
                "ipdSharingStatementModule": {
                    "ipdSharing": "NO"
                }
            },
            "documentSection": {
                "largeDocumentModule": {
                    "largeDocs": [
                        {
                            "typeAbbrev": "ICF",
                            "hasProtocol": false,
                            "hasSap": false,
                            "hasIcf": true,
                            "label": "Informed Consent Form",
                            "date": "2022-07-26",
                            "uploadDate": "2024-10-17T15:29",
                            "filename": "ICF_000.pdf",
                            "size": 5530138
                        }
                    ]
                }
            },
            "derivedSection": {
                "miscInfoModule": {
                    "versionHolder": "2024-11-18"
                },
                "conditionBrowseModule": {
                    "browseLeaves": [
                        {
                            "id": "M11172",
                            "name": "Lung Neoplasms",
                            "relevance": "LOW"
                        }
                    ],
                    "browseBranches": [
                        {
                            "abbrev": "BC04",
                            "name": "Neoplasms"
                        },
                        {
                            "abbrev": "BC08",
                            "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                        },
                        {
                            "abbrev": "All",
                            "name": "All Conditions"
                        }
                    ]
                }
            },
            "hasResults": false
        }
    ],
    "nextPageToken": "NF0g5JWOlPIvxw"
}